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ABSTRACT  
 
Mycobacterium tuberculosis (Mtb) is the bacterium responsible for the human disease 
tuberculosis (TB).  This study aimed to develop a rapid, low cost assay for screening the 
anti-mycobacterial properties of new therapies.  This assay employed a Green Fluorescent 
Protein reporter strain of Mycobacteruim avium subspecies paratuberculosis (Map), a 
pathogenic species causing paratuberculosis in ruminants that can be considered a model 
for Mtb.  Mycobacterial growth over time was monitored by fluorescence, testing new 
potential therapies including metal and drug nanoparticles (NPs), over a range of 
concentrations for up to 7 days.  The new Map-based assay was sufficiently sensitive to 
distinguish between the toxicity of different metal/metal oxide NPs, ranked: 
Ag>Cu(II)O>ZnO.   Solid drug NPs (SDNs) of TB antibiotics (rifampicin, isoniazid and 
pyrazinamide) were compared to conventional antibiotics.  SDNs of rifampicin were 
found to be 100 times more toxic to Map than the conventional antibiotics.  Fluorescence 
microscopy revealed the uptake of SDNs by infected macrophages with possible co-
localisation with Map.  Pilot data supports the ability of the SDN to kill the intracellular 
Map.  These results support the benefits of nanomedicine and suggest that drug doses 
could be reduced, if delivered as a nano-formulation.  
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to regard as the real breeding places of consumption; it is 
out of them that the disease always crops up; and it is to 
the abolition of these conditions that we must first and 
foremost direct our attention if we wish to attack the evil 
at its root and wage war against it with effective 
weapons." 
Dr. Robert Koch, 1901, the ‘father of the scientific study of tuberculosis’ 
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1.1 Mycobacteria 
 
Mycobacterium is the sole genus in the Mycobacteriaceae family, some members of 
which cause many serious infectious diseases in humans and animals.  Mycobacteria 
belong to the order Actinomycetales, which comprises the genera, Corynebacterium, 
Mycobacterium, Nocardia (the CMN group) and Rhodococcus (Cocito et al. 1994; Barry 
& Beaman 2006).  CMN members are aerobic, non-motile, non-spore forming bacilli 
which possess a complex, thick cell wall rich in lipids and glycolipids with a unique outer 
cell membrane.  Cell walls of CNM group members contain mycolic acids, long chain 
fatty acids, highly impermeable to many solutes, which makes the cell waterproof.  The 
mycobacteria grouped within the Mycobacterium tuberculosis complex (MTBC) match 
by 99.9% at the nucleotide level, but vary in their host selection, phenotypes and 
pathogenicity (Brosch et al. 2002).  Rare synonymous single-nucleotide polymorphisms 
(sSNP) in the genomes have allowed for identification of individual mycobacterial 
species, which has provided vital information on the evolution and origin of the family 
(Smith 2003).  Within MTBC, the closely related species are zoonotic and generally infect 
different hosts.  They include Mycobacterium tuberculosis (Mtb), Mycobacterium (M.) 
bovis (and the Bacillus Calmette–Guérin [BCG] strain), M. africanum, M. microti, M. 
caprae, M. canetti and M. pinnipedii (Hussain et al. 2013).  The Mycobacterium avium 
complex (MAC) is a large group of related mycobacteria, which includes M. avium subsp. 
avium, M. avium subsp. paratuberculosis, M. avium subsp. silvaticum and M. avium 
subsp. hominissuis.  
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1.1.1 Mycobacterium tuberculosis Complex (MTBC) Evolution 
The closely related bacterial species and sub-species of the MTBC have caused human 
and animal diseases for many thousands of years, with Mtb being a predominant killer by 
humans in causing tuberculosis (TB) (Smith 2003).  Humans are the only known host 
where infection by Mtb and M. africanum causes TB with rapid and efficient 
transmission.  It was originally believed that Mtb originated from M. bovis, appearing 
when cattle were very first domesticated and farmed (Collins 1997; Smith 2003).  
Domestication of cattle is thought to have occurred some 10,000-25,000 years ago, and 
early findings suggest that bacteria in the genus Mycobacterium originated in the soil, 
where they readily passed to mammalian hosts, such as cattle (Smith 2003).  As such, it 
was believed that M. bovis was the evolutionary precursor of Mtb.  However, this 
hypothesis is now widely contradicted in the literature.  It is hypothesised, due to sSNP 
data analysis, Mtb and M. bovis either evolved simultaneously but independently, they 
share the same common ancestor (e.g. M. canetti) or that early ancestral lineages of Mtb 
were the original cause of TB (Sreevatsan, Stockbauer, et al. 1997; Brosch et al. 2002; 
Smith 2003; Brites & Gagneux 2015).  As aforementioned, bacterial species and sub-
species of the MTBC share up to 99.9% DNA sequence but differ in their host range.  As 
they display great levels of genetic homogeneity it is assumed that members of the group 
are the clonal progeny of the same single species that underwent an evolutionary 
bottleneck somewhere between 15,000 and 35,000 years ago (Sreevatsan, Pan, et al. 
1997; Brosch et al. 2002; Gutierrez et al. 2005).  Evolution of the MTBC is a complex 
story, yet it is generally accepted that essential, core genes were inherited (and more 
conserved than nonessential genes) and horizontal gene transfer occurred between 
species, thus allowing the acquisition of foreign DNA, aiding in the pathogenicity of 
species like Mtb.  Whether this can be described as an evolutionary arms race or not, it is 
clear that gene transfer occurred and members of the MTBC have evolved, most likely 
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from an African origin (Gutierrez et al. 2005; Gagneux et al. 2006; Comas et al. 2013; 
Brites & Gagneux 2015).  
Debate is widespread in the literature concerning the absolute origins of the MTBC with 
many contradictory reports existing (Brosch et al. 2002; Smith 2003; Fabre et al. 2004; 
Smith 2006; Comas et al. 2010; Comas et al. 2013; Brites & Gagneux 2015).  By 
analysing the genomes of 100 strains of mycobacteria, Brosch et al state that MTBC 
descended from a human (not animal) pathogen, which is now a widely accepted 
hypothesis (Brosch et al. 2002).  Through comparing insertions and deletions in the 
genomes of various strains, they suggest that M. canetti and/or Mtb are likely to be the 
direct descendants from a tubercle bacilli, a human pathogen, from which other strains 
eventually emerged.  M. canetti is often referred to as the progenitor species from which 
Mtb evolved; yet it differs from the others in the MTBC (Gagneux 2012).  Unlike other 
members, very smooth and shiny colonies propagate on growth medium.  There is a 
distinct lack of reports that individuals infected with this mycobacteria are able to transmit 
it to others to cause disease (Gagneux 2012).  Transmission of M. canetti among humans 
has not been demonstrated, therefore it is thought that they are likely attained from the 
environment, although it is unknown where from (Brites & Gagneux 2015).  
Following the bottleneck hypothesis and knowledge of mutation rates, by characterising 
strains from patients from East Africa and using the DNA sequence of six housekeeping 
genes, Gutierrez et al., propose that the MTBC emerged from an ancient species they 
termed ‘Mycobacterium prototuberculosis’ which engulfed M. canetti and other smaller 
species (Gutierrez et al. 2005).  They state that tubercle bacilli existed with early hominids 
in East Africa, thus making the origin date to the dawn of man at the Horn of Africa some 
3 million years ago, making TB older than the plague or any other human affliction 
(Gutierrez et al. 2005), yet some debate about this dating theory exists (Smith 2006). 
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Through use of genetic markers, statistical analysis and a mathematical algorithm 
approach, another study reported that the MTBC is composed of two major lineages; one 
composed of Mtb lineages from humans only and the other of both animal and human 
isolates, thus further suggesting an original human host (not animal) (Wirth et al. 2008).  
They report that this coincides with the beginning of modern human populations 
migrating from the Horn of Africa into settlements approximately 40,000 years ago 
(Wirth et al. 2008).  Wirth et al., also termed the first tubercle bacilli ‘Mycobacterium 
prototuberculosis’ from which the MTBC clone emerged from the progenitor pool, that 
co-migrated with humans out of Africa (Wirth et al. 2008; Gutierrez et al. 2005).  This 
report affirms that humans most likely infected their livestock; cattle and goats, which 
were the first to be domesticated and not the other way around (Wirth et al. 2008). 
Comas et al., created a global genome-wide phylogeny using next generation DNA 
sequencing for 220 strains in the MTBC to demonstrate the evolutionary relationship 
between members of the MTBC (Fig 1.1) (Comas et al. 2010).  Using sequencing 
techniques and statistical modelling this work supports the theories that TB originated in 
Africa, Mtb evolved with its human host at least 70,000 years ago, an increase in 
population size (not zoonotic transfer) was responsible for MTBC’s success and that 
member species have adapted with the changing human populations to ensure survival 
(Comas et al. 2013).  It is possible that members of the MTBC did not follow the typical 
evolutionary arms race of evolution, but have instead evolved to suit their host, by 
immune subversion (Comas et al. 2010). 
A recent review by Gutierrez et al (2015) conclude that recent studies on the evolution of 
the MTBC concur on their main hypotheses; co-evolution of humans and some MTBC 
lineages occurred yet there is debate among reports on a ‘molecular’ clock for MTBC. 
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1.1.2 MTCB Lineages  
 
There are 6 phylogenetically distinguished human lineages identified from around the 
globe: Lineage 1 (Indo-Oceanic), Lineage 2 (East Asian) Lineage 3 (Central and South 
Asia/East Africa), Lineage 4 (Euro-American), Lineage 5 ([M. africanum] West African 
1) and Lineage 6 ([M. africanum] West African 2) (Fig 1.1) (Comas et al. 2010).  From 
the six main lineages identified M. africanum is the most basal and each Lineage is 
associated with different human populations (Comas et al. 2010).  By following genetic 
differences and similarities between species, many individual strains have been 
identified.  For example, following recent TB epidemics, ‘modern’ strains ‘Beijing’ 
(Lineage 2) and ‘Haarlem’ (Lineage 4) have been recognised through the loss of a genetic 
deletion (TbD1), hence all strains missing this gene are considered modern.  Modern 
strains seem to cause a diseased state in infected patients more readily over the ancient 
strains, thus suggesting that modern strains have evolved to avoid latent forms of disease 
so they are more virulent (Gagneux 2012). 
 
Figure 1.1 Global phylogeography of MTBC 
(adapted from Gagneux 2012) 
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1.2 The Mycobacterial Cell Envelope  
 
The unique make-up of the mycobacterial envelope gives the bacteria a survival 
advantage over other bacterial species, making them impermeable to many drugs and 
insensitive to most antibiotics.  It is a complex, physically resilient, layered structure 
made predominantly from sugars and lipids (Smith 2011), hence why mycobacteria are 
renowned for resistance to many compounds and chemicals (Verschoor et al. 2012).  The 
outmost layer is called the capsule, mainly composed of glycans.  Below the capsule, the 
cell membrane is highly concentrated in lipids with long chain, β-hydroxy fatty acids; 
mycolic acids.  Mycolic acids are arranged tightly packed, perpendicular to the cell 
surface making the structure highly impermeable to many solutes and waterproof (Favrot 
& Ronning 2012).  Mtb contain the largest of the mycolic acids (C60–C90), accounting for 
its great resilience, acid/alcohol fastness.  The lipid layer is attached to a layer of 
arabinogalactan polysaccharides, which in turn is attached to a peptidoglycan layer that 
surrounds the cell phospholipid bilayer (Fig 1.2).  It is this complex, layered structure that 
many anti-mycobacterial drugs target, such as isoniazid (INH), which affects mycolic 
acid synthesis.  
 
 
 
 
 
 
 
Figure 1.2 Basic Structure of Mtb Cell Wall 
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1.3 Mycobacterium tuberculosis (Mtb) and tuberculosis (TB)  
 
Mtb has been of particular interest to medical science for many decades.  Mtb developed 
as a facultative intracellular parasite, which usually infects and takes up residence within 
two of the host’s immune cells; macrophages and dendritic cells.  Hence, the disease is 
essentially a disease of the immune system.  Mtb is an unusual bacterial species, falling 
somewhere between Gram-positive and Gram-negative bacteria.  It has a very slow 
generation time dividing approximately every 16-20 hours, and a complex, waxy cell 
surface.  TB continues to kill up to 2 million people each year (WHO 2013; WHO 2014b; 
WHO 2015b).  A third of the world’s population is estimated to be infected with latent 
TB (LTBI [latency is defined as the presence of an Mtb infection, without the diseased 
state of active TB])  (WHO 2015b).  LTBI presents a vast reservoir of possible disease 
reactivation and transmission. 
Skeletal remains from Neolithic Europe (8000 BC), ancient Egypt (1000 BC) and the 
United Kingdom (UK) during the Iron Age (800 BC) displaying evidence of TB in the 
form of osteotuberculosis lesions assert that this disease is not a new affliction infecting 
only modern populations (Collins 1997; Ohara 2012; Brites & Gagneux 2015).  Although 
such evidence suggests that the disease has long been infecting humans (although Comas 
et al (2013) predate all archaeological evidence), it was during the Industrial Revolution 
of the 18th and 19th centuries that the TB rapidly spread.  During this period, great influxes 
of individuals migrating from their rural homes to the developing cities for employment 
were cramped in appalling conditions, suffering from malnutrition, poor health and great 
physical hardship.  These unsanitary working and impoverished living conditions 
subsequently led to a TB epidemic, as the infection positively thrives in such 
environments (Collins 1997).  By the 20th century, the mortality rates of TB had 
significantly decreased through improved living conditions, the administration of 
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antibiotics and the use of the M. bovis-BCG vaccine (Cooper 2009).  However, in 
poverty-stricken countries, infection rates and deaths from the disease are still alarmingly 
high, due to poor living conditions, inadequate medical supplies and antibiotic resistance.  
As a result, the disease is still classified as a health epidemic by the World Health 
Organisation (WHO) (WHO 2011; WHO 2012; WHO 2013; WHO 2014b; WHO 2015b). 
After centuries of infecting humankind, TB has evolved to become the greatest killer of 
humans along with the Human Immunodeficiency Virus (HIV)/Acquired 
Immunodeficiency Syndrome (AIDS), where 95% of TB deaths occur in the developing 
world (Pandey & Khuller 2006; Sosnik et al. 2010; Seth et al. 2011; WHO 2014b; WHO 
2015b).  The ever-increasing number of drug resistant strains and the susceptibility of 
HIV patients to TB infection add to this burden and equates to the global crisis.  Reports 
of ‘totally-drug resistant TB’ emerging from India only increases concerns for health 
practitioners (Rowland 2012).  Current literature suggests that after nearly 50 years only 
10 new drug candidates and 15 vaccine candidates are in the pipeline, with only the 
diarylquinoline Bedaquiline (BDQ) and Delamanid (in special circumstances) recently 
being approved by the Food and Drug Administration (FDA).  The only approved vaccine 
is the BCG vaccine, developed almost 100 years ago, and its efficacy among adults and 
some ethnic populations is debatable (genetic differences, exposure to different pathogens 
are some possible reasons) (Ohara 2012).  The disease is highly transmittable; passing 
from infected individuals to others when expelled through coughing and sneezing.  Hence 
the disease prevails in countries such as Africa, India and Bangladesh where many 
individuals live in crowded, restricted and destitute conditions, often slums, with little 
access to medical aid (WHO 2012; WHO 2013; WHO 2014b; WHO 2015b).   
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1.3.1 World TB 
 
The WHO has published a report on global TB annually since 1997.  Last year, 2015, 
marked the deadline set in the Millennium Development Goals (MDGs) and ‘Stop TB 
Partnership’ aims whose main vision was to reduce TB deaths by 50% by 2015 (compared 
to 1990), and to create a TB-free world by 2050 (WHO 2014b; WHO 2015b).  Established 
by the United Nations, MDGs offers a framework for the International community 
relating to improving health of the poor and reducing global poverty with a strong 
emphasis on TB.  The Stop TB Partnership is a collective organisation including 
governments, funding agencies and researchers who work towards accelerating progress 
on TB research into diagnostics and treatments.  TB deaths have been reduced by 47% 
since 1990 at an average rate of 1.5% per year and disease incidents in all countries 
surveyed has been reduced with approximately 43 million lives saved, thus being a hugely 
significant achievement (WHO 2015b).  An annual report is produced by Public Health 
England, Wales, Northern Ireland and the Scottish Mycobacteria Reference Laboratory 
(who report to Health Protection Scotland), which covers TB incidents and rates in detail 
for the UK.    
 
1.3.2 Main points from recent WHO reports  
 
TB remains the deadliest infectious disease to humans and is present in all parts of the 
world surveyed with 1.5 million deaths occurring in 2014 (Table 1.1, Fig 1.3).  As shown 
in Figure 1.3, TB remains most prevalent in developing parts of the world.  Overall 
incidents are slowly declining, however approximately 3.5% of global cases are multi 
drug resistant (MDR) and 9% of these cases are considered to be extensively drug 
resistant (XDR) (see section 1.7) (Figs 1.4, 1.5).  MDR TB cases largely occur in India 
and China (Fig 1.4) whereas XDR is mostly found in South Africa, Ukraine and India 
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(Fig 1.5).  Last year, India reported the highest reports of XDR in 5 years and incidents 
in India are higher than elsewhere (The Times of India 2016) (Fig 1.4, 1.4).  Over half of 
reported TB cases occurred among men (60%), but TB remains in the top three killers of 
women globally (WHO 2015b).  Approximately 13% of global cases were HIV infected 
(Choudhary & Kusum Devi 2015).  WHO has reported that $8 billion (USD) is required 
per year for TB detection and treatment, and a new target to reduce TB deaths by 95% by 
2035 has been set (WHO 2014b; WHO 2015b). 
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Table 1.1 TB Patterns from the WHO Global TB Reports 
(created using WHO 2011, 2012, 2013, 2014, 2015b) 
 
YEAR 
  
APPROXIMATE 
GLOBAL CASES 
OF TB* 
GLOBAL 
INCIDENT 
CASES OF 
HIV-TB 
GLOBAL TB 
RELATED 
DEATHS 
GLOBAL 
NUMBER OF 
INFECTED 
CHILDREN 
(<15 years)** 
MDR TB 
CASES 
XDR TB 
CASES*** 
UK TB 
Cases**** 
2010 8.8 Million 1.1 Million 1.45 Million - 650, 000 - 8,587 
2011 12 Million 1.1 Million 1.4 Million 490,000 630, 000 56,700 8,963 
2012 12 Million 1.1 Million 1.3 Million 530,000 450,000 43,200 8,751 
2013 9 Million 1.1 Million 1.5 Million 550,000 480,000 43,200 7,863 
2014 9.6 Million 1.1 Million 1.5 Million 350,000 480,000 46,560 7,077 
 
* Of this number, the majority of cases occurred in Asia and Africa 
** 2012 was the first WHO report to include the estimates of the burden of TB on children  
*** 9.7% of MDR TB cases are estimated to be XDR-TB (2014) 
**** Approx. 60% of UK cases are pulmonary 
 
 
 
 
Figure 1.3 Estimated TB Incident Rates, 2014  
(Taken from WHO 2015b) 
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Figure 1.4 Number of MDR TB cases estimated to occur among the 2014 pulmonary cases 
(Taken from WHO 2015b) 
 
 
 
 
Figure 1.5 Number of Patients with confirmed XDR-TB on treatment 
(Taken from WHO 2015b) 
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1.3.3 TB in the United Kingdom  
 
The occurrence of TB in the UK generally increased between 2000 and 2011, but there 
has been a gradual annual decline over the past 4 years (Public Health England 2015).  
TB is predominantly found in the larger cities (Fig 1.6), with current levels sitting at 
approximately 7,000 cases per year with 350 of these from Scotland in 2014 (Table 1.2) 
(Public Health England 2014b; Public Health England 2015; Health Protection Scotland 
2015; Laurenson & Smith 2015).  In Scotland 2014 there was an increase in the number 
of drug resistant cases reported (22 cases), thus being the highest number since 2000 
(Health Protection Scotland 2015).  The UK has the second highest rate of TB in western 
Europe, with many cases occurring in London and as such the NHS in England is 
investing £11.5 million to try to eradicate the disease here (NHS 2015).  Disease incidents 
in the UK remain very high (73%) among those born out-with the country (e.g. India, 
Pakistan and Somalia) with most cases reported in deprived areas of the UK and patients 
having at least one social risk factor (e.g. imprisonment and/or drug, alcohol dependency) 
(Public Health England 2014a; Public Health England 2015).  A recent news report 
highlighted that London now has higher rates of TB than parts of Iraq and Rwanda (BBC 
Health News 2015).  The BCG inoculation introduced as a routine vaccine for all UK 
schoolchildren in 1953 was discontinued in 2005 and is now only available to children 
living in certain regions or those deemed to be at high risk of exposure.  This is arguably 
not the best strategy and is linked to funding.  The BCG is recommended for babies born 
in London, yet out of the 32 London boroughs, 24 do not offer this as a routine vaccination 
(BBC Health News 2015).  The UK government is one of the main donors to TB funding 
(along with the US and Canada [Fig 1.7]) but there is a reported gap in the funding 
required to tackle the increase in MDR and XDR TB (WHO 2015b).   
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Figure 1.6 Three-year average TB rates by local authority health boards in the UK, 
2011-13 (London area enlarged). 
(taken from 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/360335/TB_Annual_report
__4_0_300914.pdf) 
 
 
Table 1.2 Recent UK TB cases  
(created using Tuberculosis in England 2015 Public Health Report, Health Protection Scotland 
website and the Scottish Mycobacteria Reference Laboratory Annual Report 2015) 
 
Country 2014 TB 
cases 
Rate per 100,000 
(95% CI*) 
MDR 
cases 
Comments 
England 
(London) 
6520 
(2,572) 
12.0 (11.7 -12.3)  
(30.1 [29.0 -31.3]) 
 
52 Incidents of TB are 
unacceptably high 
Scotland 350 6.5 (5.8 -7.2)  
 
 2 Incidents of TB are 
generally stable and 
low 
 
Wales 115 3.7 (3.1 -4.5)  
 
 As above 
Northern Ireland 95 5.2 (4.2 -6.3)  
 
 As above 
                                    
  *Confidence Interval (CI)  
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1.3.4 TB Funding 
 
Treating and diagnosing TB is very expensive.  The cost of treating a drug susceptible 
patient is $100-1000, whereas treating a MDR TB strain ranges from $6000-21000 (WHO 
2015b), with hospitalisation requirement being a main factor influencing costs.  
Approximately $8 billion was required to respond to the global TB epidemic in 2015 
(excluding funding for drug, vaccine and diagnostics development).  The WHO (2015) 
reported that only $6.6 billion was available in 2015, thus highlighting a significant 
shortfall.  As shown in Figure 1.7 the USA, UK, Germany, France and the Bill and 
Melinda Gates foundation are main donors to TB research with Asian countries 
(predominantly China and India) being major recipients.  
 
 
 
 
Figure 1.7 TB funding 2011-13 ($, million USD) showing donors on the left and recipients 
on the right. 
(Taken from WHO 2015b) 
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1.4 Aetiology of TB 
 
Historically, TB was described as “the white plague”, “the consumption” or the “wasting 
disease” (Ducati et al. 2006) and the aetiology was much debated throughout the 19th and 
20th centuries until the persuasive work of Robert Koch in 1882.  In 1865, the French 
surgeon Jean Antoine Villemin undertook research into the disease and through 
inoculation of rabbits using serum from human TB patients, he concluded that the disease 
was highly contagious and did not affect only certain ‘classes’ of people as proposed by 
Herman Pidoux who believed it to be hereditary (as did Hippocrates [460 BC]).  However 
Villemin’s findings were initially ignored, until Koch’s research almost two decades later 
(Smith 2003).  Koch’s work confirmed Villemin’s theory, which was later reasserted by 
Edward Trudeau.  Koch, described as the founder of modern bacteriology, was awarded 
the Nobel Prize for his fundamental discovery and scientific evidence that TB was caused 
by an infectious bacterium.  Trudeau suggested that a healthy diet, rest and fresh air aided 
in the survival and development of immunity from Mtb, thus being the rationale behind 
the ‘Adirondack Cottage Sanatorium,’ the first of its kind in 1884, set up for wealthy city 
dwellers suffering from the disease (Collins 1997).  Trudeau concluded that those living 
in poverty were more at risk from contracting the disease and dying from it, as they were 
unable to receive appropriate aid, which unfortunately remains the case today.   
 
1.5 Pathogenesis  
 
Mtb is an acid fast, non-sporing, non-motile, obligate aerobe, which is long, thin, slightly 
curved/rod-like in shape and 2-4 μM in length.  The bacilli have a thick waxy coat and 
tend to reside in the upper lobes of the lungs where oxygen levels are highest (Health 
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Protection Agency 2012).  The most common route of infection is the respiratory route 
whereby bacteria enter through aerosol droplet nuclei (1-5 µM), passed from an 
individual infected with pulmonary or laryngeal TB to a susceptible individual through 
coughing and sneezing.  Once infected, the time lapse to when TB develops into the active 
diseased state, can vary (Smith 2003).  Initiating from the inhalation of tubercle bacilli 
into the lungs, the bacilli are ingested by alveolar macrophages and dendritic cells; the 
host’s first line of defence (Crevel et al. 2002).   
Macrophages are ‘eaters’ which clear cellular debris as well as foreign bacteria and are 
capable of engulfing particles up to 10 μM in diameter (Byrne et al. 2011).  Upon 
maturing from monocytes, they provide immune surveillance.  Following bacterial 
contact with alveolar macrophages, Mtb is recognised as a pathogen through pattern 
recognition receptors that sense various components of the mycobacterial structure.  This 
leads to a specific intracellular signalling cascade, triggering the assembly of the globular 
protein actin and associated proteins, initiating the secretion of pro-inflammatory 
cytokines (e.g. tumor-necrosis factor alpha [TNF-α], interferon gamma [IFN-γ]) thus 
allowing macrophage uptake of Mtb into cytosolic vesicles in the phagosome, where 
bacteria are usually destroyed through the process of phagocytosis.  The entry of Mtb into 
immune cells can occur via one of many receptor molecules due to its complex cell 
surface, and the entry route taken relates to the type of immune response by the host 
(Pieters 2008).  For example, if the pathogen enters via Fc receptors, this leads to an 
inflammatory response within the macrophages, however if it enters the host cell via a 
CR3 receptor (requiring host plasma membrane cholesterol), macrophages are not 
activated (Byrne et al. 2011; Pieters 2008).  Toll-like receptors (TLRs) interact with Mtb-
specific ligands, leading to the uptake of Mtb, and initiate an intracellular signalling 
cascade in which induces production of cytokines thus being essential to inducing the 
adaptive immune response (Hossain & Norazmi 2013).  
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Upon bacterial uptake, phagosome-lysosome fusion occurs and undergoes a series of 
fusion and fission events within the endocytic pathway creating a hostile internal 
environment within the phagosome.  Acidification, release of enzymes/toxic peptides, 
activation of the NADPH oxidase (which generates superoxide) and other reactive 
nitrogen intermediates occur, which ultimately kills most microorganisms (Smith 2003).  
However, studies reveal that living Mtb remains in vacuoles where usually dead bacteria 
reside following phagocytosis along the endosomal-lysosomal pathway (Crevel et al. 
2002; Russell et al. 2010).  In the lungs a primary lesion of inflammation; the ‘Ghon 
Focus’ rapidly appears, thus being the initial site of parenchymal concentration.  Within 
the host cell, the surviving Mtb multiply, inhibit phagosome maturation and disrupt the 
macrophages.  The disrupted macrophages attract other immune cells such as monocytes 
and dendritic cells to the infection site through the production of chemokines, leading to 
the second stage of infection (Crevel et al. 2002; Ehlers & Schaible 2012).  Monocytes 
differentiate into macrophages, and again attempt to engulf and kill all the mycobacteria, 
but prove unsuccessful (Smith 2003).  Dendritic cells (as well as others) present antigens 
to T-cells, thus prompting adaptive T-cell immunity, which develops to create antigen 
specific T lymphocytes (particularly CD4+ and CD8+ T-cells) that activate macrophages 
to destroy the Mycobacterium (Crevel et al. 2002; Tameris et al. 2013).  This build up 
forms granulomas; clusters of Mtb infected macrophages surrounded by many immune 
cells (Pieters 2008), securing Mtb, preventing both its growth and replication due to the 
acidic conditions with low oxygen availability, but not destroying the pathogen or 
preventing it from generating energy (Smith 2003; Ehlers & Schaible 2012).  
Granuloma formation is a hallmark trait of Mtb infection (particularly pulmonary LTBI) 
and plays a pivotal role in immune-pathogenesis.  Their main function is to localise and 
contain the infection.  These complex aggregates of immune cells protect the host from 
the infectious mycobacteria in 90% of cases, and it has been found that HIV infected 
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patients exhibit a lack of granulomas, further asserting their role in host protection (Ehlers 
& Schaible 2012).  The granuloma is composed of many immune cells, blood derived 
infected and uninfected macrophages, epithelioid cells surrounded by lymphocytes (T-
cells and B-cells) and foamy macrophages (caused by the accumulation of intracellular 
lipids) (Fig 1.8).  The high lipid content foamy macrophages are a nutrient rich reservoir 
for long-term persistence.  Infected macrophages will eventually die, releasing Mtb into 
the centre of the granuloma, forming a necrotic zone (Fig 1.8), which over time, can 
rupture (if a host’s immune system is breached [e.g. HIV infection, diabetes, cancer]) thus 
releasing the dormant mycobacteria into circulation.  Disease may progress weeks or even 
years later (Crevel et al. 2002; Russell et al. 2010).   
Therefore, upon initial exposure and the uptake of Mtb by alveolar macrophages, the 
immune system calls for an inflammatory response, which slows the spread/growth of 
Mtb, but a time where the pathogen can lay dormant, housed within the immune cells.  
The severity of the infection that follows depends on the efficiency of the host’s immune 
system and/or the time lapsed in receiving antibiotics.  
 
Figure 1.8 Schematic diagram of the TB Granuloma Complex 
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1.5.1 Intracellular Survival of Mtb 
 
Mtb virulence is often defined by its transmission and intracellular survival ability, which 
is complex and is yet to be fully understood (Hussain et al. 2013; Simeone et al. 2015).  
It is established that the pathogen can adapt, allowing it to avoid the hostile environment 
of the phagosome, but the means by which Mtb achieves intracellular survival is not fully 
elucidated, as the lysosome is a complex organelle, which holds many different enzymes 
with the capability of degrading many microorganisms.  For these enzymes to function 
efficiently, they must be maintained in optimum conditions within the lysosome.  The 
enzymes must be kept at a pH of approximately 5 which is maintained by a proton-
pumping ATPase (Dubnau & Smith 2003).  Upon phagosome-lysosome fusion, the 
enzymes are transferred into the subcellular compartment holding the microorganism to 
be phagocytosed.  Mtb is known to disrupt the phagosome fusion, thus preventing its 
exposure to a highly acidic environment and allowing it to reside within a partly fused 
phagosome, in a pH of approximately 6.2 (Song et al. 2012).   
Mtb glycolipids block trafficking regulated by phosphatidylinositol 3-phosphate (PI3P), 
a membrane protein, required for phagosome-lysosome fusion (Pieters 2008).  By 
inhibiting the activity of a phosphatidylinositol 3-kinase (PI3 kinase) vHP34 using a cell 
wall component lipoarabinomannan (LAM), Mtb prevents PI3P being generated on the 
phagosomal membrane.  Mtb also prevents the build-up of PI3P on phagosomes, through 
secretion of a phosphatase (SapM), preventing fusion of the phagosome complex (Pieters 
2008).  
It has also been suggested that Mtb targets Ca2+ dependent signalling mechanisms (Malik 
et al. 2000).  Ca2+ is an important regulator of pathogen responses such as the regulation 
of the reactive nitrogen intermediates and the release of microbicidal proteins/peptides 
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and TNF-α.  Malik et al., demonstrated that Mtb residing in the phagosome inhibited Ca2+ 
mediated signal transduction (Malik et al. 2000).  The generation of reactive oxidative 
species (ROS) by macrophages is also affected by Mtb infection.  Certain proteins 
secreted by Mtb were found to directly down regulate ROS production in the immune 
cells, thus preventing antibacterial responses used by macrophages during infection 
(Ganguly et al. 2008).   
Tan et al., has shown that Cl- concentration increases during phagosomal maturation (Tan 
et al. 2013).  Cl- channels are found on the endosomal membrane, involved in the 
regulation of [H+].  The role of Cl- channels on a phagosome is not well understood, but 
it was observed that an increase in Cl- resulted in a lowering of pH within the phagosome 
complex, and intriguingly, Mtb displayed a transcriptional response to Cl- levels.  This 
research has suggested that Cl- and pH have an inverse correlation, but most importantly, 
it suggested that Mtb utilises host signals to its own advantage, using Cl- as an 
environmental indicator of pH levels (Tan et al. 2013). 
Dubnau & Smith outline some other possibilities, such as retention of certain proteins 
which interfere with the processes of the phagosome complex (Dubnau & Smith 2003) 
whereas Simeone et al., discuss Mtb instigating phagosomal rupturing (Simeone et al. 
2015).  Overall, it seems the mechanism of Mtb intracellular survival is by no means a 
straightforward feat.  It is through highly complex cell signalling pathways and genetic 
mutation, most of which are not well documented and/or understood.  
 
1.5.2 Adaptive immunity 
 
The adaptive immune system in a highly complex organisation but reacts in two main 
ways to Mtb invasion; antibody and cell-mediated response executed by B-cell or T-cell 
lymphocytes.  Mtb infection control is generally determined by the efficacy of the host’s 
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adaptive immune system.  T-cells, which include antigen specific CD4+ and CD8+ cells, 
are the most important in the immune response against Mtb.  CD4+ T-cells (type 1 helper 
cells [Th1 cells]) produce the cytokines IFN-γ and TNF-α which are known to be 
protective through the activation of functions in macrophage cells, that can control 
intracellular Mtb (Kaufmann 2013).  Th17 cells are known to produce interleukin (IL)-17 
(a pro-inflammatory cytokine), which attracts and activates neutrophils, often to the site 
of a granuloma formation, thus asserting their protective role (Prezzemolo et al. 2014).  
Although over production of IL-17 can cause tissue damage, (Prezzemolo et al. 2014), it 
has been discovered that from this recruitment, over half of the bacilli present in infected 
patients are found within neutrophil cells (Wong & Jacobs 2016).  Upon encountering 
Mtb that have burst from necrotic macrophages (Repasy et al. 2013), neutrophils undergo 
‘NETosis’ whereby they produce an extracellular trap which prevents the spreading of 
Mtb (Wong & Jacobs 2016).  These traps are chromatin structures with antimicrobial 
molecules and the process of NETosis is described as a form of pathogen-induced cell 
death (Remijsen et al. 2011).  CD8+ T-cells are known to differentiate into effector cells 
which produce cytolytic molecules and cytokines which can kill Mtb (Kaufmann 2013).  
They recognise antigenic peptides in cytosolic compartments following Mtb uptake into 
immune cells.  The process of adaptive immunity in an Mtb infection is highly complex, 
with activation of many immune cells, pathways and modulators.  
 
1.5.3 Primary and Secondary TB 
 
Primary TB infection is the initial exposure to the infectious bacilli, which enter the 
respiratory tract and are ingested by alveolar macrophages.  Depending on whether the 
bacilli are destroyed or not, will depend on whether active primary TB results.  If active 
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TB results, the onset of clinical symptoms soon occurs.  If bacteria are ingested and 
inhibited by the hosts immune system, characterised by a Ghon focus/granuloma, 
containing a parenchymal subpleural lesion, and enlarged lymph nodes, the bacilli will 
be contained (Health Protection Agency 2012).  
Secondary TB is the reactivation of a past, usually a subclinical infection.  The bacilli are 
released following rupture of the granuloma centre housing them, as aforementioned.  The 
released bacilli spread throughout the lungs, and onto other sites.  Consequently, the 
individual becomes contagious, and the bacilli are transmittable to other individuals.  
Secondary TB is usually symptomatic (Health Protection Agency 2012).  
 
1.5.4 Clinical Symptoms  
 
Symptoms can vary between individuals and can be very nonspecific.  Clinical 
manifestations vary by the severity and type of infection.  The common pulmonary strain 
of the disease causes a persistent cough (often containing blood in the spittle), fatigue, 
elevated temperature, loss of appetite, chest pain and weight loss (NHS 2011; NHS 2014).  
Miliary TB, being the most serious form, is found throughout the body and can cause 
leukaemia-like symptoms.  If the bacilli reach the bone marrow, the infected patient can 
become severely anaemic (NHS 2011).  TB pleuritis, identified by lymphocytosis in the 
pleural fluid, can be self-limiting whereas extrapulmonary forms of the disease can 
manifest in the brain, spine/joints (Pott’s disease) and skeleton, the latter giving an insight 
into the ubiquitous nature of TB (Crevel et al. 2002).  Depending on the location of 
infection, some patients suffer with haematuria and if the brain becomes infected in severe 
cases, seizures and psychosis. 
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1.6 Diagnosis of TB 
 
Rapid diagnosis of TB is vital; it prevents morbidity and decreases mortality rates 
(Boehme et al. 2011; WHO 2015b).  The tuberculin skin test (TST) or Mantoux test, is 
an easy and effective way of diagnosing TB (Yang et al. 2012).  The individual is injected 
with tuberculin purified protein derivative (PPD) into their forearm and are monitored for 
48-72 hours.  The level of induration is measured at the injection site, which directly 
relates to the diagnosis of TB.  The TST can be problematic in giving false-positives, as 
it can detect readings from other mycobacteria or even the BCG vaccination because PPD 
is prepared from the culture filtrate of Mtb containing many antigens which are 
homologous to vaccine strains of the BCG and non-tuberculosis mycobacteria (Higuchi 
et al. 2007; Yang et al. 2012).  It also requires skilled staff, which increases the costs of 
its use.    
Where the global burden of TB is greatest in the developing countries, diagnosis is mainly 
carried out by microscopic analysis of stained sputum smears for the identification of the 
acid-fast bacilli, with each diagnosis requiring three specimens per patient (Patino et al. 
2008).  Sputum smear microscopy is an inexpensive means with few technical 
requirements, yet it often misdiagnoses many infected patients (in extra pulmonary 
cases), allowing for disease progression and there are always problems associated with 
detection of MDR/XDR strains (Boehme et al. 2011; Patino et al. 2008).   
Conventional light microscopy uses carbol fuchsin Ziehl-Neelsen acid-fast stained 
smears.  The diagnostic tests’ sensitivity can depend on the quality/quantity of the 
specimen, and the quality of laboratory staff training (the process is labour intensive).  
However, this test is generally deemed highly specific and therefore particularly useful 
in global areas of high TB prevalence (Patino et al. 2008).  Fluorescence microscopy 
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using fluorochrome dyes has reported sensitivity 10% higher than direct sputum smear 
microscopy and hence it is regarded as more conclusive (Patino et al. 2008).  This means 
of testing however, has a greater financial burden related to the high costs of fluorescent 
staining dyes/microscopes.  Based on sensitivity, cultivation of the tubercle bacilli is the 
most sensitive means, detecting 100 bacilli per mL of sputum.  This is a slow and 
expensive process and unfortunately not commonly used in developing countries.  A more 
modern technique is the use of the light-emitting diode fluorescent microscopy (LED-
FM).  It is deemed to be cheaper as a mercury lamp is not required, it has less power 
requirements and it does not require a dark room (Bhadade et al. 2015).  
A real-time PCR assay; Xpert MTB/RIF®, has been developed to detect rifampicin (RIF 
[a first line TB antibiotic]) resistant strains of Mtb (Boehme et al. 2011).  This molecular 
diagnostic test developed by the GenXpert platform is highly recommended by WHO in 
cases where MDR TB strains are suspected or in HIV infected individuals.  WHO suggest 
that Xpert MTB/RIF® will offer a 3 fold increase in diagnosis in patients with MDR TB 
and a 2 fold increase in HIV infected patients (WHO Factsheet 2012).  WHO is currently 
endorsing the Xpert MTB/RIF® assay as a means of accurate diagnosis, with results being 
available as soon as 2 hours.  WHO reports that 69% of countries use it as the initial 
diagnosis test when patients are at risk of being MDR TB infected (WHO 2015b).   
Other methods of diagnosis have been investigated, such as the QuantiFERON®-TB Gold 
test (QFT-2G) which measures cellular immune response to Mtb specific proteins; early 
secreted antigenic target-6kDa (ESAT-6) and culture filtrate protein-10 kDa (CPF-10) 
which are encoded by the RD-1 region of Mtb genome (Ganguly et al. 2008).  Both 
ESAT-6 and CPF-10 are absent from all BCG strains, and most other non-tuberculosis 
mycobacteria (Higuchi et al. 2007).  It has been reported to show low levels of false-
positives, high specificity for Mtb and the diagnosis is unaffected by previous BCG 
vaccinations, thereby allowing its use in diagnosing LTBI (Higuchi et al. 2007).  QFT-
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2G uses whole blood samples for in vitro laboratory testing for IFN-γ presence through 
ELISA, which is secreted upon Mtb infection, however, the requirement of blood samples 
to be transported to laboratories allows room for contamination and as this test involves 
cell culture, the time taken in getting samples to a laboratory can be a problem.  
Additionally, more testing of the diagnosis is required on individuals infected with HIV.  
As aforementioned QFT-2G is able to detect LTBI, but it cannot differentiate between 
LTBI and active TB.  
Recommendations from the National MDR TB Task Force following an increase in drug 
resistant strains, state that drug susceptibility testing must be performed on all Mtb 
isolates collected from patients (Ardito et al. 2001).  This is mainly carried out in the 
liquid culture system BACTEC MGIT 960 (and the original BACTEC 460) (Becton, 
Dickinson and Company, USA) (Robbe-Austerman et al. 2013).  These systems detect 
acid-fast bacilli growth, differentiation and allows for susceptibility testing (this system 
is not Mtb specific and PCR is required to identify strains).   
The widely adopted MGIT (mycobacteria growth indicator tube) system is used for the 
detection and recovery of mycobacteria.  As growing Mtb utilise oxygen, the BACTEC 
MGIT 960 system records the level of oxygen depletion from the tube via fluorescence 
readings, thus indicating both mycobacterial presence and growth.  The BACTEC 460 
radiometric system works by supplying Mtb with radioactive labelled substrate that is 
utilised by the mycobacteria to produce 14CO2, detected in the system.  The level of 
14CO2 
produced is directly proportional to rate of bacterial growth.  The MGIT 960 is often 
referred as the world’s first automated drug testing system, by testing the antimicrobial 
susceptibility to SIRE (streptomycin [STR], INH, RIF, ethambutol [EMB] [and 
pyrazinamide [PZA]]) through use of a modified Middlebrook 7H9 broth in a tube, 
impregnated with a fluorescence quenching oxygen sensor on the test tube base (Ardito 
et al. 2001).  Results are available within 4-7 days, which cut previous waiting times by 
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weeks.  The BACTEC 460 system has been replaced the BACTEC MGIT 960 since 
becoming commercially available in 2002, although throughout the literature there are 
reports of higher contamination rates using this system (Robbe-Austerman et al. 2013).  
A recent report states that both systems (the MGIT 960 and Xpert MTB/RIF®) are 
imperfect at detecting MDR TB and that further investigation (e.g. gene sequencing) is 
required to confirm RIF resistance (Mokaddas et al. 2015). 
 
 
1.7 TB vaccine  
1.7.1 M. bovis bacillus Calmette-Guerin (BCG) vaccine 
 
Currently there is only one vaccine available against TB, the M. bovis-BCG vaccine, 
created in 1921 by Albert Calmette and Camille Guérin (Ohara 2012).  To create the 
vaccine, Calmette and Guérin subcultured a virulent strain of M. bovis collected from an 
infected cow.  Over 13 years and 230 passages later, the strain was no longer virulent and 
could be used as a vaccine in animal models (Ohara 2012).  The efficacy of the vaccine 
against adult pulmonary TB is debated throughout the literature, however, common 
agreement is made on its effectiveness at preventing childhood forms of TB, such as 
miliary and TB meningitis (Ohara 2012; Trunz et al. 2006). 
In the UK, the BCG was introduced in 1953, during a period where the incidents of TB 
were already on the decline due to the improved health services and standards of living, 
but it was decided to vaccinate all children.  However, this vaccination of school children 
was withdrawn from the NHS in 2005 (NHS 2012).  Vaccination is now based on risk 
assessment, depending on where the baby/child will be living and whether they are likely 
to visit high risk TB areas (NHS 2012).  
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Upon infection of Mtb, effective phagocyte activation can reduce the growth of the 
mycobacteria, but this requires an acquired specific cellular response which is the basis 
of vaccine development (Cooper 2009).   Unfortunately, the vaccination for tuberculosis 
has not improved since the introduction of the BCG, which is often not available in many 
high TB burden countries.  The BCG vaccine is not recommended in infants known to be 
infected with HIV due to; the risk of BCG disease, it is not always effective at preventing 
pulmonary TB in adults and its overall efficacy is questionable, ranging from 0 to >80% 
depending on the global region (WHO 2014b).  There are 2 main strategies in vaccine 
development; to develop a new vaccine to replace the BCG, or create a booster vaccine 
to accompany the BCG for use in adolescents and adults (WHO 2014b).  Vaccine 
development is expensive and slow especially when beginning human trials, but for the 
first time there has been a great surge in vaccine development with many (up to 15) 
reaching clinical trials (phase I-III), although nothing suitable has yet been developed this 
is a positive step (Montoya et al. 2013; Tameris et al. 2013; WHO 2014b).  
 
1.7.2 Vaccine development  
1.7.2.1 MVA85A 
 
A potential novel vaccine has recently been developed by Oxford University; modified 
Vaccinia Ankara virus.  It is an attenuated vaccinia virus-vectored vaccine expressing 
immunodominant Mtb antigen 85A (MVA85A) (Tameris et al. 2013).  Developed as a 
booster vaccine to accompany the BCG, Phase IIb clinical trials have been completed and 
results are published (WHO 2014b; Tameris et al. 2013).  Although it was well tolerated 
by infants, with few adverse side effects reported, it had no significant efficacy against 
Mtb and results overall were very disappointing (Tameris et al. 2013).  The results 
differed greatly from in vitro and animal trials, where the vaccine induced a great increase 
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in CD4 T-cells, which enhanced protection against Mtb.  It was found to enhance IFN-γ 
secreting T-cells significantly, particularly in infants who had been previously vaccinated 
with the BCG, and it has been suggested that this vaccine may be able to enhance the 
current BCG vaccine and be more suitable for adolescents rather than infants but clearly 
further work is required (Tameris et al. 2013).  
 
1.7.2.2 M72 +AS01E 
 
GlaxoSmithKline (GSK) and Aeras combined their efforts to create a protein subunit 
vaccine to enhance immunogenicity (Montoya et al. 2013).  ‘M72’ is an antigen, a 
recombinant fusion of 2 proteins expressed in Mtb, which induce IFN-γ production and 
‘AS01E’ is a liposome based Adjuvant System, which can activate the innate immune 
system to enhance the adaptive system, specifically inducing a strong T-cell mediated 
response.  Trials have been undertaken to determine dosages and tolerance (Phase IIb), 
no adverse side-effects were found and further trials are continuing (Montoya et al. 2013).  
 
1.7.2.3 M. vaccae 
 
Anhui Zhifei Longcom’s vaccine is currently in Phase III of clinical trials in China (WHO 
2014b) and is being investigated for preventing a diseased state in LTBI (WHO 2015b).  
M. vaccae is an environmental mycobacterium with a low pathogenicity to humans and 
it expresses antigens common to Mtb, thus a lysate of M. vaccae has been developed as a 
vaccine to modify host immune responses following infection.  It is the largest trial of its 
kind in over a decade with 10,000 people enrolled (WHO 2015b).  Further information is 
not yet available.  
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1.8 Current Treatments 
 
Before the discovery of STR in 1944, there was no effective treatment against Mtb 
infection.  STR, being the first antibiotic in the fight against TB, provided hope for a TB-
specific treatment.  It was administered intramuscularly and initially it was an effective 
treatment.  As resistant mutant strains of the disease persisted, treatments had to be 
increased and disease management now includes long-term administration of multiple 
antibiotics (four); a regime of drugs over a long time period, usually between 6 months 
and 2 years.  The WHO currently recommends the DOTs (directly observed treatment 
short-course) strategy for treating TB (Davies 2003; WHO 2015b).  This strategy has five 
distinct components, government commitment (political), detection by microscopy 
(sputum smear), adequate drug supplies, a standardised, monitored treatment and 
efficacious drug regimens supported by health professionals (Davies 2003).  The first 
phase of intensive treatment is 2 months (every day) of RIF, INH, EMB and PZA then a 
further 4 months (every day) of RIF and INH (Table 1.3) (NHS 2014) reducing the 
treatment period by 12 months.  This regime was designed 40 years ago and currently has 
a cure rate of approximately 90% in HIV-negative patients (WHO 2014b; WHO 2015b).  
There have been recent clinical trials to further reduce this period from 6 to 4 months, 
through the addition of a fluoroquinolone, yet this proved unsuccessful  (Gillespie et al. 
2014; Gninafon et al. 2014).   
As resistant mutant strains of the disease persist, treatments have had to be adapted and 
increased.  Therefore, disease management includes a regimen of second line drugs over 
a longer period, usually up to 2 years (Table 1.4).  Second-line TB treatments include the 
oral and/or injectable aminoglycosides and fluoroquinolones.  Such treatment plans are 
not possible to maintain in certain parts of the world, particularly sub-Saharan Africa, an 
area heavily burdened with TB infection (Russell 2011).  MDR TB strains which are 
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resistant to first line drugs RIF and INH, take over 20 months to treat and XDR TB strains 
which are resistant to first and second line drugs and at least one of the injectable drugs 
(amikacin, kanamycin, or capreomycin) are very complex to treat and often have high 
mortality rates (Green & Garneau-Tsodikova 2013).  Except for BDQ, Delamanid and 
Pretomanid (formally PA-824) (Table 1.5), drug development for TB is inadequate and 
due to the propensity of Mtb to develop resistance, treatment is difficult.   
There are a number of ‘prodrugs’ currently in use; these are substances that must be 
metabolically activated before they can effectively attack the TB causing pathogen.  The 
fundamental objectives in the development of novel TB drugs is to curtail the long 
treatment period, tackle the problem of drug resistance, provide safer treatments and 
eradicate the drug-drug interactions seen in patients with HIV/TB infections (Franzblau 
et al. 2012). 
A list of the first line drugs and their minimum inhibitory concentrations (MICs) are 
displayed in Table 1.3*.  Generally, MICs are defined as being the lowest concentration 
of drug that inhibits the measurable (≥99%) growth of an organism after incubation.  
Minimum bactericidal concentrations (MBCs) are the lowest concentration of drug 
required to kill an organism.   
*please note drug structures were obtained from manufacturer’s websites.  
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Table 1.3 First Line TB Drugs  
Drug Name/ 
Structure 
Minimum 
Inhibitory 
Concentrations 
Mechanism of Action(s) Further information 
Streptomycin (STR) 
 
 
0.5-2 µg/mL STR inhibits Mtb protein 
synthesis through binding the 
30S ribosomal subunit thus 
causing the misreading of the 
mRNA during translation.  
STR is an 
aminoglycoside 
antibiotic, the first used 
to treat TB.  It affects 
only replicating bacilli 
(Yajko et al. 1995a).  
 
Rifampicin (RIF) 
 
 
 
0.05-1 µg/mL 
 
RIF inhibits RNA synthesis of 
Mtb by binding the β subunit of 
the RNA polymerase thus 
preventing elongation of the 
RNA chain.  RIF is active against 
bacilli in both growth and 
stationary log phases. 
 
 
RIF is a bactericidal 
antibiotic, which is 
often termed the 
primary ‘backbone’ of 
TB treatment (Zhang & 
Yew 2009). 
 
 
 
Isoniazid (INH) 
 
 
0.02-0.2 µg/mL INH targets the InhA enzyme 
(enoyl-acyl carrier protein 
reductase) involved in mycolic 
acid synthesis, thus it affects the 
cell wall structure of Mtb.  It is 
active against bacilli in the 
growth log phase and is used in 
conjunction with other drugs. 
 
INH is a hydrophilic, 
bactericidal prodrug, 
hence it is administered 
in an inactive state 
requiring activation 
from a catalase-
peroxidise KatG, 
encoded by the katG 
gene in Mtb (Zhang & 
Yew 2009).   
 
Ethambutol (EMB) 
 
 
0.5-2 µg/mL EBM increases the Mtb cell wall 
permeability through inhibition 
of the arabinosyl transferase, thus 
inhibiting arabinogalactan (a 
structural component of the 
mycobacterial cell wall) 
synthesis.  
 
EMB is bacteriostatic 
affecting growing 
bacilli (Laurenzo & 
Mousa 2011).   
Pyrazinamide (PZA) 
 
 
 
16-50 µg/mL PZA works in an unusual manner 
against Mtb.  It is only effective 
in acidic pHs in anaerobic 
conditions during active 
inflammation and is not active 
against Mtb in ‘normal’ culture 
conditions at neutral pHs levels.  
PZA kills non-replicating bacilli 
which is the opposite to many 
antibiotics and it seems to disrupt 
the membrane potential of Mtb. 
PZA is a bactericidal 
prodrug, activated to 
pyrazinoic acid (POA) 
by the pyrazinamidase 
enzyme encoded by the 
pncA gene of Mtb and 
it is used in 
conjunction with INH 
and RIF (Zhang et al. 
2003; Zhang & Yew 
2009). 
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Table 1.4 Second Line TB Drugs 
Drug name/type 
Structure 
Mechanism of Action(s) Further information 
 
Ethionamide (ETH) 
 
 
 
ETH is both a bacteriostatic and 
bactericidal thioamide antibiotic prodrug 
activated by S-oxidation, which inhibits 
InhA thus preventing mycolic acid 
synthesis.  Its activity is therefore similar 
to that of INH and it is a derivative of 
isonicotinic acid (Zhang & Yew 2009; 
Laurenzo & Mousa 2011).  
 
 
 
As ETH shares the same 
target as INH, if drug 
resistance is found in 
one of these drugs, it is 
also found in the other 
(Laurenzo & Mousa 
2011). 
 
Metronidazole 
(MTZ) 
 
 
 
MTZ (specific for anaerobes) is a 
nitroimidazole and an antitubercular, 
which can kill dormant bacilli in 
hypoxic/anaerobic conditions.  MTZ 
inhibits DNA synthesis and causes DNA 
damage by oxidation, which leads to DNA 
degradation and cell death (Löfmark et al. 
2010).  
 
MTZ has been 
investigated as a 
treatment to prevent the 
reactivation of LTBI 
(Lin et al. 2012).  It is 
hoped it will be useful 
against MDR TB strains.  
Fluoroquinolones Fluoroquinolones are a group of anti-
bacterial drugs, which work by inhibiting 
the essential mycobacterial enzyme DNA 
gyrase encoded by gyrAB.  DNA gyrase is 
a type II topoisomerase that catalyzes the 
ATP-dependent negative super-coiling of 
double-stranded DNA and its inhibition 
results in microbial death.   
 
Includes ciprofloxacin, 
oxfloxacin, 
levofloxacin, 
gatifloxacin and 
moxifloxacin. 
Gatifloxacin and 
moxifloxacin in 
particular have become 
important in the 
treatment of MDR TB 
and appear to have 
minor/no side effects 
(Laurenzo & Mousa 
2011). 
 
Aminoglycosides Aminoglycosides are a group of 
antibiotics including STR, kanamycin, 
amikacin and capreomycin.  Kanamycin 
(and its derivative amikacin) prevent Mtb 
protein synthesis by modifying the 16S 
ribosome and capreomycin, a polypeptide 
bacteriostatic antibiotic commonly used to 
treat MDR TB, works in a similar means. 
Discovered in the 1940’s 
these drugs have had 
unprecedented use since.  
Although resistance is 
seen in some of these 
drugs, when used in 
combination they can be 
effective (Zhang & Yew 
2009).   
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Table 1.5 MDR TB Drugs 
Drug name/ 
           Structure  
Mechanism of Action(s) Further information 
 
Bedaquiline (BDQ) 
 
 
 
 
 
BDQ works by inhibiting the 
proton pump of Mtb 
adenonsine triphosphate 
(ATP) synthase, by binding 
to the oligomeric and 
proteolipic subunit C, which 
is essential for energy 
production. It is effective 
against bacilli in both the 
growth and stationary log 
phase. 
 
BDQ was approved by the FDA in 
late December 2012.  It was the first 
new anti-TB drug to be licensed for 
human use in over 40 years.  It must 
be used with cautioned as its safety 
is still under investigation (Goel 
2014).  Five time higher death rates 
(compared with placebo) in clinical 
trials have recently been observed 
(Gumbo, Angulo-Barturen, et al. 
2015).  
 
 
Delamanid (OPC-
67683) 
 
 
 
 
 
 
Pretomanid 
 
 
 
 
 
 
Delamanid affects cell wall 
components of Mtb by 
effecting mycolic acid 
synthesis. It is a prodrug, 
activated by cellular enzyme 
Rv3547. 
 
 
 
 
 
Mechanism of action is not 
well understood, but it 
requires activation and 
appears to inhibit protein and 
lipid synthesis (not nucleic 
acids) and generates ROS 
(Ginsberg et al. 2009). 
 
Currently undergoing Phase III 
clinical trials, it was granted 
conditional approval by the 
European Medicine Agency in 2013 
in certain medical cases (WHO 
2015b).  Its use in treating MDR TB 
in children is also ongoing (WHO 
2014b). There is hope it may be used 
in XDR TB strain treatment (Lee et 
al. 2015).  
 
 
Developed by the Global TB 
Alliance, it is being tested for drug 
susceptible and MDR TB strains 
(WHO 2015b).  MICs range from 
0.015-0.53 µg/mL.  
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1.9 The Antibiotic Apocalypse 
Through lack of availability and/or poor drug management, drug resistant strains of TB 
have emerged and are constantly developing new resistance to drug therapies (Minh et al. 
2012).  Drug resistance and MDR TB is an ever increasing problem in all areas of 
medicine and with the media reporting that an ‘Antibiotic Apocalypse’ is imminent, it is 
becoming of increasing public concern (BBC Health News 2013; WHO 2015b).  
However, this is often attributed to over-prescription of antibiotic drugs or through 
improper use, hence drug resistant TB can be described as a manmade phenomenon.  
MDR TB is present in nearly all countries surveyed, with approximately 480,000  cases 
worldwide in 2014 (WHO 2015b).  Such strains only respond to some specific drug lines, 
while XDR TB strains are often deemed untreatable (Smith 2011).   
MDR TB can be separated into 3 categories; primary resistance is a newly infected 
patient with a drug resistant strain of TB, acquired resistance is when a previously 
infected patient with a susceptible strain of Mtb eventually develops a MDR TB strain 
and mixed resistance terms cases where the patients treatment history is not known, thus 
making it impossible to determine whether the MDR TB strain was due to infection by a 
drug resistant strain or due to acquired resistance following drug therapy (Laurenzo & 
Mousa 2011).  
XDR TB strains have prevented successful eradication attempts by WHO and currently 
9% of MDR cases are reported to be XDR TB, a figure which is expected only to increase 
(WHO 2012; WHO 2013; WHO 2014b; WHO 2015b).  In 2014 there were 46,560 cases 
of XDR TB (Table 1.1) (WHO 2015b).  First-line TB treatments INH and RIF are 
ineffective on XDR TB strains and therefore patients require longer treatment time with 
more toxic drugs.  First line drug treatments in combination with other drugs and 
expensive fluoroquinolones along with one of the second line antibiotics; amikacin 
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(AMK), kanamycin (KAN) or capreomycin (CAP) are ineffective on XDR TB strains, 
for which there is no consensus on how to treat (Georghiou et al. 2012; Maartens & 
Wilkinson 2007).  Cases without treatment unfortunately have high mortality rates, and 
HIV positive patients are more susceptible to early development of the disease when 
infected (WHO 2015b).  In southern parts of Africa, the spread of HIV has caused a great 
increase in the number of TB cases; approximately 1.2 million of the TB cases (12% 
globally) were HIV positive and 390,000 people who died from TB in 2014 were HIV 
positive (WHO 2015b).  
 
1.9.1 Problems with current treatments  
 
Adverse effects from drug regimens are often problematic in treating any disease, but this 
is augmented when multiple drugs are administered over prolonged periods as in the 
treatment of TB.  As aforementioned, poor therapy, management and patient 
noncompliance can lead to complications and the adverse reactions to anti-TB drugs can 
cause significant problems.  There have been reports that the drug-drug interactions 
between RIF and INH can lead to severe liver damage (Makhlouf et al. 2008; Onoshita 
et al. 2010).  Infact hepatotoxicity has been linked to RIF, INH and PZA use, which is 
enhanced when these drugs are in combination.  Studies outline that up to 31% of patients 
following a first line anti-TB drug regime experienced drug related hepatotoxicity 
(Tostmann et al. 2008; Hassen Ali et al. 2013), so being a serious concern.  Other reported 
side effects from the use of RIF include gastro-intestinal problems, headache, acute retinal 
failure, menstrual disturbances, discolouration of body fluids and influenza-like 
symptoms. 
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There are an estimated 36.9 million people infected with HIV (WHO 2015a) and due to 
immunosuppression in these patients they are highly susceptible to contracting active TB 
and reactivation of LTBI, therefore, treatment regimes become complicated.  RIF induces 
the activity of the CYP3A enzyme system in the liver, this cytochrome metabolises most 
antiretroviral drugs, therefore decreasing the concentration of these drugs in the blood 
(Swaminathan & Narendran 2008).  As such, they cannot be used in conjunction. 
A recent review by Longo et al., discusses a major problem following initial treatment.  
After the first 2-month intensive phase, there are subpopulations of bacilli that respond 
differently to the drugs, as one is rapidly killed whereas the other is not (Longo et al. 
2015).  These surviving bacilli are known as persistent bacteria, or ‘persister’ cells (Longo 
et al. 2015).  Persister cells are subpopulations of tubercle bacilli that survive following 
antibiotic treatment (Zhang et al. 2012; Zhang 2014).  They are heterogeneous bacterial 
populations that can inhabit intra- and extracellular locations.  Persister cells are 
genetically identical to drug susceptible strains, but are capable of surviving, either in a 
non-replicating or slow replication state, but under the appropriate conditions, can regrow 
(Zhang et al. 2012).  These subpopulations are thought to be in a distinctly different 
metabolic state, or genetically or phenotypically different under host immune pressure 
which renders them less susceptible to antibiotics (Longo et al. 2015).  The authors then 
go onto explain that another reason for the poor killing of the persistent subpopulations 
is the poor absorption of some drugs, for example when drugs are taken alongside food, 
(RIF, INH and PZA) antibiotics levels are reduced (Longo et al. 2015).  Such phenomena 
are well defined by the ‘Yin-Yang’ TB model (section 1.9.2).  
 
 
  
39 
 
1.9.2 The Yin-Yang model 
 
Two Yin-Yang models have been proposed to explain the problems with bacillary 
response to drug treatment.  The first model is the persister/heterogeneous model and the 
second is on LTBI over active disease.  Model one is the Yin and Yang of persisters and 
replicating bacteria, illustrating a subpopulation of persisters (Yin) and a subpopulation 
of growing bacteria (Yang) (Fig 1.9).  This model is used to demonstrate why after initial 
treatment (2 months) of RIF, INH, PZA and EMB, Mtb can begin to grow again, but can 
be killed by further treatment in the continuing treatment regime (Zhang et al. 2012).  This 
model highlights the possible transition of latent persister cells to actively growing cells.  
Model two is the Yin and Yang of latent infection (Yin) and active, overt disease (Yang) 
(Fig 1.9).  Active disease states can vary, and following treatment/immune response, 
persister cells can remain and become latent (Zhang et al. 2012).  The latent persister cells 
can then go onto reactive disease.  The endurance of persister cells makes TB treatment 
immensely difficult.  Even with the appropriate treatment, an active diseased state can be 
reintroduced.  
 
 
 
 
 
a)                                                                               b) 
Figure 1.9 (a-b) The Yin-Yang models of (a) persisters and replicating bacteria and (b) 
latent infection (LITB) and overt disease. 
(adapted from Zhang et al., 2012) 
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1.9.3 Mechanisms of Mtb Drug Resistance  
 
The sporadic appearance of drug resistant strains of Mtb was an inevitable consequence 
of multi-drug therapy.  MDR and XDR TB phenotypes are acquired by a sequence of 
cumulative mutations in specific genes. 
RIF resistance is often deemed as an indicator of a MDR TB strain, as resistance to this 
drug is generally uncommon, but usually indicates resistance to both RIF and INH 
(Laurenzo & Mousa 2011).  RIF resistance is caused by the mutation(s) in the well-
defined 81 bp (21 codons) region of the rpoβ gene.  The rpoβ gene encodes the β subunit 
of the RNA polymerase; RIF’s main target.  The mutations in amino acids 507-533, the 
main cluster region (with mutations in 516, 526 and 531 being the most common) of the 
rpoβ gene are responsible for 95-97% of RIF resistant strains (Laurenzo & Mousa 2011; 
Zhang & Yew 2009; Somoskovi et al. 2001).  Strains with a mutation in codon S531L 
are particularly resistant and such strains are classed as having high level of drug 
resistance with resistance also to other drugs of the rifamycin family (Zhang & Yew 
2009).   
Mutations in different codons confer different levels of RIF resistance; 526 and 531 
mutations result in very high levels of resistance (MIC> 64 µg/mL) which total up to 86% 
of resistant strains, whereas mutations in codons 511, 516, 519 and 522 confer low levels 
of resistance (MIC<64 µg/mL) (Somoskovi et al. 2001).  It is reported that this 81 bp 
region of the genome is the main region searched for mutations, but that other areas may 
also have alterations, that may lead to MDR TB.  Heep et al., 2000 reported that mutations 
in the 59 region of the rpoβ gene could possibly lead to rifamycin resistance in Mtb, as it 
had in similar species.  Also three out of six Mtb species carried the V176F mutation 
conferring a high level of RIF resistance (Heep et al. 2000).   
  
41 
 
INH resistance is relatively common.  Strains resistant have lost the catalase-peroxidase 
KatG encoded by the katG gene in Mtb.  Mutations within katG are the main cause of 
resistance to INH, as the pro-drug is not activated, which are associated with high levels 
of resistance.  The KatG S315T mutation is the most common.  However, other mutations 
resulting in the over-expression of InhA or mutations effecting the InhA active site, have 
lowered the affinity to INH, are also responsible for resistance (Zhang & Yew 2009).  
Strains with mutations in the inhA gene are generally deemed to have low levels of 
resistance, but commonly also have resistance to EMB. 
EMB like INH is a pro-drug requiring activation, thus mutations leading to resistance are 
found mainly in the ethA, inhA, embB genes (particularly codon 306 of the embB gene) 
which effect the drug’s activation, or through the increased production of arabinosyl 
transferase which overwhelms the drug (Bakuła et al. 2013).  As much as 4% of all Mtb 
clinical isolates tested displayed resistance to EMB, thus it is relatively common.  The 
concurrent persistence of resistance between INH and EMB has been reported to be as 
high as 96.6% (Madison et al. 2002), yet overall there is scarce literature on EMB 
resistance and mechanisms.  
PZA resistance occurs though mutations in the pncA gene that encodes the 
pyrazinamidase enzyme, which allows activation of this pro-drug (da Silva & Palomino 
2011).  Mutations include deletions throughout the 561bp of the pncA gene, similar to the 
mutations in the rpoβ gene in RIF resistance (Degano et al. 2014).  
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Table 1.6 Some main factors influencing the development of MDR/XDR TB and treatment 
problems 
(created using Kato-Maeda et al. 2001, WHO 2014 & 2015b, Russell et al. 2010) 
 
Factors Reasons  
 
1. Patient non-
compliance 
 
 Not completing full prescriptions 
 Drug side-effects 
 Selling of prescription drugs to others 
 Myths/perceptions of TB/TB treatments 
 Financial 
 Time required off work/school 
 
2. Medical profession 
errors 
 Wrong dosing 
 Wrong drug prescription 
 Failure to detect MDR/XDR 
 
3. Genetic 
 
 
4. Persister cells                                        
 Mutations 
 Gene transfer 
 
 Re-growth of cells following treatment 
 Re-activation of disease  
 
5. Other  Lack of funding 
 Inadequate storage facilities for drugs 
 Drug addiction/alcoholism  
 Drug supply shortage  
 Financial  
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1.10 Mycobacterium avium subsp. paratuberculosis  
 
Mycobacterium avium. subsp paratuberculosis (Map) is an infectious mycobacterium 
principally of ruminants, which causes paratuberculosis or Johne’s disease, a chronic 
granulomatous enteritis resulting in diarrhoea, anorexia and eventually death (Hermon-
Taylor 2009; Zhang et al. 2015) yet only 3-10% of animals are asymptomatic (Hughes et 
al. 2007).  Map is a slow growing (over 20 hours doubling time), acid-fast pathogen of 
0.5-1.5 µM and infects its host primarily through the faecal-oral route, through the 
ingestion of contaminated faeces, feed, water and/or milk (Cocito et al. 1994).  Like Mtb, 
experiment studies show that Map is found in intestinal macrophages soon after infection 
via the orofecal route.  Map is shed from infected animals in faeces and milk where it can 
survive in the environment for prolonged periods of time (Zhang et al. 2015). 
Map has been studied extensively due to its prevalence among many animal species, 
particularly dairy and beef cows, goats and sheep.  There is currently no effective 
treatment for the disease.  Antibiotics used for treating TB can be utilised but this is not 
advisable for animals destined for the food chain therefore treatment is used for valuable 
animals such as zoo specimens or rare breeds.  Control measures are practised such as 
vaccination, the testing and culling of infected animals and management procedures to 
reduce exposure to infected animals or a contaminated environment (Beard et al. 2001).   
Younger animals are more susceptible to infection than older, however the disease 
displays no clinical signs until over 2 years of incubation within the infected host (Beard 
et al. 2001).  As ruminants shed live Map in their faeces and milk, the spreading of 
infection among farm animals has become a great problem, particularly when these 
animals are in the dairy and food production chain (Beard et al. 2001).  Johne’s disease 
creates a major financial burden on livestock producers in terms of reduced milk 
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production and high infection rates.  Infected animals, at the clinical stage, produce 19.5% 
less milk than those uninfected (Benedictus et al. 1987).  
 
1.10.1 Aetiology of Johne’s disease 
 
Johne’s disease was first identified over 100 years ago by Johne and Frothingham, 1895, 
who recognised a connection between cattle enteritis and accumulation of acid-fast 
microorganisms in the intestine (Cocito et al. 1994).  Johne’s disease was originally 
believed to be caused by an intestinal mycobacterial infection (which caused TB in birds 
[later called M. avium]), but Twort and Ingram, 1912 isolated and recognised Map as the 
causative agent thus providing the aetiology.   
 
1.10.2 Diagnosis of Johne’s disease 
 
Infection can be detected by measuring an animal’s immune response and these tests are 
relatively quick (Burrells et al. 1998; Waters et al. 2003).  Screening processes for the 
detection of the bacteria are slow however, with Map taking 6-8 weeks to culture in liquid 
broth and up to 16 weeks on agar (Behr & Collins 2010).  Faecal culture offers high levels 
of sensitivity, and is considered the gold-standard for diagnosis, but it is a slow and highly 
expensive process requiring medium additives such as mycobactin J, and hence not ideal 
for high throughput (Stevenson & Sharp 1997).  Faecal smears are used to detect Map 
infection through staining, however this is highly dependent upon the number of 
organisms present and thus the disease stage the infected animal is at, so overall this 
means is not deemed reliable for early diagnosis.  The widely used ELISA assay is 
regarded as a rapid technique in detecting antibodies in sera or milk yet displays low 
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sensitivity and specificity in early stages of the disease (Behr & Collins 2010).  As ELISA 
offers a quick diagnosis, this is the preferred method for herd screening.  
 
1.10.4 Crohn’s disease  
 
Whether Map is a zoonotic agent or not, is still under investigation, but as Crohn’s disease 
has no known aetiology, Map has been suggested as a possible aetiological agent.  There 
are many pathological similarities between Johne’s disease and Crohn’s disease (Beard 
et al. 2001; Li et al. 2005; Sartor 2005).  Crohn’s disease is a chronic inflammatory 
intestinal disease which displays lesions from the mouth to the anus of humans (along the 
gastrointestinal tract), and is described as being episodic (Chacon et al. 2004).  Evidence 
whether Map is the causative agent or not is contradictory, but the hypothesis dates back 
to almost one century ago (Dalziel 1913; Sartor 2005).  Symptoms in both Johne’s and 
Crohn’s disease are clinically analogous, with the infected suffering from chronic 
diarrhoea, excessive weight loss and eventually death if left untreated.  Crohn’s disease 
currently has no known cure; courses of antibiotic drugs are available yet relapses of the 
diseased state do frequently occur (Behr & Collins 2010). Experimental evidence 
confirms that Map infects many different hosts and causes a diseased state in ruminants, 
camelids, rabbits and hares, hence another possible link of Map to humans.  However, 
Map is rarely visualised using Ziehl-Neelsen staining in the tissues of Crohn’s disease 
patients and the number of human Map isolates grown in pure culture in epidemiological 
studies have been low, suggesting that disease caused by Map in humans is uncommon 
(Behr & Collins 2010).  Yet many studies report that Map DNA has been detected in 
many Crohn’s patients (Kirkwood et al. 2009; Sechi et al. 2005; Zhang et al. 2015) and it 
has been cultured from the breast milk of Crohn’s sufferers (Naser et al. 2000).  
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Additionally, a recent study reported that M. avium subsp. hominissuis was successfully 
cultured from a Crohn’s patient, this being a very close member to Map in the MAC 
(Zhang et al. 2015).   As viable Map has been detected in commercially sold pasteurised 
milk, it seems reasonable that the human population is exposed to Map (Ellingson et al. 
2005; Kirkwood et al. 2009; Botsaris et al. 2016).  It is a very controversial topic in the 
literature, yet overall data seems to be more in favour of Map being pathogenic to some 
humans than not (Kuenstner et al. 2015; Hermon-Taylor 2009; Kuenstner 2006; Cohen 
2005; Zanetti et al. 2006; Botsaris et al. 2016).  
 
1.10.5 Map K10 strain 
 
Map is particularly homologous to M. avium subsp. avium (Maa), M. avium subsp. 
hominissuis and M. avium subsp. silvaticum (Mas) at the genetic level (Li et al. 2005), 
however, Map is structurally comparable to Mtb, with a very similar cell envelope.  The 
Map strain K10 was isolated from a clinically affected American dairy cow and the 
genome was sequenced by Li et al 2005 (Li et al. 2005).  The strain has been successfully 
subjected to genetic manipulation and a reporter strain transformed with the Green 
Fluorescent Protein (GFP) marker is available (Map K10/GFP) (Harris et al. 2002b).  Map 
K10 has a circular sequence of 4,829,781 bp with a very high G and C content of 
approximately 69.3% and 4300 genes (Li et al. 2005).  Mtb (laboratory strain H37Rv) has 
a circular sequence of 4,411,529 bp with approximately 67% G and C content and 4000 
genes (Smith 2003).  Map (K10) and Mtb (H37Rv) both have 1 rRNA operon, 45 tRNAs 
and > 3000 homologous genes (Li et al. 2005).  Additionally, Map is known to be 
particularly heat resistant compared to other mycobacteria, as well as resistant to many 
chemicals, akin to Mtb. 
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Map K10/GFP was used as a surrogate organism in this project as it is representative of 
the slow growing pathogenic mycobacteria for which survival within macrophages is a 
hallmark trait, akin to Mtb, and is very similar at the structural and genetic level (Hostetter 
et al. 2002; Tan et al. 2013; Plain et al. 2011; Li et al. 2005).  It is also resistant to a broad 
spectrum of antibiotic drugs similar to Mtb.   
 
1.11 Nanotechnology  
 
Nanotechnology holds great promise to improve human health and is predicted to 
significantly benefit all of human society (Etheridge et al. 2013).  The ability to create 
nano-scaled materials has allowed advancements  in medicines, targeted drug delivery, 
diagnostic tools as well as offering a novel set of anti-microbial agents (Byrne et al. 2011).  
Nanomaterials (NMs) are natural or manufactured particles with one or more external 
dimensions between 1-100 nm while nanoparticles (NPs) have three dimensions in the 
nano-scale (European Commission 2015 retrieved from 
(http://ec.europa.eu/health/scientific_committees/opinions_layman/nanomaterials2012/e
n/glossary/mno/nanoparticle.htm on 11/11/15).  NMs often exhibit novel properties that 
differ from the larger forms of the bulk material, and these novel properties are exploited 
in diverse applications (Albrecht et al. 2006).  NPs can be made from many materials 
such as metals, organic molecules etc., and with varying physical characteristics such as 
size, morphology, charge or surface chemistry.  A categorisation scheme for NPs based 
on their chemical composition e.g. metals (e.g. gold), metal oxides (e.g. silicon dioxide), 
carbon based materials (e.g. carbon nanotubes) and organics (e.g. polymers) has recently 
been discussed by the Organisation for Economic Co-operation and Development 
(OECD) working party on manufactured nanomaterials (OECD 2015, retrieved from 
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http://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-
tsca/meeting-materials-oecd-expert on 10/10/15).   
Nanotechnology is applied to many disciplines including engineering, medicine, 
electronics and alternative energy research (Oberdörster et al. 2007) and NPs are found 
within an array of products, from toothpastes, wound dressings and paints, to applications 
in the treatment of diseases (section 1.10.1).  Their exploitation in many areas allows for 
pioneering developments within each field.  NPs can be created to interact with 
cells/tissues at the molecular level, thus allowing their breakthrough into the medical 
industry (Navalakhe & Nandedkar 2007).  Exploitation of nanomedicine in a clinical 
setting is expected to be diverse and this area of research is very exciting.  For example, 
the anti-microbial properties of some NPs are well established so they can be exploited 
in many areas of medicine (e.g. use in wound dressings, plasters, coatings on surgical 
equipment) (Zinjarde 2012).  NPs can also be used as delivery systems for therapeutics 
and/or diagnostics (Pandey & Khuller 2006; Liu et al. 2007). 
 
1.11.1 Nanomedicine 
 
The European Technology Platform on Nanomedicine (ETPN) gives the following 
definition for nanomedicine “…Nanomedicine is the application of nanotechnology to 
achieve innovation in healthcare… It exploits the improved and often novel physical, 
chemical, and biological properties of materials at the nanometric scale… nanomedicine 
has the potential to enable early detection and prevention and to drastically improve 
diagnosis, treatment and follow-up of many diseases…” (ETPN 2015 retrieved from 
http://www.etp-nanomedicine.eu/public/about-nanomedicine/what-is-nanomedicine on 
26/01/16).   
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Studies investigating the uses of NPs in medicine are becoming hugely popular, 
evidenced by the dedication of journals to nanomedicine and nanotoxicology, and the 
increased prevalence of international conferences focusing on this topic.  Some of the 
benefits (and risks) offered by nanomedicine will be discussed.  
Research into the use of NPs in medicine is predominantly focused around cancer and 
their use as drug carriers to treat and diagnose diseases.  Nano-devices (e.g. nanowires 
and cantilevers), nanocrystals, dendrimers and nanoshells are nanomedicine structures 
that are becoming more customary in medical research (Navalakhe & Nandedkar 2007).  
As of 2013 there were 32 FDA approved nanomedicines available on the market and 
many different nano-devices available (Etheridge et al. 2013) this number is thought to 
now be over 50 (McDonald et al. 2015) with 70 currently undergoing clinical trials (ETP 
2015).   
There are currently 4 main types of nanomedicine; nanocarriers (e.g. liposomes), polymer 
therapeutics (e.g. polymer-drug conjugates), solid drug nanoparticles (SDNs [e.g. 
nanocrystals]) (Fig 1.10) and NPs themselves (e.g. metal NPs for magnetic resonance 
imaging [MRI]) (Busquets et al. 2015; Niemirowicz et al. 2012; McDonald et al. 2015).  
By encapsulating drugs either in NPs or by adhering them to NP surfaces, nanocarriers 
are utilised to transport drugs.  Through the conjugation of water-soluble polymers and 
drugs, polymer therapeutics are achieved.  Upon degradation of the joining bond between 
the polymer and drug, the drug is released, ideally in a target site, which offers controlled 
release.  SDNs are a novel development in nanomedicine (McDonald et al. 2014).  These 
are simply NPs of solid drug (Fig 1.10), often stabilised by polymers and will be further 
discussed in Chapter 5.  
There are many advantages to using nanomedicine for therapeutic uses.  A main 
advantage is the possibility of lowering the drug dose administered to patients, thus 
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causing fewer side effects and possibly reducing the treatment time.  This is achieved 
through improved targeting of the NP (e.g. nanocarrier/SDNs) to the required target site, 
therefore enhancing the drug concentration at specific sites while decreasing delivery to 
non-target sites (Byrne et al. 2011).  Targeting (which can be active or passive) can be 
achieved by modifying NP surfaces with polymers and/or through bio-conjugation of 
antibodies and specific ligands.  This can prevent NPs binding with non-specific blood 
components and targets them to specific receptors (McCarron et al. 2008; Kamaly et al. 
2012a).  This can also increase the blood circulation time of nanomedicines which may 
be achieved by reducing the phagocytic clearance of a drug (Kamaly et al. 2012b).  
Polyethylene glycol (PEG) is a polymer and when added to the surface of NPs, renders 
the NP hydrophilic.  This addition reduces reticuloendothelial system uptake of NPs (e.g. 
liver, spleen), thus allowing it to stay in circulation longer (Jokerst et al. 2011).  PEG is 
also reported to reduce to the formation of aggregates (Jokerst et al. 2011).  Additionally 
if drugs are encapsulated by NPs (e.g. liposomes), they can be protected from enzymatic 
degradation (e.g. in the blood) and this could also improve drug stability.  Nanocarriers 
can be designed to control drug release (e.g. some carriers will only release drugs at a 
certain pH) possibly further enhancing drug absorption at specific sites (McDonald et al. 
2015). 
NPs can aid in early diagnosis, which can be paramount in many diseases to lower 
mortality rates (Niemirowicz et al. 2012; Choudhary & Kusum Devi 2015; Cheon et al. 
2016).  For example, quantum dots (QDs [semiconductor devices]) are NPs which can be 
designed with specific antibodies on their surface that have been utilised to detect cancer 
biomarkers (e.g. in blood or tissue samples) via fluorescence (Farias et al. 2009).  This 
breakthrough has been very advantageous for cancer diagnostics, where due to metastasis 
early diagnosis is paramount.  QDs have been shown to be highly specific, accurate and 
sensitive at detecting cancer cells during early tumour formation where conventional 
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methods are not (Pericleous et al. 2012).  This also offers a direct financial benefit, as 
early disease diagnosis often means less treatment time, less medication requirement and 
therefore a better overall prognosis.   
Drugs can be administered (pulmonary, intestinal, subcutaneous and intravenous) and 
transported into the blood from the exposure site.  Some nanomedicines can pass through 
the blood brain barrier (BBB), fine capillary blood vessels and offer improved drug 
uptake across other barriers (e.g. lung and intestinal) (Onoue et al. 2014; De Jong & Borm 
2008).  This advantage provides alternative routes of drug delivery and allows the drug 
to avoid pathways where it may be lost or reduced (e.g. acid digestion in the stomach).  
There are effective barriers (e.g. epithelial) designed to prevent the entry of foreign 
particles/substances into the human body, cells and organs.  Such barriers can prevent 
optimal drug delivery and concentration reaching target sites.   
NPs have a large surface area relative to their volume, and their size is comparable to 
intracellular macromolecules and organelles such as proteins and DNA.  Their small size 
allows nanomedicines to interact with targets on cell surfaces and internally (Navalakhe 
& Nandedkar 2007).  Macrophages uptake and phagocytose smaller entities more readily 
than larger forms of the same material (Clift et al. 2008).  Therefore, if drugs are in the 
nano-form this could be advantageous in treating some diseases where bacteria reside in 
immune cells (e.g. TB) or in cancer treatments where its reported that liposomes <130 
nm have a higher level of selectivity and tumour accumulation over larger liposomes 
(Meerovich et al. 2008).  This is a phenomenon of the ‘enhanced permeability and 
retention’ (EPR) effect, another means of targeting NPs to specific sites (size dependent).  
Additionally, in the nano-form, drug bioavailability can be increased due to the relatively 
high surface area available allowing for higher local concentration as illustrated in Figure 
1.10.  
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Figure 1.10 Schematic diagram of a ‘native’ drug compared to a nanomedicine passing 
through a barrier.  As illustrated, in the nano-form there is increased bioavailability.  The 
passing (diffusion or transcytosis or endocytosis etc) through a barrier (e.g. the gut wall, BBB, 
capillaries) is likely enhanced when in the nano-form.  
 
 
 
In the design stages of nanomedicines, particle size, shape and surface chemistry is highly 
important to allow for effective delivery and targeting (Byrne et al. 2011; Perry et al. 
2011).  There are various methods to construct nanomedicines (e.g. PRINT, nanomilling, 
emulsion templated freeze drying) (Perry et al. 2011; Mcdonald et al. 2014).  Nanomilling 
works by adding powered drug in water (containing stabilisers) to a milling chamber 
where shear forces reduce the powered drug (with adhered stabilisers) to SDNs.  Although 
well established, this technique has reportedly low drug loading ability for single SDNs 
(rarely > 25%) (McDonald et al. 2014).  Emulsion templated freeze-drying is a similar 
technique which can also be employed to create SDNs and it was this method that the 
SDNs utilised in this project were created (Chapter 5).  
 
1.11.2 Health Implications of NPs 
 
The toxicology literature provides evidence that there are potential health risks associated 
with exposure to some types of NPs (Kermanizadeh et al. 2014; Fernández-Cruz et al. 
2012; Song et al. 2009; Christensen et al. 2010; Johnston et al. 2015; Johnston et al. 2012; 
Chen et al. 2011; Onoue et al. 2014).  Therefore, prior to use in products (e.g. foods and 
e.g. gut wall 
Native Drug 
Nanomedicine  
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medicines) the hazards must be evaluated (Johnston et al. 2012; Semete et al. 2010; Song 
et al. 2009; Onoue et al. 2014).  Much of the evidence available, is indicative that the 
unique properties of NPs (which make them useful in some fields) also renders them more 
harmful to humans (Bondarenko et al. 2013a).  NP physico-chemical properties are 
different to their bulk counterparts and as such investigations into the toxicology of NPs 
is an important area of research.  The USA and EU are therefore urgently seeking the 
health and safety status of NPs to be established.  Although NPs may be more suitable at 
targeting desired cells, organs (e.g. liver) or organisms (e.g. bacteria) their effects on non-
target cells, organs or organisms may be detrimental.    
The risk (i.e. probability of causing an adverse health effect) of a NP is founded on the  
level of exposure, the toxicity of the NP and exposure route (Kermanizadeh et al. 2014).  
Following exposure to NPs (e.g. oral [intestine], inhalation [lung], dermatological [skin]), 
it is possible for the NP to induce toxicity at the exposure site (local toxicity) and 
secondary target sites (systemic toxicity)  (Johnston et al. 2012).  (Johnston et al. 2012).  
Only a small proportion of NPs can cross lung, skin and intestinal barriers (Vandebriel & 
De Jong 2012; Jachak et al. 2012).  However, bio-distribution studies have identified that 
the liver is a primary site of NP accumulation, regardless of exposure route 
(Kermanizadeh et al. 2014).  Hazard studies therefore need to assess NP toxicity at a 
range of target sites.  The mode of action of NP toxicity has not been extensively 
investigated.  However, the main toxic effects observed from NP exposure include 
oxidative stress, inflammation, ROS production, carcinogenicity and genotoxicity 
(Johnston et al. 2015; Li et al. 2008; Kermanizadeh et al. 2012; Kermanizadeh et al. 2014; 
Gaiser et al. 2013).  The relationship between NP physico-chemical properties and their 
toxicity has been investigated.  Size (and surface area), shape, charge, crystallinity, 
surface modifications, and aggregation/agglomeration status, are all characteristics that 
play significant roles in influencing toxicity (Warheit et al. 2009).  The large surface area 
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of small NPs is assumed to mediate the formation of free radicals that consequently leads 
to a signally cascade involving many factors which drives oxidative stress, thus ultimately 
triggering an inflammatory response (Byrne & Baugh 2008; Johnston et al. 2015).  The 
large surface area provides a large surface over which ROS can be produced as at small 
sizes the curvature of the NP surface is high therefore there is limited space available for 
electrons to form stable bonds between atoms within the particle structure, making the 
bonds more reactive, hence the surface reactivity.   
The exposure route is important to consider for NP toxicology studies.  As with the 
disastrous effects following asbestos (micron scale fibres) exposure to the lungs, 
inhalation is one of the main routes for the entry of NPs and once inhaled they are 
deposited in the lungs.  Like most foreign bodies, NPs are likely to be engulfed by alveolar 
macrophages (Geiser 2010).  Studies have revealed that exposure to some NPs (e.g. 
Cu(II)O or ZnO NPs), over certain time points (e.g. 1 day), doses (e.g. 5 mg/kg) and size 
(e.g. < 50 nm), caused chronic lesions and inflammation in the lungs (inflammation is 
generally characterised by increased cytokine/chemokine production) and prolonged 
exposure to the NPs increased the risk of pulmonary infection (Sandhya et al. 2013; 
Gantedia et al. 2012).  The transport of NPs across the lung epithelium is still under 
investigation, but the literature provides evidence for trafficking via endocytosis and by 
other means (Elsaesser & Howard 2012).  Choi et al., found that organic NPs < 34 nm 
were rapidly translocated from the lung to the kidneys via the bloodstream in vivo (Choi 
et al. 2010) and Geiser et al., reported the uptake and clearance of titanium dioxide (TiO2) 
NPs by lung phagocytes which was said to be ‘sporadic’ and unspecific (Geiser et al. 
2008).  Yacobi et al., reported translocation of NPs, but not via the usual endocytic 
pathways, but by possible diffusion through plasma membranes (Yacobi et al. 2010).  As 
it is assumed that NPs can be trafficked from origin sites, this increases the requirement 
to recognise the potential toxicity these NPs may have following inhalation/ingestion, on 
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sites such as the liver or brain.  Investigations into the effects of NPs on hepatocytes (the 
major cellular component of the liver) has demonstrated that both silver and zinc oxide 
NPs increased pro-inflammatory cytokine production using a human cell line (C3A) 
(Kermanizadeh et al. 2012).  The route of administration and the size of the NPs were 
important factors in toxicity, with intravenous administration and smaller NPs producing 
adverse effects (Kermanizadeh et al. 2014).  
Song et al., reported a human case study where healthy females contracted progressive 
lung fibrosis following exposure to a spray paint.  Upon analysis of the paint as well as 
the chest fluid of the patients, 30 nm diameter NPs were detected (Song et al. 2009).  By 
use of specialised microscopy techniques, aggregates of NPs were revealed in the 
cytoplasm of epithelial and mesothelial cells and the authors believe this lead to malignant 
tumour formation and various other disorders.  The authors concluded that as these results 
were similar to controlled in vivo animal experiments, it was very likely that the NPs in 
the paint caused this advanced diseased state in the females over a very short period of 
time (5-13 months), where 2 out of 7 patients died within 21 months from symptoms 
onset (Song et al. 2009).  Although these were industrial NPs, it warrants great concern 
and this appears to be the first documented case on human fatalities following NP 
exposure.  However, there are serious problems with this report and although there is 
compromising evidence suggesting the NPs were the causative agents, the authors were 
unable to offer specific information on the NPs, or on exposures the women may have 
had to other toxic chemicals (either in the work place or at home).  No characterisation 
or chemical analysis on the NPs was performed, thus highlighting many flaws in the study 
design.  
It is widely accepted that smaller NPs exert greater toxicity (Donaldson et al. 1998; Ferin 
et al. 2009; Kermanizadeh et al. 2014).  Which concurs with reports that exposure to 
smaller NPs (<50 nm) exerts a greater inflammatory response than exposure to larger 
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particles (200 nm) (Byrne & Baugh 2008; Donaldson et al. 1998; Ferin et al. 1992).  
Actually, most of the literature on the toxicity of NPs has data that strongly advocates NP 
exposure can cause an inflammatory response in both in vivo and in vitro settings.  Going 
back nearly 25 years, Ferin et al., reported that when rats were exposed (via inhalation) 
to ‘ultrafine’ (<21 nm) or ‘fine’ (250 nm) TiO2 NPs, the smaller NPs were found to 
translocate across the pulmonary interstitium more readily and were retained in the lungs 
for longer periods of time compared with the larger NPs.  The NPs caused an acute 
inflammatory response indicated by an increase in polymorphonuclear leukocytes (Ferin 
et al. 1992).  Johnston et al., reported that silver NPs (< 50 nm) induced production of 
pro-inflammatory cytokines following exposure (4-24 hours at 7-15 µg/mL) to 
neutrophil-like cells, eventually leading to apoptosis (Johnston et al. 2015).  Cha et al., 
demonstrated that when silver NPs were fed to mice over 3 days, there was a strong 
inflammatory response in the livers (lymphocyte infiltration).  Using microarray analysis, 
the authors detected changes in gene expression of genes directly related to apoptosis and 
inflammation, supporting their initial conclusions (Cha et al. 2008).  As well as 
occupational exposure to NPs (as with the case study outlined), combustion derived NPs 
exist in the atmosphere (e.g. diesel NPs) and in vivo studies have shown them to cause 
inflammatory and fibrotic events  in the lungs (Tran et al. 2000). 
The use of poly (lactide-co-glycolide) acid (PLGA) polymer NPs as drug delivery 
systems is very popular in nanomedicine (McCarron et al. 2008; Semete et al. 2010; 
Panyam et al. 2002; Dube et al. 2013; Onoshita et al. 2010).  PLGA are biodegradable 
polymers, particularly attractive as they are FDA approved for clinical use in humans, 
they convey very low toxicity and due to the ability to modify surface properties they 
offer enhanced interaction with biological materials (Onoshita et al. 2010).  Using PLGA, 
drugs can be delivered to specific sites, where the polymer can degrade intracellularly 
thereby releasing the drug(s) (Kalluru et al. 2013).  Although PLGA polymers are FDA 
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approved, their use as nanocarriers required investigation.  A study investigated the 
toxicity exerted by PLGA NPs compared to industrial NPs in vitro and in vivo.  The 
authors reported that PLGA NPs had no cytotoxic effect on both human colorectal 
carcinoma and epithelial carcinoma cells lines (Semete et al. 2010).  However, following 
7 days of ingestion of NPs in vivo (mice) tissue distribution tests were carried out and 
40% of PLGA NPs were detected in liver, 25% in the kidney, 11% in the heart and 3% 
in the brain (Semete et al. 2010).  Although the authors report no cytotoxicity from in 
vitro tests on two cell lines, caution must be exercised from these results.  For example, 
there was no investigation into whether there was an inflammatory response and it 
demonstrated that PLGA NPs can cross the BBB efficiently, which is advantageous when 
considering drug transportation to sites in the brain (e.g. for some chemotherapies), yet 
this may also have harmful consequences, especially if aggregates were to form.  If 
aggregates formed, the drug may not be able to be cleared or metabolised thus preventing 
efficiently drug delivery.  Additionally, the formation of aggregates of drug-loaded 
carriers in organs could have serious consequences, possibly leading to an inflammatory 
response. 
Overall, there are many desirable characteristics associated with the use of NPs in 
consumer products and medicines, but in spite of these traits, due to the possibility of 
inducing oxidative stress and genetic damage, their use for clinical applications should 
be thoroughly investigated. 
 
1.12 NPs and TB: current literature review 
 
The antimicrobial properties of NPs are well documented (Ansari et al. 2011; Sharma et 
al. 2009; Ren et al. 2009; Neyrolles et al. 2013; Azam, Ahmed, M. Oves, et al. 2012; 
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Islam et al. 2013; Rai et al. 2009), hence it is logical to hypothesise that they may have 
anti-mycobacterial properties also.  The mechanisms by which they exert antimicrobial 
properties are discussed in depth in the following chapters (4 and 5).  Delivering an 
effective concentration of anti-TB drugs to sites where Mtb resides in the immune cells, 
deep within the lungs, is a huge feat, as often drugs dissolve rapidly and are absorbed by 
the blood (Mizoe et al. 2008).  Cells take up molecules/particles through phagocytosis 
and pinocytosis: ‘cell drinking’, processes generally defined as endocytosis.  By 
engulfing NPs, particularly in the case of macrophages where Mtb resides, the particles 
may be co-localised with the microorganism.  This would allow for very accurate 
targeting, for both anti-microbial NPs, as well as drug delivery.  Furthermore, it is 
accepted that smaller NPs are efficient at crossing epithelial barriers following oral 
administration, hence the branching of nanotechnology into TB research (Hussain et al. 
2001).  As such, nanomedicine has led to an original path of research undertaken within 
the therapeutic field of TB.  
Recent literature on using nanomedicines to target TB is predominantly based on the use 
of polymers or liposomes with drugs such as RIF (Ohashi et al. 2009; Aboutaleb et al. 
2012; Raj et al. 2012; Chuan et al. 2013; Pandey & Khuller 2006; Pandey & Khuller 
2005; Dube et al. 2013; Hirota et al. 2010).  Studies have highlighted the possibilities of 
encapsulating anti-TB drugs within biodegradable polymer NPs thus offering assistance 
in increasing the concentration of drugs at specific sites (e.g. infected macrophages) 
through targeting.  NPs containing anti-TB drugs are usually made from biodegradable 
materials (e.g alginate or solid lipids) and most TB research focuses on the use of PLGA 
synthetic polymers (Gelperina et al. 2005; Onoshita et al. 2010; Ohashi et al. 2009; Hirota 
et al. 2010; Kalluru et al. 2013).  Hirota et al., carried out a study to determine the uptake 
and cytotoxicity of PLGA microspheres (MS) loaded with RIF on NR8383 cells derived 
from rat alveolar macrophages (Hirota et al. 2010).  It was determined that RIF PLGA 
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MS had little/no cytotoxicity against the NR8383 cells (at 5 µg/mL for 48 hours) and 
were readily taken up by the cells, significantly more than when compared with RIF in a 
non-nano form (native drug).  Additionally, they reported that high concentrations of RIF 
were detected within phagosomes, suggesting that RIF entrapped in PLGA MS can enter 
membranes of macrophages (probably through phagocytosis) more readily that native 
RIF.  NR8383 cells were then infected with M. bovis-BCG and exposed to the RIF PLGA 
MS.  The RIF PLGA MS were found to be bactericidal against intracellular M. bovis-
BCG, significantly more so than native RIF at both concentrations tested (0.25, 2.50 
µg/mL) over a period of 7 days incubation (Hirota et al. 2010).  Comparing RIF 
administered via a nano-carrier compared to a solution in an in vitro setting offered very 
encouraging results, and could be very useful in the treatment of LTBI.   
Aboutaleb et al., created RIF loaded solid lipid NPs (SLNs [NPs with a solid hydrophobic 
core coated with a phospholipid monolayer]) for intravenous administration.  The aim 
was to create spherical, stable RIF SLNs <100 nm in diameter.  They found that RIF was 
released over a 120 hour period in vitro in a biphasic pattern when in SLNs form, thus 
indicating that the drug release was controlled and did not occur instantaneously 
(Aboutaleb et al. 2012).  The anti-mycobacterial properties of the SLNs were tested 
against a surrogate strain of M. fortuitum and results show an 8-fold higher efficacy at 
inhibiting growth when delivered in the SLNs compared with native RIF solution.  
Controlled release could offer potential to lowering dosages therefore these were 
promising results.  However, the SLNs were prepared with 2 g of Tween 80.  Tween 80 
(a detergent) can have a toxic effect on some mycobacterial species and at high 
concentrations an effect would be expected (Van Boxtel et al. 1990).  A suitable control 
measure was not in place, which may have altered the results on the mycobacterial growth 
observed.  
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Dube et al., have designed a 1,3-β-glucan (Glu) functionalised chitosan shell (CS), PLGA 
core NPs loaded with RIF drug (Glu-CS-PLGA+RIF [Fig 1.11]) with the aim of both 
stimulating some antimicrobial responses which Mtb suppress within the host 
macrophage, and delivering RIF intracellularly (Dube et al. 2013).  The spherical Glu-
CS-PLGA+RIF NPs created were approximately 280 nm in size with a zeta potential of 
+12.47 ±8.49mV.  
 
Figure 1.11 Preparation of Glu-CS-PLGA+RIF NPs 
(created using Dube et al., 2013) 
 
Using human alveolar-like-macrophages (ALM), NP uptake was achieved through 
incubation (6 hours) and confirmed by confocal microscopy.  Cytotoxicity testing proved 
no significant change in macrophage viability when incubated with Glu-CS-PLGA NPs 
NPs (at 0.1% v/v nanoparticle suspension in water) for 2 hours (although there was great 
variation in the data) (Dube et al. 2013).  The focus was on Mtb’s ability to prevent the 
host cell (macrophage) from producing bactericidal ROS and reactive nitrogen species 
(RNS) and pro-inflammatory cytokines (eg: IL-12 and IFN-γ).  This suppression aids in 
Mtb’s intracellular survival.  In the design of Glu-CS-PLGA+RIF NPs, 1,3-β-glucan was 
selected as it can interact with Dectin-1 macrophage surface receptors which promote 
both pro-inflammatory cytokine production, ROS/RNS generation and also enhance the 
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process of phagocytosis (Dube et al. 2013).  Results suggest that CS-PLGA+RIF NPs 
successfully increased the anti-microbial activities of macrophages; TNF-α, IFN-γ and 
IL-12 secretion were all enhanced by the NPs.  Interestingly, it was reported that this 
work confirmed that RIF could be delivered 4 times faster when delivered as a NP 
construct rather than as a free RIF solution (in vitro), however the efficacy of the drug in 
this NP formulation is not known as no tests with Mtb infected macrophages were carried 
out (Dube et al. 2013).  Also, this study utilised human monocytes that differentiated in 
vitro to alveolar-like-macrophages.  As such, alveolar macrophages have not yet been 
tested and would require an in vivo study to confirm the preliminary cytotoxicity data. 
In a more recent study, Edagwa et al., demonstrated that PLGA NPs encapsulating RIF 
and a modified INH drug (INHP), localised in subcellular organelles within phagosomes 
in monocyte derived macrophages (MDMs) (MDMs) (Edagwa et al. 2014).  Their results 
display confocal microscopy images of PLGA RIF and INHP in endosomal 
compartments.  To determine whether these NPs were trafficked to the same compartment 
as mycobacteria, the MDMs were infected with M. smegmatis and then treated with the 
NPs.  Imaging suggested that co-localisation also occurred for the particles and the 
mycobacteria within the MDM cells (Edagwa et al. 2014).  To assess their anti-
mycobacterial activities, MDMs were exposed to RIF PLGAs (loaded with approximately 
10% drug) and INHP PLGAs (loaded with approximately 5% drug) for 24 hours, then 
MDMs were infected with M. smegmatis for 1-10 days.  The same experiment was carried 
out for RIF and INHP in native forms.  Comparing the results between the 2 types, the 
PLGA NPs exerted over 1.3-fold greater toxicity after 1 day incubation with M. 
smegmatis at 300  µM (Edagwa et al. 2014).  It was found that when MDMs were infected 
with mycobacteria following 10 days of exposure to the PLGAs or native drugs, the 
PLGA NPs inhibited mycobacterial growth by 50%, whereas the native drugs had no 
effect on mycobacterial growth in macrophages.  This suggesting that in the nano-form, 
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drugs are retained for extended periods inside macrophage cells.  It must be noted 
however, that this was a somewhat unorthodox means of measuring anti-mycobacterial 
activity, as the macrophage cells were first treated with the drug (in both nano and native 
forms) before being infected with mycobacteria.  It is unclear whether this is a means to 
prevent infection rather than clearing an infection.  Additionally, for an in vitro 
experiment, the authors tested relatively high concentrations of drugs (up to 300 µM).  
Overall however, these results were encouraging from a nano-medicine perspective.  
With published reports demonstrating PLGA NPs carrying anti-TB drugs being engulfed 
by macrophages, the possibility of targeting granulomas has begun to be investigated.  
Granulomas are concentrated masses of Mtb infected macrophages (section 1.5) and are 
poorly accessed by drugs, thus they harbour mycobacteria which could cause reactivation 
to a diseased state or lead to the development of MDR TB.  Grobler et al., have reported 
that delivering NPs to granulomas is possible (Grobler et al. 2016).  Using colloidal 
Pheroids (NPs with an oil, gas and water phase that are filled with RIF [dissimilar to 
PLGAs]) and an in vitro granuloma model, it was possible to target NPs to the 
macrophages.  Pheroids are a patented drug delivery system, with the ability to control 
the rate of drug clearance and offer protection to drugs (e.g. from enzyme degradation) in 
vivo (Steyn et al. 2010).  The analytical model presented by Grobler et al., demonstrate 
that when RIF was delivered using Pheroids, there was a significantly higher 
concentration of RIF in the macrophages than in the blood (of 16 patients following their 
fourth daily dose of drug) when compared to native RIF.  This suggesting that RIF can 
be targeted to macrophages when delivered in this form (Grobler et al. 2016).  
Additionally, using the delivery system, higher drug concentrations were measured at 
several positions in the granuloma model when compared with the native RIF.  This work 
correlated nicely with the previous reports; when RIF was administered in a nano-
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formulation (loaded on either PLGAs, SLNs or packaged in Pheroids) a higher 
concentration of drug reached the desired site compared to a solution of native RIF. 
 
1.13 Summary 
The effective treatment of TB remains one of the world’s biggest challenges.  This 
primitive disease has killed more than 100 million people, and even with tremendous 
advances in medicine, it is still evading eradication.  The rise of MDR and XDR TB is 
extremely concerning and the problems facing medical practitioners are only set to 
increase with the growing population.  Any advance in reducing TB treatment time and 
the number of different drugs administered would be advantageous.  As the use of NPs 
in the management of other human diseases increases, including infectious diseases, it is 
hoped that they will be found to be equally useful in the fight against TB. Nanomedicines 
may be the alternative to current drug regimes, but thorough investigations into their use 
is required first.  
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1.14 PhD Proposal 
 
Given the global situation of TB and the advances offered by nanomedicine, this project 
had four main aims: 
 
1. To develop, optimise and validate an in vitro screening procedure for the 
identification of effective anti-TB drugs or NPs.  
2. Using the above assay, screen for anti-mycobacterial properties of a range of NPs.  
3. To utilise an in vitro macrophage infection model to investigate the uptake of 
SDNs by infected macrophages and the relative intracellular localisation of SDNs 
in comparison to mycobacteria. 
4. To assess the ability of SDNs to kill or inhibit the growth of mycobacteria within 
infected macrophage models in vitro.  
 
 
 
 
 
 
 
 
 
 
 
 
  
65 
 
 
 
 
 
 
CHAPTER II  
GENERAL METHODS AND 
MATERIALS 
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2.1 Culture of mycobacteria (using aseptic techniques in a microbiological safety 
cabinet [class 2])  
 
2.1.1 Growth conditions 
 
Mycobacterium avium. subsp paratuberculosis (Map) was supplied by Raul Barletta, 
University of Nebraska, Lincoln (Harris et al. 2002).  Map strain K10 was supplied 
transformed with a plasmid carrying the gfp gene and a kanamycin resistance gene (Map 
K10/GFP).  Map K10/GFP from agar stock was cultured in 10 mL of Middlebrook 7H9 
broth medium (see 6.2.1) supplemented with 10% (vol/vol), Middlebrook ADC 
enrichment (albumin/dextrose/catalase [Becton Dickinson, UK]), with 0.2% (vol/vol) 
glycerol, 0.05% (vol/vol) Tween 80 (+ [Sigma-Aldrich®, UK]), 2 μg/mL mycobactin J 
(Allied Monitor, France) and 25 µg/mL of kanamycin (K) (hereafter named 7H9K+) in 
sterile universals at 37ºC gently stirred continuously with magnetic stirrers. 
 
2.1.2 Sub-culturing: broth cultures  
 
To produce mycobacterial liquid stocks, Map K10/GFP was grown in sterile plastic 
universals containing 10 mL of 7H9K+ as outlined in 2.1.1.  Growth was monitored by 
McFarland (McF) standards using a Densimat® (Peñuelas-Urquides et al. 2013).  Cells 
were harvested in the log phase of growth (McF 3-5); 2 mL of the bacterial suspension 
was pelleted by centrifugation at 3080 g for 20 minutes at 20ºC.  The pellet was then re-
suspended in the appropriate volume of 7H9K+ to give McF standard 3, from which 100 
uL was sub-cultured into 10 mL of 7H9K+ and allowed to grow for 7 days, in the dark at 
37ºC, gently stirred continuously with magnetic stirrers, before the sub-culturing process 
was repeated.  Universals were only seeded from liquid broths as above or directly from 
7H11 slopes (2.1.3).   
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2.1.3 Sub-culturing: slopes 
 
To maintain mycobacterial stocks, Map K10/GFP was grown in sterile plastic universals 
containing 10 mL of 7H9K+ as outlined in 2.1.1, 2 mL of the bacterial suspension was 
pelleted by centrifugation at 3080 g for 20 minutes at 20°C.  The pellet was then re-
suspended in the appropriate volume of sterile PBS to give a McF standard > 3, from 
which 100 uL was sub-cultured onto 10 mL 7H11 agar slopes (see 2.6.3 [in glass 
McCartney bottles]).  The cell suspension was evenly spread over the slopes (bottle lids 
loosened for 7-10 days to allow drying).  Slopes were left for a minimum of 8 weeks (or 
until good visible coverage of cells) incubated at 37ºC in the dark.  
 
2.1.4 Preparation of glycerol stocks 
 
To freeze down stocks at low passage numbers, using a sterile swab, colonies were 
removed from a 7H11 slope and added to 30% glycerol and mixed well.  Cell density was 
monitored using a Densimat® (wanted McF >5).  From this, 1 mL was added to a cryovial 
for storage at -80ᵒC.  Later, these stocks could be defrosted at room temperature and 
inoculated onto 7H11 agar slopes.  
 
2.1.5 Retrospective colony counts  
 
Following inoculation of 100 µL of a serial dilution onto 7H11 (90 mm petri dishes) the 
dishes were inverted, placed in airtight containers and incubated at 37ºC.  Colony counts 
(colony forming units [cfu]/mL) were performed after 12 weeks.  Plates were checked 
regularly for contamination.  To calculate CFU from counts, dilution factors were 
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accounted for and numbers were multiplied by 10 to determine CFU/mL (not per 100 
µL).  
 
2.2 Nanoparticles (NPs) 
 
2.2.1 Preparation 
 
All NPs were sub sampled under sterile conditions and kept in the dark at ambient 
temperature until use.  NPs were weighed into sterile bijou using a Sartorius balance 
(ME36S [Sartorius, UK]) to 3-6 mg per sample.  NPs were suspended in sterile fetal calf 
serum (FCS [2% (vol/vol) prepared in sterile distilled water]) at a concentration of 1 
mg/mL and sonicated for 16 minutes at 400 W in a bath sonicator from Ultrawave® 
(Cardiff, UK) and then placed on ice prior to use following the ENPRA (Risk Assessment 
of Engineered Nanoparticles) protocol (www.enpra.eu) (Jacobsen et al. 2010; 
Kermanizadeh et al. 2013).    NPs were then diluted in Middlebrook 7H9 medium 
supplemented with 10% (vol/vol) Middlebrook ADC enrichment 
(albumin/dextrose/catalase [Becton Dickinson, UK]), 0.2% (vol/vol) glycerol, 2 μg/mL 
mycobactin J (hereafter named 7H9) or RPMI (1640 [Thermo Fisher Scientific, UK] 
supplemented with 10% heat inactivated FCS, 100 µg/mL STR, 100 IU/mL penicillin, 
0.1 mM non-essential amino acid and 1 mM sodium pyruvate solution [hereafter named 
complete medium]).  Concentrations were achieved by further serial dilutions in the 
appropriate medium.  
 
2.2.2 Dynamic light scattering (DLS) 
 
Agglomeration/aggregation status, zeta potential, hydrodynamic size and polydispersity 
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index (PdI) of all NPs were analysed by dynamic light scattering (DLS) at a concentration 
of 100 µg/mL in 7H9 (NPs were prepared as outlined in 2.2.1) at a temperature of 25ºC 
using a Zetasizer Nano-ZS instrument with a 4 mW He–Ne, 633 nm laser (Malvern 
Instruments Ltd., UK).  Samples were first vortexed for 10 seconds and slowly (to avoid 
air bubbles) syringed into disposable capillary zeta cells.  Malvern Zetasizer software 
(version 7.03) was used for data analysis.  Averages were obtained from a minimum of 
three individual measurements and were obtained using the instrument’s automatic 
optimisation settings.  Generally, agglomerates are defined as NPs held together by weak 
bond and can be dispersed (e.g. by ultrasonication) whereas aggregates are NPs held by 
much stronger bonds (e.g. covalent bonds) (Müller et al. 2014). 
 
2.3 Macrophage (J774A.1) cells  
2.3.1 Macrophage cell culture conditions 
 
J774A.1 murine mouse ‘macrophage-like’ cell lines were obtained from the European 
Collection of Cell Cultures (ECACC).  J774A.1 cells (hereafter referred to as 
‘macrophages’) were cultured in complete medium in 75cm2 T5 flasks (Corning, canting 
neck [Sigma-Aldrich®, UK]) and incubated at 37ºC, 5% CO2 until confluent.  Sub-culture 
was achieved using a gentle scraping method in sterile conditions to remove adhered cells 
which were re-suspended in fresh complete medium in sterile 75cm2 T5 flasks.  
 
2.3.2 Macrophage stocks (storage) 
 
Macrophage stocks were maintained by culturing them in complete medium in 75 cm2 
T5 flasks and incubating at 37ºC, 5% CO2 until confluent. Cells were detached from flasks 
using TrypLETM Express Gibco® (Thermo Fisher Scientific, UK) and centrifuged at 850 
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g for 5 minutes.  The supernatant was removed and the pellet was resuspended in 
complete medium (1 or 2 mL depending on pellet size) and at a density of 2.4 x107/mL 
(using trypan blue [section 2.5] for accurate cell counts) added to 0.5 mL of DMSO and 
0.5 mL of FCS (heat inactivated) in a cryovial then stored at -80ᵒC for 24 hours (in a 
Nalgene box with 250 mL isopropanol) before transferring to liquid nitrogen for longer 
term storage.  
 
2.3.3 Macrophage stocks (revival)  
 
Pre-warmed complete medium (30 mL) was added to macrophage stocks from liquid 
nitrogen storage and the semi-frozen solution was added to 30 mL of complete medium 
and centrifuged at 850 g for 5 minutes.  The supernatant was removed and the pellet was 
resuspended in 5 mL of complete medium and added to 25 cm2 T5 flasks incubated at 
37ºC, 5% CO2.  Growth was monitored daily and once confluent, cells were re-seeded 
into 75 cm2 T5 flasks for use.  
 
2.4 Alamar blue assay 
 
Macrophages were grown as outlined in section 2.3 until confluent.  The alamar blue 
assay set up was achieved by using a gentle scraping method in sterile conditions to 
retrieve the cells which were re-suspended in 6 mL of complete medium and centrifuged 
at 850 g for 5 minutes.  The supernatant was removed and the pellet was resuspended in 
complete medium (1 or 2 mL depending on pellet size) and then seeded into the wells of 
flat-bottomed, cell culture 96 well plates at a density of 5 x105/mL (using trypan blue 
[section 2.5] for accurate cell counts) at a total volume of 100 μL per well and incubated 
at 37ºC, 5% CO2 for 24 hours to allow adherence.  The supernatant was removed from 
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the wells after 24 hours incubation.  NPs/drugs at pre-determined concentrations (each 
concentration was prepared in triplicate treatment groups) were prepared as outlined in 
2.2.1 (in an appropriate volume of complete medium) and were added to the wells and 
incubated at 37ºC, 5% CO2 for a further 24 hours.  Positive (macrophages and 0.1% Triton 
[to indicate 100% of lysis of cells]) and negative (macrophages and medium only) 
controls were included in each plate.  The supernatant was removed and cells were 
washed twice with PBS, 0.1 mg/mL of alamar blue cell proliferation reagent (Sigma-
Aldrich®, UK) was added to each well (1:10 dilution in complete medium) and incubated 
for an additional (and final) 4 hours at 37ºC, 5% CO2.  Fluorescence was then read at an 
excitation wavelength of 560 nm and an emission wavelength of 590 nm using a 
SpectraMax M5 plate reader (USA).  To account for NP interference, the 96 well plate 
was centrifuged at 850 g for 2 minutes and the supernatant was removed from each well 
and transferred into a fresh plate to be re-read at an excitation wavelength of 560 nm and 
an emission wavelength of 590 nm.   
 
2.5 Cell counts 
 
2.5.1 Macrophage counts  
 
Macrophages were cultured in complete medium in 75cm2 T5 flasks and incubated at 
37ºC, 5% CO2 until confluent.  As above, using a gentle scraping method in sterile 
conditions, cells were resuspended in 6 mL of complete medium and centrifuged at 850 
g for 5 minutes then resuspended in 1 or 2 mL of complete medium.  To obtain a 
homogenous suspension with evenly distributed cells, using a 1000 μL Gilson tip the 
pellet was gently extracted and expelled in complete medium.  Using Trypan Blue 
Reagent (Sigma-Aldrich®, UK) at a 1:20 dilution with suspended cells, approximately 10 
μL of the cell solution was added to a Neubauer chamber (when adding the coverslip to 
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the counting slide, ensured Newton rings were present confirming the coverslip was 
firmly adhered).  Trypan blue is a vital stain therefore it is excluded from live cells.  To 
gain an average number of cells, the colourless/bright cells (under phase contrast) in the 
four larger corner squares were counted on both sides and averaged, disregarding any 
dark stained cells (indicating dead cells) and taking into account the dilution factor and 
the conversion factor (x104), the number of cells were determined per 1 mL of medium. 
K10/GFP using microscopy.  
 
2.5.2 Mycobacteria counts 
 
Map K10/GFP cultured in 10 mL 7H9K+ was centrifuged at 3080 g at 20°C for 20 minutes 
to pellet the bacterial suspension.  The pellet was re-suspended in the appropriate volume 
of PBS to give a McF standard 2.  As above, to obtain a homogenous suspension with 
evenly distributed mycobacteria, using a 1000 μL Gilson tip the pellet was extracted and 
expelled in PBS and approximately 10 μL of the solution was added to a Helber (Thoma 
grid) bacteria counting chamber (when adding the coverslip to the counting slide, ensured 
Newton rings were present confirming the coverslip was firmly adhered) and left for 10 
minutes to settle (otherwise cell counting was difficult).  The 80 small squares (5 large 
squares with 16 internalised squares) were counted and the total number was divided by 
80 to give the average number of cells per square.  Using the conversion factor (2 x 107) 
and taking into account the dilution factor, the number of cells was determined per 1 mL 
of PBS.   
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2.6 Medium preparation 
 
2.6.1 Middlebrooks 7H9 (+ Tween 80) broth (7H9K+) 
 
Into a large Duran bottle 4.7 g of Middlebrooks broth (7H9) powder (Becton Dickinson, 
UK), 2 mL glycerol (Sigma-Aldrich®, UK), 0.5 mL Tween 80 (Sigma-Aldrich®, UK) and 
1 vial of mycobactin J (dissolved in 2 mL ethanol) was added to 900 mL distilled water 
and repeatedly inverted until no visible powder remained.  This solution was autoclaved 
at 121ᵒC for 10 minutes.  Broth was stored at -5ᵒC (for up to 6 months) until use.  Prior to 
culturing, 100 mL of Middlebrook ADC enrichment (albumin/dextrose/catalase) and 25 
µL of kanamycin (Sigma-Aldrich®, UK) was added aseptically. 
 
2.6.2 Middlebrooks 7H9 (- Tween 80) broth (7H9K) 
 
As above, but without addition of Tween 80. 
 
2.6.3 Middlebrooks 7H11 agar 
 
Into a large Duran bottle 21 g of Middlebrooks agar (7H11) powder (Becton Dickinson, 
UK), 0.3 g L-Asparagine (BDH lab supplies, UK), 25 mL glycerol, and 1 vial of 
mycobactin J (dissolved in 2 mL ethanol) was added to 700 mL distilled water and 
repeatedly inverted until no visible powder remained.  This solution was autoclaved at 
121ᵒC for 15 minutes.  Prior to decanting, 200 mL newborn calf serum (heat inactivated 
at 56ᵒC), 100 mL OADC (oleic acid/ albumin/dextrose/catalase enrichment) enrichment 
medium (Becton Dickinson, UK) and 2 Kirchnew Selectatabs (polymyxin B, ticarcillin, 
amphotericin B, trimethoprim [Mast Diagnostic, France]) was added aseptically, then 33 
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mL was poured into sterile petri dishes (90 mm) and left to dry for 30 minutes.  Agar 
filled petri dishes were stored at -5ᵒC (for up to 3 months) until use.  
 
2.6.4 RPMI 
 
Into the 500 mL RPMI (Roswell Park Memorial Institute) medium (1640 + L-glutamine 
[Thermo Fisher, UK]) bottle 5 mL of MEM non-essential Amino Acid Solution (100×) 
without L-glutamine (Sigma-Aldrich®, UK), 5 mL of sodium pyruvate solution (Sigma-
Aldrich®, UK), 5 mL penicillin-STR solution liquid (5000 units/mL [Thermo Fisher, 
UK]) and 50 mL of heat inactivated FCS was added and mixed well prior to use.  Medium 
was stored at -5ᵒC for use up to 3 months.   
 
2.7 Fixatives 
 
2.7.1 4% Paraformaldehyde 
 
In a fume hood, 10 g of paraformaldehyde powder (Sigma-Aldrich®, UK) was weighed 
and dissolved in 475 mL of pre-heated PBS (60-70ᵒC) and 1-2 drops of 5 M NaOH 
(Thermo Fisher Scientific, UK) was added thus turning the cloudy suspension clear.  This 
solution was allowed to cool at room temperature before use (up to 2 hours).  Solution 
was stored at -5ᵒC for use in up to 2 days or aliquots were stored at -20ᵒC for up to three 
months.  
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2.7.2 3% Glutaraldehyde in 0.1M sodium cacodylate 
 
In a fume hood 1.38 g sodium cacodylate powder (Agar Scientific, UK) was weighed into 
50 mL distilled water and mixed.  Glutaraldehyde (Sigma-Aldrich®, UK) was pipetted 
into distilled water, yielding a 6% solution and 50 mL of each of the above solutions was 
mixed together.  Solution was stored at -5ᵒC for use up to 1 week.   
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CHAPTER III  
 
FLUORESCENCE MICROTITER 
ASSAY FOR SCREENING THE 
ANTI-MYCOBACTERIAL 
PROPERTIES OF NPS 
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3.1 Introduction 
 
Given the global situation, novel ani-bacterial agents are urgently required to fight 
infections and fill the void with new substances.  Nanomedicines may be the solution to 
this, but a novel means of screening their efficacy at killing bacterial species is required.  
There are great challenges associated with developing new anti-mycobacterial drugs, in 
particular anti-TB drugs.  Pharmaceutical companies are reluctant to undertake new drug 
discovery, screening or development because it involves exorbitant costs with insufficient 
profit margins or investment return (Gumbo, Pasipanodya, et al. 2015).  There are 
challenges in identifying new substances that can kill both actively growing and persistent 
or latent bacteria, in evaluating new substances and testing them in clinical trials.  
Generally, there has been an overall void in the discovery of novel anti-bacterial agents 
for the past 25 years (Boogaard et al. 2009; Silver 2011; WHO 2014a) in part attributed 
to the costs and problems involved in screening procedures.  The continual emergence of 
drug resistant strains of mycobacterial species augments this problem.   
 
Pathogenic Mycobacterium species are slow growing and difficult to culture in vitro 
(taking 4-16 weeks for colonies to be visible on agar plates), in fact some species like M. 
leprae cannot be propagated in the laboratory.  As there are problems with their 
cultivation, the assessment of the anti-mycobacterial activity of therapies can take several 
months (Boogaard et al. 2009; Ohara 2012).  Generally, pathogenic mycobacteria are 
very challenging to work with (Elguezabal et al. 2011) which makes drug screening 
procedures additionally expensive and time consuming.  
 
  
78 
 
Historically it has been a slow path to evaluate substances which might offer some 
toxicity against mycobacteria.  From Koch’s initial identification of the infectious 
bacillus in 1882, it was a further 6 years until a suitable medium was created allowing its 
culture in vitro and it was not until 1940 when the first treatments became available 
(Franzblau et al. 2012).  There are now various methods of screening for new drugs 
available, which can be computational (virtual screening [VS]) or real screening 
(preferably high throughput screening [HTS]).  VS is in silico drug screening/design 
using computational models to predict the efficacy of different molecular structures 
against characterised targets, whereas HTS is the screening of large numbers of 
compounds simultaneously (e.g. using robotics) to try and find activity or affinity for a 
selected target (or model) of a specific disease.  The ultimate goal of both is to find 
effective relationships between chemical structures and biological targets (Giacomotto & 
Segalat 2010).  
 
3.1.1 Virtual screening 
 
The completion of the human genome project has accelerated the development of 
computational screening, a means to virtually search vast libraries of molecules (e.g. 
proteins) to find suitable drug binding targets (Meng et al. 2011).  VS has a number of 
advantages.  Compared to laboratory based experiments, VS is financially attractive, has 
no requirement of specialised laboratories (e.g. high containment), products, drugs or 
pathogens, and can be used to screen theoretical compounds, thus being a unique and very 
powerful feature (Bielska et al. 2011).  VS can be categorised into ligand (e.g. quantitative 
structure-activity relationships [QSAR] and pharmacopoeia mapping) and structure (e.g. 
molecular docking) methods (Meng et al. 2011).  QSAR and pharmacopoeia mapping are 
employed when active ligands are identified but there is no information on the target 
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structure.  Molecular docking is used to predict the binding site of a ligand to a 3D protein 
structure (Meng et al. 2011).  Adversely, VS cannot substitute real screening.  Although 
useful for preliminary screening, VS cannot replace physical screening and the results 
real screening generates.  
 
3.1.2 High throughput screening 
 
HTS is a means to screen many compounds (large libraries can contain many thousands 
of compounds) via a fast and automated operation platform, ideally using microtiter plates 
(96 or 384 well plates) on cells in culture (Liu et al. 2004).  Traditionally, HTS is based 
on in vitro cell culture, biochemical or receptor binding assays (Pandey & Nichols 2011).  
By screening a number of compounds (monitoring a biological modulator against specific 
targets), investigators are looking for a ‘hit’ to try and quickly identify biologically 
relevant compounds displaying promising results which can be taken to secondary 
validation stages (Liu et al. 2004).  This system is rapid, and allows ineffective 
compounds to be disregarded at early investigatory stages thus significantly saving time 
(and money).  Up to 10,000 compounds per day can be tested and if a hit is observed, half 
maximal inhibitory concentration (IC50) values are then calculated (Szymański et al. 
2012).  Unfavourably, HTS has relatively large operating costs.  HTS also requires 
laboratory space, equipment, trained staff and the purchase, or manufacture, of all 
compounds for testing which quickly incurs large expenses.  
The BACTEC 460 TB radiometric system revolutionised mycobacterial culture as it 
offered an automated, faster liquid culture system.  This has now been replaced by the 
BACTEC MGIT 960, which is utilised for many applications including drug screening 
and drug susceptibility testing.  The BACTEC MGIT 960 system is arguably the best 
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system available for screening, yet requires relatively large quantities of compounds (and 
mycobacteria) for drug screening, increasing costs and safety issues.  There are some 
problems with quantifying data from the system (i.e. it is non-specific therefore can detect 
other bacterial species), its sensitivity is often reported to be low and there are problems 
with contamination (compared to the older BACTEC 460) (Lucas et al. 2002; Robbe-
Austerman et al. 2013) consequently making it less desirable for HTS.  As such, other 
screening tests have been utilised and developed, such as the luciferase, alamar blue 
(Ozeki et al. 2015; Collins & Franzblau 1997) and GFP assays (Primm & Franzblau 
2007).  
Luciferase is a class of oxidative enzymes, isolated from various organisms and animal 
species (e.g. click beetles and fireflies [Photinus pyralis]) that have inherent 
bioluminescence.  It is a highly efficient biological reporter molecule.  The luciferase 
assay produces a photon of light via excitation energy following an enzymatic reaction; 
bioluminescence is produced when luciferase uses ATP to catalyse the oxidation of 
luciferin (the substrate) producing oxyluciferin (Deb et al. 2000).  This assay measures 
viability via the presence of ATP, found in live cells.  As cell populations multiply, so 
will the bioluminescence signal due to the increased ATP available from metabolically 
active cells (e.g. a yellow green light [557 nm] in the case of Photinus pyralis).  The signal 
produced is therefore a product of the number of cells and the viability of those cell. 
Luciferase has been used successfully in drug screening for anti-malarial drugs (Che et 
al. 2012).   This assay, which is reported to be amenable to HTS, used the ONE-GloTM 
luciferase assay system (using a transgenic luciferase expressing parasite) to screen 
compounds from which 67 hits were found to inhibit >85% parasite growth.  From these 
compounds, 3 hits and 3 non-hits hits were re-analysed via a fluorescence assay (SYBR 
green-based assay) to determine if they matched the results generated via the luciferase 
assay, which they did.  The authors reported overall repeatability and reliability (Che et 
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al. 2012).  However, using a transgenic parasite may differ from the hits generated using 
a wildtype parasite. 
Andreu et al., have developed a screening assay utilising luciferase expressing Mtb that 
can be used to screen for anti-mycobacterial drugs both in vitro and within macrophages 
in a 96 well format.  The authors use both the firefly luciferase system and a construct 
with the whole operon expressing the bacterial luciferase, which rendered the Mtb 
autofluorescent and so did not require the addition of substrate (Andreu et al. 2012).  
MICs could be available in only 3 days.  Ozek et al., also developed a screening assay 
utilising luciferase expressing recombinant M bovis BCG (rBCG) to screen for 
compounds in vitro in a 96 well format (Ozeki et al. 2015).  By culturing luciferase 
expressing rBCG and comparing the growth (via relative light intensity) to CFU 
following convention plate-outs, they found that the two methods correlated.  The authors 
discovered that when anti-TB drugs were added, the decrease in the light intensity 
readings and CFU still correlated, thus allowing them to successfully screen compounds 
using a luciferase based assay (they screened 10,080 drug extracts) (Ozeki et al. 2015).  
From the screening, 137 drug extracts were identified to inhibit rBCG, and from this, 41 
inhibited both Mtb (H37Rv) and an XDR TB strain (Ozeki et al. 2015).  A luciferase 
reported mycobacteriophage system has also been used in drug susceptibility testing for 
Mtb (Banaiee et al. 2008; Banaiee et al. 2001).  Results were found to be 98.4% in 
agreement with the BACTEC 460 system, it was semi-automated and had low costs 
associated with its use (Banaiee et al. 2008).  These studies highlight the advantages of 
the use of a luciferase system. 
There are a great number of commercially available luciferase assay kits and 
luminometers. Cell viability results can be used to determine gene expression and many 
cellular processes involved in gene regulation following exposure to a compound.  As 
this assay often requires the addition of luciferin (construct dependent) (which reacts with 
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ATP in living cells to fluoresce) (Deb et al. 2000), it is also an endpoint assay, therefore 
often no MBCs or drug kinetic information is obtainable following it.  Luciferase assays 
vary greatly and there seems to be no consensus in the literature on a set protocol (Primm 
& Franzblau 2007).  Furthermore, luminometers are regarded as expensive laboratory 
equipment, luciferin is a costly substrate and often the assay lacks reproducibility between 
tests.  Most importantly however, is a publication highlighting that some compounds (e.g. 
PTC124) can directly affect the reporter, leading to nonspecific but reproducible assay 
signal modulation, which was actually just an artefact.  Auld et al., demonstrated that 
PTC124 (a drug for cystic fibrosis in clinical trials) and its analogues were strongly 
associated with the luciferase reporter, this leading to increased luciferase activity (Auld 
et al. 2009).  This association would cause a false positive, incorrectly showing a 
compound to have desirable drug effects. 
Redox-based techniques, such as the alamar blue assay (Chapter II, [section 2.4]), have 
been employed for drug screening (Collins & Franzblau 1997; Hamid et al. 2004) 
although the assay tends to be more popular for drug susceptibility testing (Martin et al. 
2003; Yajko et al. 1995b).  The alamar blue assay measures metabolic activity as an 
indicator of cell viability.  A non-fluorescent, oxidised blue dye resazurin (the alamar 
blue reagent [which is non-toxic and can pass through cell membranes]) is reduced by 
living cells to resorufin, which is a highly fluorescent pink.  The alamar blue assay is 
generally deemed cost effective, with growth monitored visually (no equipment required 
but not quantitative), fluorometrically and spectrophotometrically.  This assay is widely 
used, is simple to implement and cost effect but it is more relevant for mammalian cells.  
Hamid et al., compared the alamar blue to the 3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyl 
tetrazolium bromide (MTT) assay for in vitro screening of 117 compounds using human 
hepatoma cell lines.  Authors reported general comparability between the two assays, but 
found increased sensitivity when using the alamar blue assay (Hamid et al. 2004).   
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This microtiter assay however is an endpoint test (following the colour change after set 
incubation time points) like the luciferase assay.  Drug kinetics or MBCs therefore cannot 
be determined as bacterial growth would not be possible following the addition of a stop 
reagent into the wells.  Additionally, there are other reductases which may be able to 
reduce alamar blue causing a colour change, therefore it may not necessarily detect 
cellular metabolism impairment (Rampersad 2012), which is important when testing 
potential clinical-use drugs.  Due to the inducers or inhibitors of other metabolic enzymes, 
false positives and/or negatives could be produced (Hamid et al. 2004).  Furthermore, 
absorbance readings will differ according to the microtiter plate utilised in the experiment 
and most studies only use this assay in combination with another testing means thus 
increasing timeframes and costs in drug screening (Rampersad 2012). 
GFP found in the jellyfish Aequorea victoria, is a self-fluorescing (in the presence of UV 
or blue light) protein (Parker & Bermudez 1997).  It has been described as the most widely 
exploited protein in cell biology, often harnessed as a marker of gene expression or 
protein targeting.  Wildtype GFP has a 238 amino acid structure and has two excitation 
(ex) peaks; a major one at 396 nm (UV) and a smaller one at 475 nm (blue), with emission 
(em) at 509 nm (green) (Heim & Tsien 1996).  By incorporating a foreign plasmid with 
the gfp gene into bacteria, it can be amplified and therefore expressed thus allowing 
fluorescence to be used as an indicator of cell number.  Mycobacteria strains that have 
been successfully engineered to express GFP using plasmids include Mtb, M. bovis BCG, 
M. avium, M. aurum, M. smegmatis and Map (Collins et al. 1998; Srivastava et al. 1998; 
Parker & Bermudez 1997; Kremer et al. 1995; Blokpoel et al. 2003; Harris et al. 2002a).  
The use of these strains has allowed successful screening of anti-mycobacterial 
substances (Donnellan et al. 2015; Srivastava et al. 1998; Collins et al. 1998).  As such, 
GFP was chosen as a reporter molecule for this PhD project.  
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Assays that utilise the GFP protein have many advantages associated with their use as 
GFP is intrinsically fluorescent, only requires oxygen for stimulation and exhibits very 
low toxicity, is extremely stable and allows for easy visualisation/imaging (Collins et al. 
1998; Chalfie et al. 1992).  GFP is encoded by a small DNA sequence thus making the 
construct of gene fusions possible.  Natural, intrinsic fluorescence allows detection and 
monitoring of bacterial species without the requirement of any staining.  GFP assays are 
generally more desirable over the alamar blue and luciferase assays as there is no 
requirement for a dye or substrate (disregarding recombinant luciferase constructs), 
which decreases the labour and increases the assays safety aspects.  Additionally, repeated 
measures from the same cells are possible, allowing easy track proliferation over time for 
the same culture.  GFP provides a means of tracking viable cells in vivo, monitoring 
growth, quantifying gene expression and investigating protein localisation in living cells.  
GFP based assays can be used for in vitro drug testing as well as intracellular drug testing 
(inside macrophages) (Parker & Bermudez 1997).  Fluorescence can be monitored using 
a fluorometer, flow cytometry and microscopy (Blokpoel et al. 2003).  Furthermore, GFP 
assays are amenable to HTS (Fortin et al. 2005; Collins et al. 1998; Lu et al. 2004).  
 
3.1.3 Aims 
 
The aim of this chapter was to develop and optimise a rapid, inexpensive assay to screen 
and compare the anti-mycobacterial effects of NPs against mycobacteria.  The approach 
used was adapted, modified and optimised from previous work by Collins et al., (1998), 
employing a GFP reporter strain of Map K10 (Collins et al. 1998; Harris & Barletta 2001).  
This chapter highlights some of the technical issues which were overcome during the 
development stages and outlines the advantages and limitations of the assay.  Some results 
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from this chapter have been published in ‘A rapid screening assay for identifying 
mycobacteria targeted nanoparticle antibiotics’ (Donnellan et al. 2015). 
 
3.2 Materials and Methods   
3.2.1 Mycobacterium avium subsp. paratuberculosis (Map) K10/GFP: the surrogate 
organism 
 
Map an acid-fast pathogen (see Chapter I [section 1.9.4]), strain K10, was chosen as a 
surrogate for Mtb for this study.  Unlike Mtb, Map is classified as a Hazard Group 2 
organism by the UK Advisory Committee for Dangerous Pathogens and therefore has the 
advantage that it can be handled in Containment Level 2 rather than Containment Level 
3 laboratories.  In addition, the reporter strain was available (Harris et al. 2002b).  Map 
K10/GFP is a reporter strain of Map K10 capable of expressing GFP thus enabling growth 
to be monitored via fluorometry.  This strain was kindly supplied by Dr Raul G Barletta 
(University of Nebraska-Lincoln, USA) (Harris et al. 2002a).  Map K10/GFP is 
representative of the slow growing pathogenic mycobacteria for which survival within 
macrophages is a hallmark trait, akin to Mtb (Hostetter et al. 2002; Tan et al. 2013; Plain 
et al. 2011).  As well as the genetic similarities it has to Mtb, outlined in Chapter I, it is 
also resistant to a similar broad spectrum of antibiotic drugs.  
 
To engineer this reporter strain, Harris et al., (2002a) transformed Map K10 with plasmid 
pWES4, containing the gfp gene under the control of the M. bovis BCG promotor hsp60 
and a kanamycin resistant gene (kan) for selection (Fig 3.1) (Harris et al. 2002a).  (It 
should be noted that the antibiotic used for selection of the plasmid is not used for TB 
treatment, and therefore did not impinge on the drug screening).  
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Figure 3.1 The recombinant plasmid pWES4.  Plasmid pWES4, containing the gfp gene 
under the control of the M. bovis BCG promotor hsp60 and a kanamycin resistant gene (kan) for 
selection 
(adapted from Parker and Bermudez, 1997) 
 
3.2.2 A new protocol for screening the anti-mycobacterial properties of NPs  
 
Map K10/GFP was grown in 7H9K+ (see Chapter II [section 2.1.1]) until the exponential 
stage of growth was reached.  Growth was monitored by McF standards using a 
Densimat® (Peñuelas-Urquides et al. 2013).  Centrifugation at 3080 g at 20°C for 20 
minutes was used to pellet 3 mL of the bacterial suspension in the exponential phase of 
growth.  The pellet was re-suspended in the appropriate volume of 7H9 to give a McF 
standard 2, approximating to 3.2 x 108 CFU per mL.  Map K10/GFP was further diluted 
(1/16 in 7H9) and cells were seeded in a 96 well, sterile, black plate (2x106 CFU/well) 
(Nunc, Themo Fisher) in a volume of 100 µL per well.  The outer wells were filled with 
200 µL of distilled water (DW) to prevent dehydration of the experimental wells.  
pWES4 
5262 bp
Hsp 60
gfp
kan
oriE
oriM
pWES4 
5262 bp
Hsp 60
gfp
kan
oriE
oriM
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Although a full working example of NP/drug screening is not given in this chapter, (this 
can be found in Chapters IV and V), an overview of the assay and plate set up is.  Serial 
dilutions of NPs (or drugs) were prepared to give the desired final concentrations per well, 
and were added to the wells containing Map K10/GFP, giving a final volume of 200 µL 
per well.  The 96 well plates were incubated at 37ºC with medium agitation (250 rpm) for 
7 days and kept in the dark throughout the experimental procedure.  To check for NP/drug 
interference in fluorescence readings, wells of medium and medium plus NPs/drugs were 
included.  Fluorescence was measured (top read) using a GloMax® Multi+ plate reader 
(Promega, UK) at an ex/em of 490/510-570 nm using the blue optical kit, the plate was 
shaken for 0.3 minutes in an orbital motion before each reading.  Bacterial fluorescence 
was monitored immediately before and after NP addition (day 0), then at the same time 
each day for 7 days.  Plates were incubated at 37 ºC wrapped in tin-foil between readings.  
All screening experiments were performed at least in triplicate under sterile conditions. 
 
3.2.3 Mycobacterial growth on solid agar  
 
Map K10/GFP was grown in 7H9 with NPs/drugs or without (control) for 7 days in a 96 
well plate format as described in 3.3.1.  After the final fluorescence reading, 100 µL of 
the mycobacterial solution was serially diluted (in 7H9+) onto 7H11 agar (see Chapter II 
[section 2.6.3]) and incubated at 37ᵒC for 12 weeks.  Each set of serial dilutions were 
performed in duplicate under sterile conditions. 
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3.3 Results 
3.3.1 Bacterial Growth: monitored by McF and fluorescence  
 
The McF standard of 10 mL liquid cultures (inoculated with a defined number of cells 
according to McF standards) of Map K10/GFP and wildtype Map K10 (without the 
plasmid for GFP) was plotted against time to generate a growth curve over a period of 35 
days (Fig.3.2a,b).  Figure 3.2(a) demonstrates the overall biphasic growth of the 
Mycobacterium, with three distinct phases of growth; the lag phase, the exponential phase 
and the stationary phase.  The first exponential growth stage was determined to be 
between days 5-11 for Map K10/GFP (Fig 3.2a).  Map K10/GFP in the exponential 
growth phase was found to be optimal for monitoring fluorescence in the microtiter assay 
over a period of 7 days (taking Map K10/GFP between days 9-11).  Figure 3.2(b) 
demonstrates the growth of wildtype Map K10.  The first exponential growth stage was 
determined to be between days 3-7 (Fig 3.2b).  As shown, the growth patterns differ 
between the two species with Map K10/GFP taking longer to reach the exponential 
growth phase.  Additionally, wildtype Map K10 had a longer stationary phase 
(approximately 7 days) than Map K10/GFP (approximately 5 days) (Figs 3.2a,b).  This 
was important for the assay optimisation.  Figure 3.3 depicts the growth of Map at 
different passage numbers over a period of 11 days, passage number was found not to 
significantly affect the growth rate.  To determine the growth pattern for Map K10/GFP 
(starting with cells in the first exponential growth phase) using the 96 well plate format, 
2x106 CFU/well of Map K10/GFP (in 200 µL of 7H9K+) was monitored by fluorescence 
readings (GloMax® Multi+ plate reader [Promega, UK]) (ex/em 490/510-570 nm) over a 
period of 7 days (Fig 3.4).  Generally, mycobacterial growth increased steadily over the 
week long assay.  
 
  
89 
 
0
5
10
15
20
25
30
35
0 3 6 9 12 15 18 21 24 27 30 33
M
cF
Days
 
 
 
   
 
 
 
 
Figure 3.2(a) Biphasic growth of Map K10/GFP over 35 days in 10 mL cultures in 7H9K+ 
(using McFarland [McF] standards).  The curve displays biphasic growth of the mycobacteria, 
where the organism is switching between carbon sources in the 7H9K+ medium.  The first 
exponential growth phase was between days 5 and 11, the second exponential growth phase began 
at approximately day 16.  Map K10/GFP was taken between days 9 and 11 for the fluorescence 
assay (n=2).  
 
 
 
Figure 3.2(b) Biphasic growth of wildtype Map K10 over 35 days in 10 mL cultures in 7H9K+ 
(using McF standards).  The curve displays biphasic growth of the mycobacteria, where the 
organism is switching between carbon sources in the 7H9K+ medium.  The first exponential 
growth phase was between days 3 and 7, the second exponential growth phase began at 
approximately day 14 (n=2).  
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Figure 3.3 Growth of Map K10/GFP over 11 days in 10 mL cultures in 7H9K+ (using McF 
standards) at different passage numbers.  This was used to compare the first exponential 
growth phase (5-11) between 3 passage numbers.  No significant difference between growth 
rates/patterns was observed (n=1). 
 
 
 
 
 
 
Figure 3.4 Growth of Map K10/GFP over 7 days monitored by fluorescence in 7H9K+.  
Growth was monitored over 7 days in a microtiter format, with each point displaying 2* standard 
error of the mean (SEM) (n=12) (AFU= Arbitrary fluorescent units).  
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3.3.2 Fluorescent microtiter assay optimisation 
 
During the microtiter assay optimisation, a number of variables were manipulated 
including CFU/mL and plate type.  Figure 3.5 (a) shows the effect of plate type and 
depicts the assay performed with different numbers of CFU/mL in black versus white 
plates and the readings obtained via fluorometry.  As shown, the white plates gave very 
high readings due to background fluorescence.  As the CFU/mL increased, the 
fluorescence increased beyond a readable scale.  To determine the optimum CFU/mL of 
Map K10/GFP for seeding into the black plates, to allow optimal growth over the 7 day 
period, various cell densities were tested using the fluorescence assay, Figure 3.5 (b) 
displays the results obtained.  Using these results a value between the two lower numbers 
was selected for the assay (2 x106 CFU/mL); a low CFU number was sought but not too 
low that a GFP signal was barely measureable.  As shown above (Fig 3.2), the growth 
pattern of Map K10/GFP was an important factor to consider, as it differed from the 
wildtype strain.  As such, the fluorescence assay was begun after cells were incubated for 
9-11 days, instead of 7 days as would occur with the wildtype strain.  Figure 3.6 depicts 
the 96 well plate set up.  As illustrated, each concentration was carried out in triplicate 
and DW filled the outer wells.  Two separate NPs/drugs could be tested at once, with each 
run in triplicate.  Three sets of controls were included; mycobacteria only (wells B2-B7), 
7H9 and 7H9+ medium only (to account for any interference from tween 80 [B8-B10]) 
and NP/drug at each concentration with medium (rows 8,9,10 [Fig 3.6]).   
Other variables that were manipulated include the sample mixing time, medium volume, 
evaporation/dehydration rates during incubation etc, many being determined through 
visual observations.  For example, if outer wells were not filled with distilled water, by 
the 7th day the experimental wells began to experience evaporation.  Different ex/em 
peaks were tested on the GloMax® Multi+ plate reader (Promega, UK) (e.g. the UV optical 
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kit [ex/em 360/410-460 nm]) but interestingly, readings were found to be more stable and 
reproducible using the blue optical kit.  Overall the growth stage of the mycobacteria, cell 
number per well and plate type were found to be particularly important factors for optimal 
performance.   
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Figure 3.5 (a) Assay Optimisation: determining plate type.  Black plates were chosen to 
minimise background fluorescence found when using white plates (n=1).  
 
 
 
 
 
Figure 3.5 (b) Assay Optimisation: determining colony forming units (CFU) per well.  To 
obtain an optimal number of cells to begin the 7 day assay 2x106 CFU/mL was chosen based on 
these results; high enough that a signal was obtainable but keeping cell numbers low to start 
with (n=1).  
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                                  Experiment 1                      Experiment 2                Controls 
                               (columns 2,3&4)                       (columns 5,6&7)               (Columns B and  
                                                                                                                      8,9&10)  
 
 
 
 
 
Figure 3.6 The 96 well plate set up for NP/drug efficacy screening.  Drug/NP increasing (serial 
dilutions) from 2C-2G.  Row B (2-7) are control sets (for mycobacteria and medium only) and 
row B (8-10) are medium only controls.  Columns 8,9 & 10 (rows C-G) are NP/drug and medium 
controls. 
*DW=distilled water 
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3.3.3 Fluorescence microtiter assay  
 
Figure 3.7 depicts a working example of the assay after optimisation.  The 
aminoglycoside antibiotic hygromycin was screened (6.25-100 µg/mL) over the 7 day 
period as a pilot study, to monitor the mycobacteria growth via fluorescence taking into 
account all the controls.  Map K10/GFP was inhibited in a clear dose and time dependant 
manner by hygromycin (Fig 3.7).  Hygromycin was utilised in the early stages of 
optimising the assay and in the initial experiments as it was available and because Map 
K10 is known to be susceptible to this drug.  
 
 
 
 
Figure 3.7 Map K10/GFP growth with hygromycin in 200 µL of 7H9 in a microtiter format.  
Mycobacteria were exposed to hygromycin at different concentrations (6.25-100 µg/mL) over a 
period of 7 days.  Results are plotted using the raw data, with each point displaying 2* the SEM 
(n=3). 
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3.3.4 Processing raw fluorescence data: novel approach 
 
Working with large, complex data sets can be time consuming and challenging.  
Therefore, it was important to devise an analytical procedure by which the data generated 
from the fluorescence readings in this novel assay could be analysed and easily visualised.  
It was important to be able to compare the effects different substances had on the 
mycobacterial growth at many different concentrations and several time points, as well 
as taking all the controls into account.  Working with the raw fluorescence readings 
generated huge data sets that quickly became unmanageable; therefore a novel approach 
was designed.  
Fluorescence readings obtained from the GloMax® Multi+ plate reader (Promega, UK) 
were expressed as Arbitrary Fluorescent Units (AFU) and were plotted against time 
(days) (Fig 3.4).  Each treatment was carried out in triplicate and the mean was calculated.  
From this mean value, the control triplicate mean (of medium only or medium plus 
NPs/drugs in experimental wells) was subtracted.  This gave a true reading of the 
fluorescence emitting from Map K10/GFP and not any medium/NP/drug interference.  
The results expressed as AFU against time were transformed and normalised to obtain 
the usual dose response relationship, to compare the effects of NPs/drugs on the growth 
of the mycobacteria.  The exponential growth of the bacteria was calculated: G= 
G0.exp(βt) 
(where G= fluorescent units, G0=bacterial growth at time 0, β= growth rate [per day] and 
t=time [days]).   
To estimate β, first the collected data was transformed by taking the log of G: Log G= 
LogG0 + βt, allowing β to be estimated by linear regression (calculated using Excel 
[Microsoft Office Worksheet]).  The data could then be normalised to the slope of the 
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control (0 µg/mL) for each data set (e.g. controls, NPs/drugs) by dividing each value by 
the control value and 2* the standard error for each data point using the LINEST function 
in Excel (Microsoft Office Worksheet).  This analysis is further outlined, with working 
examples given, in the following chapters (IV and V). 
This data was then plotted using the dose response modelling software PROAST (version 
38.9 [RIVM, Bilthoven, The Netherlands]) or further explored in packages such as 
Minitab to obtain statistical information (Chapters IV and V).  
 
3.4 Discussion  
 
The aim of this study was to design a low cost assay to screen NPs and/or drug toxicity 
against mycobacteria.  The assay was adapted and refined to use a GFP modified Map 
strain.  It can be successfully used to screen the relative toxicity of different NPs/drugs 
within just 7 days, representing a significant saving of both time and money compared 
with traditional bacteriological culture methods.  Additionally, a novel method for 
analysis of the data was developed to permit easy comparisons between data sets and 
therefore assess the relative potency of different anti-mycobacterial agents, and it has 
been employed in the following chapters.  It is hoped that the adoption of the technical 
and data analysis protocols will allow greater numbers of potential anti-mycobacterial 
agents to be screened (including NPs).   
 
3.4.1 Assay optimisation  
 
Optimisation of the assay was relatively time consuming, but the factors which had a 
significant impact on generating true results have been identified.  The growth pattern of 
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Map K10/GFP was found to differ to the wildtype strain.  If the assay began at the wrong 
stage of growth (e.g. the lag phase), the control wells (no treatment) may not have 
provided a suitable negative control, as growth would have been slowed.  It was important 
the Map K10/GFP was cultured from the start of the exponential phase of growth and not 
the end of the lag phase or the start of the stationary phase.  To prevent readings being 
too high, a low cell density was chosen in order to allow optimal growth of the 7 day 
period in a microtiter well.  If too many cells were added, the mycobacteria may change 
the carbon source too rapidly thus altering the growth pattern, plus clumping may have 
occurred which would affect the GFP readings, while if too few cells were added the GFP 
signal may have been too weak to monitor.  Finding a suitable plate manufacturer which 
was widely and commercially available was important to allow for standardisation and 
black plates were essential to ensure the fluorescence detected was from the mycobacteria 
and to minimise background noise.  The changes made were informed by published 
literature (Collins et al. 1998), experimental observations over many repeats and 
knowledge of the exceptionally fastidious nature of this microorganism.   
Developing a data analysis protocol was time consuming and took many different routes 
before it was optimised.  Although bigger data sets can give greater significant reporting, 
they need to be managed accordingly to prevent loss and misinterpretation of information.  
Therefore, a novel method to work mycobacteria growth fluorescence data needed to be 
established; firstly to manage the vast quantity of numbers generated from the microtiter 
assay and secondly due to problems encountered when comparison were made  between 
the controls (mycobacteria only [0 µg/mL]) from individual experiments.  During the 
experiments there was variation between the controls, therefore normalising all the results 
to a mean control accommodated for this.  By fitting a linear regression to the log data, it 
allowed an estimation of fluorescence for each of the concentrations, thus summarising 
the dose response curve obtained from the raw data.  This allowed for different time points 
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(days), concentrations and fluorescence readings to be summarised into one ‘line’ on a 
graph instead of many lines for different days and/or concentrations.  A full working 
example of this is found in Chapter IV. 
 
3.4.2 Assay advantages   
 
The assay had many strengths associated with its use.  Main advantages include, it was 
an in vitro, cell-based assay that is amenable to HTS development.  The use of the reporter 
molecule GFP to monitor growth and viability of Map K10 was beneficial, as only viable 
mycobacteria fluoresce, hence fluorescence could be used to measure viability and cell 
number in the same colonies/wells over time.  The preparation for this assay was 
relatively quick (on day ‘0’ everything could be prepared in under 4 hours) and only 20 
minutes each day over the week long period was required to read fluorescence.  The assay 
generated data very rapidly.  Two substances (NPs or drugs) could be screened at once 
(with each in triplicate) thus allowing repeats to be generated quickly.  The assay required 
only small quantities of mycobacteria, thus increasing the safety aspects, as large volumes 
of liquid culture broths were not required.  Additionally, only small quantities of 
NPs/drugs were required, as the volumes required for screening were very small.  Hence, 
both these features lowered the financial costs of early stage compound screening.  Unlike 
after the alamar blue and some luciferase assays, GFP can be repeatedly measured for 
fluorescence in the same cells over time and the mycobacteria can be plated onto agar 
following fluorescence screening which allows colony counts from the same study to be 
measured to determine MICs/MBCs.  
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3.4.3 Assay disadvantages  
 
A disadvantage of exploiting GFP as a means of measuring viability is that MICs and 
MBCs cannot directly be calculated from the fluorescence assay, as GFP may linger (and 
hence be measureable) even after cell death.  However, as stated, colony counts could be 
measured.  Furthermore, this assay would not be suitable to screen all substances.  As 
outlined in the next chapter, NPs were screened for anti-mycobacterial properties, and 
this included titanium dioxide (TiO2) NPs in the first screening study of metal/metal oxide 
NPs.  TiO2 NPs have been reported to have ultraviolet (UV) protective properties for skin 
because these NPs reflect UV light (Yang et al. 2004).  As such, when screened in the 
assay, the fluorescence readings were off the scale and over three times greater than the 
control readings (mycobacteria only).  Therefore, NPs with UV reflective properties 
cannot be screened in this assay.  This may also apply for drugs with inherent fluorescent 
properties if the excitation and/or emission wavelengths overlap with GFP.  
A technical disadvantage would include the physical reading of the 96 well plate.  The 
protocol requires the lid of the plate to be removed before being inserted into the 
GloMax® Multi+ plate reader (Promega, UK), which would be problematic if this was 
used for a Hazard Group 3 organism (e.g. Mtb).  To be able to do this, the plate reader 
would be required to stay within a microbiological safety cabinet.  Additionally, by the 
6th/7th day of plate incubation during the assay, condensation formed on the inside of the 
plate lid which may have issues for contamination between wells.  
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3.4.4 Assay improvements  
 
There were alternatives to GFP that could have been utilised for screening NPs, such as 
the luciferase and alamar blue assays, but overall GFP was a suitable reporter, which 
offered reproducible results.  However, there are aspects of this assay that could be further 
improved.  Although expression of the gfp gene under control of the M. bovis BCG hsp60 
promoter was easily detected, this is a particularly powerful promoter (hence why it was 
chosen) therefore GFP may have been over expressed.  If it was over expressed, in time 
it could become insoluble due to super saturation, which may affect the metabolism of 
the Mycobacterium (although no evidence of this was found during this assay), as such, 
a different promoter may be more suitable.  Wildtype strains of GFP have a relatively 
short period of high intensity fluorescence before saturation occurs.  There are mutant 
forms of GFP available which have desirable properties; reduced saturation rates thus 
enhancing photo-stability, better temperature tolerance, increased signal intensity, 
reduced aggregation formation and increased solubility (Heim & Tsien 1996).  Imaging 
Map K10/GFP (Chapter V) was often difficult due to the problems encountered with 
photo-bleaching therefore, a mutant strain of GFP might be worth considering.  Enhanced 
GFP (EGFP) is a mutant of GFP, with a mutation of serine to threonine at amino acid 
position 65 that has the major excitation peak red-shifted to 490 nm, with emission 
staying at 509 nm (Cormack et al. 1996; Li et al. 1997).  This mutant has a reported 35 
fold fluorescence enhancement over wildtype GFP  (Li et al. 1997).  With the increase in 
fluorescence and increased photo-stability, it would be worth considering, especially as 
integrating the signal over time may become important for future studies.  
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3.4.5 Next steps  
 
The next stage following on from this assay would be to determine MIC/MBCs for the 
substances/NPs screened.  This could be done using traditional bacteriology methods.    
Generally, plating out broth cultures on to agar medium and the interpretation of data can 
give immensely varied results.  There are problems with contamination, human errors, 
and interruptions in incubation temperatures can greatly affect results and because it can 
take many weeks to gain results from colony counts, this method alone can greatly hold 
up results.  Further, bacteriological culture assays do not detect viable but non-culturable 
cells (Sharma et al. 2014).  Therefore using this fluorescence assay and the traditional 
methods side by side, they could correlate and complement each other suitably. 
In this project only one strain of mycobacteria was screened.  Although structurally and 
genetically similar, Map K10/GFP may not have the same susceptibility/resistance to 
NPs/drugs that clinical Mtb isolates do, therefore following on from the initial screening 
of substances using a surrogate, such substances would need to be re-tested for Mtb (and 
ideally MDR TB strains).  As described at a later stage of this thesis, the efficacy of the 
substances screened need to be tested on intracellular mycobacteria.  This assay only 
allows substances to be tested against mycobacteria in liquid culture, and not within a 
macrophage.  The doubling time of mycobacteria inside a macrophage is known to differ 
from liquid culture (from ~16 hours to ~24 hours for Mtb) (Ohara 2012; Hirota et al. 
2010) which could therefore alter efficacy results, meaning a wider range of 
concentrations would be needed.  
 
 
  
103 
 
3.5 Conclusions  
 
In this study, through the adaption and modification of previous work, an assay with an 
accompanying protocol that uses a GFP modified Map strain to allow quick, low cost 
screening of NP toxicity against mycobacteria has been developed.  This assay permits 
substances to be screened rapidly, to determine which may have anti-mycobacterial 
potential to be taken forward for further testing and development.  While this PhD project 
focused mainly on testing the efficacy of NPs, this protocol could be used to test a range 
of therapeutic types.  The microtiter assay itself has proven to be reliable, robust and 
reproducible, producing rapid, clear results within just 7 days.  The actual method ensures 
that the chosen ranges are robust and ensures high quality data with test/re-test reliability 
and reproducibility.  In addition to developing the in vitro screening assay, a protocol for 
data analysis was established that allows easy comparison between the efficacies of 
different substances.  
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CHAPTER IV 
ANTI-MYCOBACTERIAL 
PROPERTIES OF METAL/METAL 
OXIDE NPS 
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4.1 Introduction 
 
The anti-bacterial properties of metals (e.g. silver) are well established as they have been 
exploited as anti-bacterial agents since antiquity.  They are considered good alternatives 
to biocides, chemical disinfectants, toxic polishes etc., as they do not pollute the 
environment to the same degree and some are very cost effective (Yasuyuki et al. 2010).  
Such anti-bacterial properties have been used in a vast array of consumer products (e.g. 
food packaging, textiles) and clinical applications (e.g. alternatives to antibiotics, wound 
dressings).  The methods to which metals exert toxicity on bacterial species is not well 
understood, but it is reported that oxidative stress and membrane damage are key factors 
(Lemire et al. 2013).  Metal and metal oxide NPs are well documented for killing both 
Gram-positive and Gram-negative bacteria (Pasquet et al. 2014; Bondarenko et al. 2012; 
Ruparelia et al. 2007; Dizaj et al. 2014; Azam, Ahmed, M. Oves, et al. 2012), therefore 
it seems feasible that they would also exhibit anti-mycobacterial properties, yet there is 
limited information available for mycobacteria.  A small number of studies recently 
published on the efficacy of metal NPs against mycobacteria (e.g. M. smegmatis and M. 
bovis-BCG) exist (Mohanty et al. 2013; Larimer et al. 2014; Islam et al. 2013; Pati et al. 
2014).  Bacterial resistance to metals is rare and develops very slowly, therefore their 
anti-mycobacterial activity should be further explored (Pelgrift & Friedman 2013).    
The physico-chemical properties of NPs (e.g. composition, solubility, morphology) are 
fundamental to their anti-bacterial activity (Puzyn et al. 2011) and although it is known 
that the properties of metal/metal oxide NPs differ to that of the bulk material, the exact 
mechanism of anti-bacterial action has not been well elucidated (Dizaj et al. 2014).  
Currently, the two main hypotheses are; toxicity is exerted from the metal ions released 
from the NPs and/or oxidative stress via generation of ROS on NP surfaces (Besinis et al. 
2014), being a similar method to the bulk metal.  As most bacteria cells are in the micron 
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scale, the pores in the cell membrane (which are in the nano meter range) could facilitate 
the passing of NPs and/or metal ions intracellularly (Azam, Ahmed, M. Oves, et al. 2012), 
thus allowing disruption of many cellular processes and hence the advantage NPs have 
over bulk forms of the same material. 
Three metal/metal oxide NPs were selected to test the potential inhibition of 
mycobacterial growth, which could provide novel tools for aiding the fight against 
mycobacterial infections and be invaluable for overcoming anti-bacterial resistance 
associated with current therapies for TB (or other diseases such as leprosy or Johne’s 
disease).  
 
4.1.1 NP selection 
4.1.1.1 Ag NPs  
 
The bacterial properties of silver (Ag) were first described by Hippocrates in 400 BC 
(Morones-Ramirez et al. 2013).  Ag is inert, but when it comes into contact with moisture 
(e.g. following application to the skin) it can be employed as an anti-bacterial agent for 
wound dressings, ulcer treatments, burn healing etc., which has been the case for centuries 
(Kim et al. 2007; Jung et al. 2008; Bondarenko et al. 2013a).  A range of Ag NPs which 
vary with regards to their physico-chemical properties are reported to have toxic anti-
bacterial properties (Rai et al. 2009; Ansari et al. 2011; Yuan et al. 2012; Kim et al. 2007; 
Choi et al. 2008; Ruparelia et al. 2007; Leo et al. 2013; Sharma et al. 2009) and they are 
currently the most popular inorganic NPs used as anti-bacterial agents (Zinjarde 2012; 
Bondarenko et al. 2013b).  Ag NPs (e.g. silver nanopowder [<100 nm] from Sigma-
Aldrich®) are reported to have anti-bacterial properties against many bacterial organisms, 
including Gram-positive species Streptococcus mutans, Methicillin-resistant 
Staphylococcus aureus (MRSA), Listeria monocytogene, as well as Gram-negative 
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bacteria Escherichia coli (E.Coli), Salmonella (Ansari et al. 2011; Besinis et al. 2014; 
Choi et al. 2008; Pal et al. 2007) and mycobacteria; Mtb, M. xenopi and M. smegmatis 
(Islam et al. 2013; Seth et al. 2011).  
When Ag is in the nano-form its anti-bacterial activity is reported to increase (Rai et al. 
2009).  As proposed above, this may be due to the increased ability of NPs to enter 
through cell membranes (Fig 4.1) (Choi et al. 2008).  Once inside a cell, most studies 
suggest that Ag NPs target proteins which protect DNA molecules thus preventing DNA 
replication (Feng et al. 2000).  When Ag NPs come into contact with an oxygenated, 
aqueous environment, silver ions (Ag+) have been reported to be released (Park et al. 
2009) and Ag+ action is assumed to be a main mediator of toxicity for NPs.  The relatively 
large surface area of Ag NPs may further aid Ag+ release compared to bulk metal, 
contributing to the increased toxicity and generally it is recognised that smaller NPs (<30 
nm) increase anti-bacterial activity (Dizaj et al. 2014).  Ag+ exert their lethal effect by 
inhibiting metabolic enzyme functions through interaction with bacterial thiol 
(sulfhydryl) groups (affecting their shape and stability) found in a variety of proteins 
(Jung et al. 2008; Arai et al. 2015).  Thiols (e.g. cysteine) are able to control bacterial 
oxidative stress and govern metal and metal ion uptake, therefore if deactivated they 
cannot neutralise the activity of Ag/Ag+.  Ag+ are also reported to cause structural changes 
and damage to bacterial cells by binding to negatively charged parts of the bacterial cell 
membrane (Rai et al. 2009), creating pits in the plasma membrane surface, and gaps 
between the cytoplasmic membrane and the cell wall (Fig 4.1) (Feng et al. 2000) thus 
allowing leakage of intracellular components (Dizaj et al. 2014).  In addition, Ag+ can 
also interfere with membrane permeability and modulate signal transduction, leading to 
cell death (Park et al. 2009; Rai et al. 2009; Choi et al. 2008).   
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Figure 4.1 Schematic drawing of a bacterial structure 
Taken from https://www.boundless.com/microbiology/textbooks/boundless-microbiology-textbook/cell-structure-of-bacteria-
archaea-and-eukaryotes-4/cell-walls-of-prokaryotes-34/the-cell-wall-of-bacteria-259-5681/ 
 
 
4.1.1.2 Cu(II)O NPs 
 
Copper (Cu) has properties similar to that of the noble metals (such as silver and gold) 
but unlike these, copper NPs are considered relatively cost effective to produce.  Cu(II)O 
NPs are reported to be very stable when likened to other organic anti-microbial agents 
(Ananth et al. 2015; Das et al. 2013) and have been used in metallic coatings, batteries 
and paints (Chang et al. 2012).  Their main uses are in the electronics and technological 
industries (Bondarenko et al. 2013b), but Cu(II)O NPs have recently been reported as 
being useful in medical applications by displaying bactericidal properties against Gram-
positive species Streptococcus iniae and Gram-negative species E.coli and Pseudomonas 
aeruginosa (Ananth et al. 2015).  There is evidence that Cu-coated titanium particles 
exhibit toxicity against M. smegmatis (Wu et al. 2010) but generally the anti-bacterial 
properties of Cu(II)O NPs are poorly covered in the literature  (Ren et al. 2009).  Only 
recently have these NPs started to gain appropriate attention, hence little is known about 
their mechanism(s) of action.  It is known however, that Cu affects the cell wall by 
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interacting with amine and carboxyl groups and that Cu ions (Cu2+) promote the 
formation of ROS and, similarly to Ag NPs, they accumulate on bacterial plasma 
membranes (Fig 4.1) forming pores, negatively effecting the proton motive forces 
(Pelgrift & Friedman 2013; Chatterjee et al. 2014).  As with Ag NPs, size and the stability 
of Cu(II)O NPs plays a role in their bactericidal activity (Azam, Ahmed, M. Oves, et al. 
2012).  Overall, limited literature was found on the anti-bacterial properties of Cu(II)O 
NPs, therefore it was important to try and bridge this gap.  
  
4.1.1.3 ZnO NPs 
 
ZnO NPs (e.g. zinc oxide nanopowder [<50 nm] from Sigma-Aldrich®) are widely 
reported to have anti-microbial properties against many bacterial species (Gram-negative 
species E.coli and Pseudomonas aeruginosa and Gram-positive Bacillus atrophaeus, 
Bacillus subtilis) (Ramani et al. 2013; Dizaj et al. 2014; Sharma et al. 2012; Heinlaan et 
al. 2008; Padmavathy & Vijayaraghavan 2008).  They are found in antiseptic creams, sun 
lotions, cosmetics and many other consumer products.  Additionally they are found in 
food as additives, used in food packaging as anti-bacterial agents (Ramani et al. 2013; 
Prach et al. 2013; Sharma et al. 2012) and have even been utilised as a fungicide (Wong 
et al. 2010; Allen et al. 1956).  ZnO are one of the most widely produced and utilised NPs 
with production of 550 tons per annum worldwide (Merdzan et al. 2014).  It is reported 
that ZnO NPs exert toxicity through production of ROS on the particle surface and via 
damage to the bacterial cell wall (Fig 4.1) leading to leakage of cellular contents which 
affects membrane permeability (Ramani et al. 2013).  Oxidative stress leads to protein 
and lipid damage (e.g. peroxidation) affecting the membrane and therefore disrupting 
many other cellular processes (Heinlaan et al. 2008).  Other reports include toxicity 
resulting from ion release (Zn2+) which bind to cellular membranes causing severe 
  
110 
 
disorganisation/leakage and/or through the formation of aggregates (Chapter 2 [section 
2.2.2]) that attach directly to pathogens (Li et al. 2011; Ramani et al. 2013).  It has also 
been suggested that ZnO NPs generate toxic ROS (e.g. hydrogen peroxide) and disrupt 
transmembrane electron transport in bacterial cells (Dizaj et al. 2014).  As with both 
Cu(II)O and Ag NPs, ZnO NPs bactericidal activity is enhanced when particles are 
smaller thus increasing bioavailability (Padmavathy & Vijayaraghavan 2008). 
 
Table 4.1 Mechanisms and the attributes of metal/metal oxide NPs toxicity to bacterial 
species 
MECHANISMS  ATTRIBUTES 
Production of ROS TOXICITY OF Size 
Inhibiting enzyme function METAL/METAL 
OXIDE 
Dissolution rate 
Oxidative stress NPS TO Shape 
Disruption of cell membrane GRAM POSITIVE 
AND 
Concentration 
Disruption of membrane 
potential 
NEGATIVE 
BACTERIAL SPECIES 
Charge 
Exposure duration 
Damage to cell wall 
Genotoxicity 
Other 
 Dispersion medium 
(formation of aggregates/ 
agglomerates) 
Other 
 
4.1.2 Aims 
 
Ag, ZnO and Cu(II)O NPs were selected for investigation due to the reported effects on 
many bacterial species and for their different physico-chemical properties, highlighted in 
Figure 4.2.  It was hypothesised that the three NPs tested would differ in their potency 
against the mycobacteria and that the relative toxicity of the NPs would relate to their 
physico-chemical properties, mainly their composition and dissolution rates in the 
bacterial growth culture medium (7H9).  Using the newly developed fluorescence assay 
(Chapter 3), the aim of this chapter was to assess the relative efficacy of these three NPs 
in terms of anti-microbial impacts on Map K10/GFP.  Results from this chapter have been 
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published in Nanotoxicology ‘A rapid screening assay for identifying mycobacteria 
targeted nanoparticle antibiotics’ (Donnellan et al. 2015).  
 
4.2 Methods and Materials 
4.2.1 NP preparation and characterisation 
 
Ag (NM 300) and ZnO (NM 110) NPs were obtained from the European Commission's 
Joint Research Centre (JRC) repository of NPs, while the Cu(II)O NPs were obtained 
from Sigma-Aldrich® (UK).  All NPs were kept in the dark at ambient temperature until 
use.  NPs were diluted in sterile 2% (vol/vol) fetal calf serum (prepared in sterile distilled 
water) at a concentration of 1 mg/mL and sonicated for 16 minutes at 400 W in a bath 
sonicator (Ultrawave®, UK) and then placed on ice (following ENPRA [Risk Assessment 
of Engineered Nanoparticles] [www.enpra.eu]) (Jacobsen et al. 2010; Kermanizadeh et 
al. 2013).    NPs were then diluted (1 mg/mL) in 7H9 medium (see Chapter 2 [section 
2.6.1] for medium details).   
   
4.2.1.1 Transmission electron microscopy (TEM) 
 
Imaging of NP morphology was performed using a Philips CM120 Transmission Electron 
Microscope (FEI, UK).  Images were taken on a Gatan Orius CCD camera.  For all 
particle types, they were prepared as outlined above (at 25 and 100 μg/mL) and 10 µL of 
each suspension was pipetted onto the surface of formvar/carbon coated 200 mesh copper 
grid and allowed to dry at room temperature for 40 minutes prior to imaging. 
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4.2.1.2 DLS  
 
Agglomeration/aggregation status, zeta potential and hydrodynamic sizes were analysed 
by DLS (Pecora 2000) at a concentration of 100 µg/mL using a Zetasizer Nano-ZS 
instrument (Malvern Instruments Ltd., UK) as outlined in Chapter 2 (section 2.2.2).  For 
all particle types, they were prepared as outlined above (section 4.2.1).  
 
4.2.2 Metal salt controls  
 
For each metal/metal oxide particle utilised, a metal salt control was run alongside each 
experiment (in triplicate); silver nitrate (AgNO3), copper sulphate (CuSO4) and zinc 
chloride (ZnCl2) (Sigma-Aldrich
®, UK).  Salts were weighed and diluted in distilled water 
then serial diluted in 7H9, at a metal concentration matching the NPs. 
 
4.2.3 Inductively coupled plasma optical emission spectrometry (ICP-OES)  
 
Inductively coupled plasma optical emission spectrometry (ICP-OES), a branch of atomic 
spectroscopy, was utilised to determine metal concentrations in the broth medium.  ICP-
OES works to determine trace levels of metals in aqueous medium (providing the 
materials of interest can be solvated) by spraying the solution on to plasma whereby 
elements present are detected from the specific wavelengths and intensities emitted from 
the excited atoms/ions.  Initially several wavelengths were selected for each element and 
the following wavelengths were selected for reporting results based on the shape of the 
peaks at that wavelength, background interferences, wavelength sensitivity and the 
linearity of the calibration lines: Ag 328.068 nm, Cu 324.700 nm and Zn 334.501 nm.  
ICP-OES was carried out on a Perkin Elmer Optima 5300 DV (Llantrisant, UK) 
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employing an RF forward power of 1400 W, with argon gas flows of 15, 0.2 and 0.75 
L/min for plasma, auxiliary, and nebuliser flows, respectively (standard ICP-OES set up). 
 
4.2.3.1 Ionic fraction analysis   
 
A 10 mL aliquot of each NP type and metal salt control, prepared at concentrations 25 
µg/mL and 100 µg/mL in 7H9 medium, as outlined above (section 4.2.4), was centrifuged 
for 30 minutes at 1,320 g at room temperature in order to deposit the NP content.  
Following centrifugation, 5 mL of supernatant (without the NP pellet) from each solution 
was carefully transferred to a glass screw neck tube with 5 mL of 4% nitric acid (99.999% 
purity, trace metal basis [Sigma-Aldrich®, UK]) giving a final acid concentration of 2% 
and a final volume of 10 mL.  This analysis was done at two time points; immediately 
after addition of NPs to 7H9 (day 0) and 7 days post addition of NPs into 7H9, during 
which time the NPs and medium had been incubated at 37˚C on a plate shaker (250 rpm).  
Each acidified sample was vortexed (no further dilutions were carried out) and loaded 
into a peristaltic pump where sample solutions were taken up into a Gem Tip cross-Flow 
nebuliser and Scotts spray chamber at a rate of 1.50 mL/min (assisted by laboratory 
technician Dr Lorna Eades, School of Chemistry, University of Edinburgh).  
 
4.2.3.2 Total concentrations analysis  
 
A 10 mL aliquot of each NP type and salt control, prepared as outlined above (at 
concentrations 25 µg/mL and 100 µg/mL in 7H9), was added to 10 mL of 68% nitric acid 
(trace metal grade [Sigma-Aldrich®, UK]), giving a final acid concentration of 34%.  This 
analysis was done at two time points, as above; immediately after addition of NPs to 7H9 
(day 0) and 7 days post addition of NPs into 7H9, during which time the NPs and medium 
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had been incubated at 37˚C on a plate shaker (250 rpm).  For analysis, each sample was 
diluted 10 fold and vortexed prior to analysis.   
The instrument was operated in axial mode for all samples and a range of calibration 
standards for each element were prepared using single element 1000 mg/L standards 
(Fisher Scientific, UK), diluted with 18.2 Ω deionised water.  A 10 fold dilution of Merk 
ICP Multi element standard solution VI CertiPUR® was employed as a reference standard 
for each of the elements.  The wavelengths were selected for each element and analysed 
in fully quant mode (three points per unit wavelength).  Three replicate runs per sample 
were employed  (laboratory technician Dr Lorna Eades, School of Chemistry, University 
of Edinburgh, carried out the analysis whilst I carried out all sample preparation and 
monitoring in all cases). 
 
4.2.4 Metal/Metal Oxide NP 96 well Plate setup for toxicity assessment  
 
Map K10/GFP was cultured in 7H9K+ (see Chapter 2 [section 2.1.1]) until the exponential 
stage of growth (see Chapter 3 [section 3.1.4]) was reached and cells were seeded in a 96 
well at 2x106 CFU/mL (in 100 µL of 7H9).  Serial dilutions of NPs were made in 7H9 to 
give final concentrations per well ranging from 0 (control) to 100 µg/mL and were added 
to the wells containing Map K10/GFP, giving a final volume of 200 µL per well.  The 
samples were incubated at 37ºC with medium agitation (250 rpm) and kept in the dark 
throughout the experimental procedure.  To check for NP interference, wells of medium 
only (no bacteria, no NPs) and NPs and medium (no bacteria) were included.  
Fluorescence was measured using a GloMax® Multi+ plate reader (Promega, UK) at an 
excitation of 490 nm and emission of 510-570 nm (see Chapter 3 [section 3.3.1]).  
Bacterial fluorescence was monitored immediately before and after NP addition (day 0), 
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then at the same time each day for 7 days.  The same steps were taken for the three salt 
controls.  All experiments were performed in triplicate under sterile conditions.  
 
4.2.5 Data Analysis for fluorescence assay  
 
Results expressed in Arbitrary Fluorescent Units (AFU) against time (days) were 
transformed and normalised to obtain a dose response relationship, to compare the effects 
of the NPs and salt controls on the growth of the mycobacteria as outlined in Chapter 3 
(section 3.3.4).  This data was then plotted using the dose response modelling software 
PROAST (version 38.9 [RIVM, The Netherlands]) in the R software (version 3.1.0, [R 
Foundation for Statistical Computing, Austria]).  By setting the critical effect size (CES) 
to 50% it was possible to obtain the half maximal effective concentration (EC50 [the 
critical effect dose [CED]) and lower/upper 90% confidence intervals [CEDL/CEDU]) to 
allow for statistical comparison to determine if the NP differed significantly from each 
other, and/or their corresponding salt controls.  
 
4.2.6 Colony counts 
 
Following 7 days of Map K10/GFP incubation with NPs in 7H9, 100 µL of the cultures 
at each concentration were serial diluted and inoculated onto 7H11 agar in petri dishes 
for 12 weeks and incubated at 37ᵒC.  Using conventional colony counts (see Chapter 2 
[section 2.1.2]) NP toxicity was ranked.    
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4.2.7 Cytotoxicity of NPs to macrophages  
 
Macrophages (J774A.1 cells) were cultured until confluent and counted as outlined in 
Chapter 2 (section 2.3.1) and NPs were prepared as described in 4.2.1.  Using the alamar 
blue assay (see Chapter 2 [section 2.4]), cytotoxicity to macrophages was tested for the 3 
NP types (over a 24 hour period, at a concentration range of 0.146-150 µg/mL).  
 
4.2.8 Imaging 
4.2.8.1 Infected macrophages treated with metal/metal oxide NPs for TEM imaging 
 
Macrophages were cultured until confluent and counted as outlined in Chapter 2 (section 
2.3.1).  Cells were detached from flasks using TrypLETM and centrifuged at 850 g for 2 
minutes before being resuspended in complete medium (without antibiotic) and added on 
to NuncTM ThermanoxTM Coverslip slides in sterile 24 well plates at a density of 2x105 
cells/well (determined using Trypan blue [see Chapter 2 [section 2.5.1]).  The cells were 
then incubated for 24 hours at 37ºC, 5% CO2.  Supernatant was removed from the 
chambers and cells were washed twice with 400 µL PBS.  Map K10/GFP was cultured 
as described previously (see Chapter 2 [section 2.1.1]) and 10 mL of bacterial culture was 
centrifuged at 3090 g for 20 minutes and resuspended in 1 mL of PBS.  The 1 mL culture 
was centrifuged for 5 minutes at 670 g to remove any residual antibiotic, resuspended in 
1 mL of PBS and passed through a Gilson tip several times to break apart any clumping.  
After accurate cell counts (see Chapter 2 [section 2.5.2]) at a 30:1 multiplicity of infection 
(MOI) the macrophages were infected with mycobacteria in complete medium (without 
streptomycin or penicillin) at a final volume of 400 µL per well and incubated for 30 
minutes at 37ºC, 5% CO2.  During this time, each NP type was prepared as described 
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above (at a concentration of 12.5 µg/mL), then added to the wells with Map K10/GFP 
infected macrophages and incubated for a further 4 hours at 37ºC, 5% CO2. 
Fixation was performed using 3% glutaraldehyde in 0.1 M sodium solution in cacodylate 
for 2 hours then stored in a 0.1 M sodium solution in cacodylate buffer prior to TEM 
imaging (see Chapter 2 [section 2.7.2]).  Sample preparation for TEM was carried out by 
Mr Stephen Mitchell (Bio-Imaging Facility, The University of Edinburgh).  Briefly, the 
samples were dehydrated in 50%, 70% and 100% normal grade acetone for 10 minutes, 
followed by 2 x 10 minute washes in analar acetone before embedding in araldite resin.  
Sections of 1 uM thickness were cut with a Reichert OMU4 utlramicrotome (Leica 
Microsystems, UK) stained with toluidine blue and viewed under a light microscope 
(Olympus BX40) to select suitable areas for imaging.  Sections (60 nm thickness) were 
stained in uranyl acetate and lead citrate and the infected macrophages (treated with NPs) 
were viewed using a JEM-1400 Plus TEM* (JEOL Ltd, Tokyo, Japan).   
*please note this was a different transmission electron microscope from previous NP imaging; the 
equipment was updated in September 2015.  
 
4.2.8.2 Macrophages treated with metal/metal oxide NPs for fluorescence imaging 
 
As above, excluding the Map K10/GFP infection of the macrophages.  Uninfected cells 
were treated with all the NP types.  Cells were fixed using 4% paraformaldehyde (see 
Chapter 2 [section 2.7.1]) and imaged using a Zeiss Axiovert 200M inverted Epi 
fluorescence microscope (Zeiss, Cambridge, UK)**. 
**please refer to Chapter 5 for detailed methods on fluorescent microscopy.  
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4.3 Results 
4.3.1 NP Characterisation    
 
The NP supplier information is outlined in Table 4.2.  Ag and ZnO NPs have been 
extensively characterised previously (Table 4.3) (Kermanizadeh et al. 2013), whereas 
there is scarce literature on the characterisation of Cu(II)O NPs.  Characterisation for the 
Ag, Cu(II)O and ZnO NPs was conducted in this study using the 7H9 growth medium. 
 
Table 4.2 NP Information.  The nominal sizes and properties as provided by the supplier 
NP 
Supplier 
Name 
NP Diameter 
(supplier) 
Surface Area 
(m2/g) 
Additional 
Information 
 
Ag (NM 300) 
 
 
 
 
JRC Repository 
 
 
 
 
<20 nm 
 
 
 
 
N/A* 
 
Polyoxylaurat 
Tween 20 
capped 
Cu(II)O 
 
Sigma-Aldrich® 
 
<50 nm 
 
29 Uncoated  
 
ZnO (NM 110) 
 
JRC Repository 
 
100 nm 
 
13 Uncoated  
 
*Supplied as an aqueous suspension of nano Ag with stabilising agents 
 
Table 4.3 Kermanizadeh et al., (2013) Characterisation Data 
(used with permission from the author) 
NP  Phase TEM 
Size 
(nm) 
Surface 
area  
(m2/g) 
 Size (nm) 
in MEM* 
(DLS)** 
Primary characteristics by 
TEM analysis 
Ag (NM 300) Ag 8-47 
(av: 
17.5) 
N/A 51 Mainly euhedral NP; minor 
fractions have either elongated 
or sub-spherical morphology 
 
ZnO (NM 110) Zincite 20-250/ 
50-350 
14 306 Mainly 2 euhedral 
morphologies: 20 - 250 nm 
range and few particles of 
approx. 400 nm.  OR 50-350 
nm with minor amounts of 
particles with irregular 
morphologies observed. 
* Minimum Essential Media 
** Intensity based size average in biological media after 15 minutes 
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4.3.1.1 DLS 
 
DLS measures hydrodynamic diameter; the size of primary particles if dispersed, or 
agglomerates along with the shell of ions/water molecules associated with the surface, by 
measuring the scattered light that passes through a solution.  The larger the NP or 
aggregate/agglomerate (see Chapter 2 [section 2.2.2]), the slower light will diffuse thus 
allowing hydrodynamic diameter of particles to be determined via a measure of time.  The 
size of all the tested NPs is provided in Table 4.4.  The zeta potential, a measure of the 
charge carried by NPs when suspended in an aqueous environment, gives an indication 
of the stability of NPs in a solution.  The zeta potential for all the tested NPs is provided 
in Table 4.4.   
The average hydrodynamic diameter for Ag NPs obtained by DLS was 46.47 nm, thus 
being akin to suppliers’ information (Table 4.2).  This suggests DLS detected individual 
NPs and/or 2 NPs and there was little spread in the data as shown by the intensity graph 
(Fig 4.3a).  The zeta potential was -9.37 mV thus suggesting the NPs were unstable in the 
7H9 medium (the zeta potential distribution graphs are provided in Appendix A).  
 The average hydrodynamic diameter for Cu(II)O NPs was 408.46 nm, suggesting that 
DLS was detecting agglomerates rather than individual NPs as suppliers’ report NPs <50 
nm (Table 4.2).  The intensity graph (Fig 4.2b) displays a spread in the sizes detected by 
this method.  The zeta potential was -11.40 mV again suggesting instability in 7H9 
(Appendix A). 
The average hydrodynamic diameter for ZnO NPs was 190.61 nm, again suggesting that 
DLS was detecting agglomerates (maybe 2 NPs) (Table 4.4).  The intensity graph (Fig 
4.2c) displays 3 main peaks, showing that both smaller and larger agglomerates were 
detected in the solution and there was high variation.  The zeta potential was -8.22 mV, 
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and being very low these NPs were also unstable when dispersed in 7H9 (Appendix A).  
Overall, DLS results suggest that NP agglomeration/aggregation occurred in the growth 
medium of Map K10/GFP (7H9), particularly for Cu(II)O and ZnO NPs and that the NPs 
exhibited a very small negative charge in the aqueous environment. 
 
 
Table 4.4 DLS Results. Z-average (Hydrodynamic diameter), zeta potential (an estimate of NP 
surface charge) and polydispersity index (PdI [a measure of size variation]) of the NP panel was 
assessed using dynamic light scattering (DLS).  Data expressed as mean ± SEM (n=6).  Temp: 
25°C, dispersant: Middlebrooks 7H9 (100 µg/mL), pH 6.9, equilibrium time: 30 seconds.  
NP 
Z-Average (d.nm) 
DLS 
Zeta Potential 
(mV) 
DLS 
PdI 
DLS 
 
NP Diameter 
(TEM in 7H9) 
Ag (NM 300) 46.47±3.3 -9.37±1.3 0.465±0.01 <50 nm 
Cu(II)O 408.46±10.13 -11.40±0.26 0.365±0.02 Unknown* 
ZnO (NM 110) 190.61±25.3 -8.22±0.48 0.55±0.1 Unknown* 
*TEM showed NP agglomeration/aggregation in 7H9 therefore an accurate diameter measurement was unobtainable from TEM  
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a) 
 
b) 
 
c) 
Figure 4.2 Size intensity graphs (DLS) (n=6) 
 
(a) Ag NPs in 7H9 
(b) Cu(II)O NPs in 7H9 
(c) ZnO NPs in 7H9 
 
 
  
122 
 
4.3.1.2 TEM  
 
TEM analysis was performed to determine the size, morphology and dispersion patterns 
of the NPs in 7H9 and distilled water.  It provides primary particle size and/or 
agglomerate size.  This does not include the surface associated water and ions.  
Micrographs from TEM analysis suggest that Ag NPs were well dispersed in 7H9 at both 
concentrations imaged (Figs 4.3a,b).  Figure 4.3 (a) depicts Ag NPs at 25 μg/mL in 7H9, 
NPs are well dispersed and primary particle size was found to be <50 nm.  No 
agglomeration was evident, although slight clustering was observed but the spherical 
shape of the NPs was clearly visible.  Figure 4.3 (b) depicts Ag NPs at 100 μg/mL in 7H9.  
Overall the NPs display limited agglomeration and smaller particles were observed 
surrounding larger particles, which may have been generated via precipitation of 
dissolved Ag+ ions as silver salts.  When dispersed in distilled water (at 100 μg/mL) Ag 
NPs were found to be well dispersed, evenly spread, spherical in shape and primary 
particle size was <50 nm (Figs 4.3c,d).  Smaller particles can be seen surrounding a larger 
particle, again possibly caused via precipitation of dissolved Ag+ ions (Figs 4.3b,d). 
Cu(II)O were agglomerated/aggregated in 7H9 at both concentrations tested.  Figure 4.3 
(e) depicts agglomerates/aggregates of Cu(II)O NPs at 25 μg/mL in 7H9, where 
individual NPs were barely visible.  At 100 μg/mL (Fig 4.3 f) Cu(II)O NPs were highly 
agglomerated/aggregated and only masses of NPs were visible and so no information on 
individual NP size/shape could be obtained.  When dispersed in distilled water (at 100 
μg/mL) Cu(II)O NPs were agglomerated/aggregated, although to a much lesser extent 
than when dispersed in 7H9 medium, thus allowing mixed shaped particles to be seen 
(Fig 4.3 g,h).  Figure 4.3 (h) shows that it was possible to see individual Cu(II)O NPs in 
distilled water, but these images were difficult to obtain.   
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ZnO NPs were also agglomerated/aggregated in 7H9 at both concentrations tested (Figs 
4.3 i,j).  Figure 4.3 (i) depicts ZnO NPs at 25 μg/mL in 7H9 where 
agglomeration/aggregation was evident and mixes of different shaped/sized NPs were 
present.  As such, information on individual particle size/shape was not possible to 
acquire.  When at 100 μg/mL in 7H9 (Fig 4.3j), miscellaneous shapes were visible 
amongst large dark masses of agglomerates/aggregates.  Again individual NP size/shape 
was not possible to view when dispersed in 7H9.  The same pattern was observed when 
ZnO NPs were dispersed in distilled water (Figs 4.3 k,l).  As they behaved similarly when 
in both aqueous environments, it indicates that that ZnO NPs tend to form 
agglomerates/aggregates readily when dispersed.  Overall TEM micrographs concur with 
the DLS results, that Ag NPs were well dispersed in 7H9 at the concentrations tested, 
unlike Cu(II)O and ZnO NPs. 
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a) b) 
 
 c) d) 
Figure 4.3 (a-d) TEM-images of Ag NP suspensions in 7H9 medium (a,b) and distilled water 
(c,d) (magnification ranging from 30-52K) (scale bars all represent 50 nm). 
 
a) Ag NPs at 25 μg/mL in 7H9.  NPs were well dispersed with individual particle size <50 
nm. 
 
b) Ag NPs at 100 μg/mL in 7H9.  NPs were well dispersed with different sized NPs visible, 
generally NPs were ≤50 nm. 
 
c) Ag NPs at 100 μg/mL in distilled water.  NP were very evenly dispersed, with particle 
size <50 nm.   
 
d) Ag NPs at 100 μg/mL in distilled water.  NPs were evenly dispersed, different sized NPs 
were visible and average particle size <50 nm.   
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       e)                      f) 
 
                    g)                                                          h) 
Figure 4.3 (e-h) TEM-images of Cu(II)O NP suspensions in 7H9 medium (e,f) and distilled 
water (g,h) (magnification ranging from 30-52K) (note the different scale bars).  
 
e) Cu(II)O NPs at 25 μg/mL in 7H9.  Only agglomerates were visible.   
 
f) Cu(II)O NPs at 100 μg/mL in 7H9.  Mass agglomeration/aggregation occurred with 
individual NPs not visible.  
 
g) Cu(II)O NPs at 100 μg/mL in distilled water.  NPs were agglomerating, but individual 
NP shapes can be visualised.   
 
h) Cu(II)O NPs at 100 μg/mL in distilled water.  Individual NPs both <50 nm. 
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i) j) 
 
      k)                         l) 
Figure 4.3 (i-l) TEM-images of ZnO NP suspensions in 7H9 medium (i,j) and distilled water 
(k,l) (magnification ranging from 30-52K) (note the different scale bars). 
 
i)  ZnO NPs at 25 μg/mL in 7H9.  Agglomeration/aggregation was occurring, NP size was 
not possible to obtain 
 
j) ZnO NPs at 100 μg/mL in 7H9.  Mass agglomeration/aggregation was occurring. 
 
k) ZnO NPs at 100 μg/mL in distilled water.  NPs were highly agglomerated; a mix of varied 
shapes and sizes was visible.  
 
l) ZnO NPs at 100 μg/mL in distilled water.  NPs were highly agglomerated, forming 
masses throughout the field of view.  
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4.3.2 Assessment of NP Dissolution (ICP-OES) 
 
NP dissolution in 7H9 medium was assessed at day 0 and 7 using ICP-OES.  It is difficult 
to have confidence in this data, due to the large spread in the data and the problems 
encountered trying to detect Ag in the medium.  The data for all NPs suggested low 
solubility (Fig 4.4).  Cu(II)O NP solubility was low at day 0 but a small increase in 
solubility was observed by day 7, whereas CuSO4 dissolution was generally high in 7H9, 
suggesting that for the copper salt Cu2+ ions played a significant role in the toxicity to 
Map K10/GFP (Fig 4.4).  The solubility of ZnO NPs did not change over time, in-fact it 
slightly decreased by day 7, but the solubility of these NPs was generally very low (Fig 
4.4).  ZnCl2 solubility on day 0 was relatively high, but this did not change over time (Fig 
4.4).  It is possible that components of complex 7H9 medium (see Chapter 2 [section 
2.6.1]) interfered in this assay.   
In order to check the ability of the ICP-OES technique to accurately measure the metal 
content of both the NP and metal salt suspensions, the total amount of metal in each of 
these solutions was analysed.  For Cu(II)O and ZnO NPs (and salts), at day 0 and 7, the 
concentration of Cu and Zn detected generally reflected the concentration of metal added 
to the 7H9 medium, suggesting that this analysis worked (Fig 4.5).  In contrast Ag NPs 
and AgNO3 was not detected using the protocol applied in this study, suggesting that it 
was not possible to accurately determine the extent of Ag dissolution in the 7H9 medium 
(Fig 4.5).  
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Figure 4.4 Ionic analysis using ICP-OES: Assessment of dissolution of the NPs and salts in 
7H9.  The solubility of ZnO and Cu(II)O NPs did not change over time and ion release was very 
low for all NPs. Data for Ag NPs was very variable and therefore not reliable.  Overall, the results 
shown for the metal ion concentrations for Ag NPs, AgNO3 and ZnCl2 cast this method into doubt.  
Each point displaying SEM (n=4). 
 
 
 
Figure 4.5 A measure of the total amount of metal in each solution using ICP-OES. The 
amount of metal detected for Cu(II)O and ZnO particle types generally reflects the concentration 
of NPs/metal salt added to 7H9.  However, this method did not yield results for Ag NPs or AgNO3.  
Each point displaying SEM (n=4).  
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4.3.3 Anti-mycobacterial properties of NP 
 
Following exposure to Ag, Cu(II)O or ZnO NPs, the growth of Map K10/GFP was 
inhibited in a dose and time dependent manner.  The different stages of the data analysis 
for Ag NPs are presented in Figures 4.6 a-d, Table 4.5 and in Appendix A for Cu(II)O 
and ZnO NPs.  The results are firstly presented as AFU plotted against time obtained on 
the GloMax® Multi+ (Promega, UK) and presented using Excel (Microsoft Office 
Worksheet) as G= G0.exp(βt) (as previously described in Chapter 3 [section 3.3.4]) (Fig 
4.6 a).  The control well values (medium with NP but no bacteria) were subtracted from 
the experimental well values to exclude any NP interference in fluorescence readings.  
 There was a clear dose dependent inhibition of the Map K10/GFP growth, observable 
within 3-4 days of exposure at concentrations as low as 6.25 µg/mL for Ag NPs (Figs 4.6 
a-c).  The raw data (Fig 4.6 a) indicates that at the highest concentration tested (100 
µg/mL), Ag NPs affected mycobacterial viability after only 48 hours of incubation.  This 
inhibition was also reflected in the log data, which displays the linear relationship from 
which β was calculated (LogG=LogG0+βt) (Fig 4.6 b, Table 4.5).  Figure 4.6 (c) depicts 
the transformed and normalised change in fluorescence data for Ag NP, allowing 
development of a dose response curve for Ag NP in this case, which could be replicated 
to allow comparison between all NPs. 
Figure 4.7 depicts the 3 different NPs and their efficacy against Map K10/GFP over a 7 
day period.  Ag NPs were the most toxic, there was an obvious inhibition of growth even 
at the lowest concentration tested (6.25 µg/mL) and toxicity generally increased with 
concentration over time.  Cu(II)O NPs seemed to enhance mycobacterial growth at the 
lowest concentration, toxicity slightly increased with concentration but fluorescence (the 
indicator of viability) was not inhibited below 50% by 100 µg/mL, unlike Ag NPs (Fig 
4.7).  ZnO NPs overall displayed little toxicity over the 7 day period, although these 
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particles were more toxic than Cu(II)O NPs at 6.25 µg/mL, toxicity did not increase with 
concentration and fluorescence was not inhibited below 50% at any time point (Fig 4.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
131 
 
 
 
Figure 4.6 (a) Viability Testing: Growth of Map K10/GFP with Ag NP (raw data).   Map 
K10/GFP grown in 200 µL of 7H9 in a microplate format, with Ag NP at different concentrations 
(6.25-100 µg/mL) over a period of 7 days, represented in the form: G= G0.exp(βt) (where β 
represents the change in fluorescence [representing mycobacterial growth] per day) using the raw 
data with each point displaying 2* the SEM (n=6). 
 
 
 
 
 
 
Figure 4.6 (b) Data Transformation 1: plot of the Log data to determine β.  Linear regression 
analysis of Map K10/GFP growth with Ag NPs in the form LogG=LogG0+βt to calculate β 
(where β represents the change in fluorescence [representing mycobacterial growth] per day) (see 
Table 4.4). 
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Table 4.5 β Values calculated from the linear regression of the Log data from Figure 4.7 (b) 
normalised to the slope of the control (0 µg/mL) to plot Figure 4.7 (c).  
Concentration (µg/mL) Slope of the line (β) β (Normalised) 
0 0.2243 
 
1 
 
6.25 0.1534 
 
0.683905 
 
12.5 0.1027 
 
0.457869 
 
25 0.0255 
 
0.113687 
 
50 0.0574 
 
0.255907 
 
100 0.02 
 
0.089166 
 
 
 
 
Figure 4.6 (c) Data Transformation 2: Growth of Map K10/GFP with Ag NP normalised to 
the control.  Normalised, transformed data showing the growth of Map K10/GFP grown in 200 
µL of 7H9, in a microplate format, with Ag NP at different concentrations (6.25-100 µg/mL), 
normalised to the slope of the control (where β represents the change in fluorescence [representing 
mycobacterial growth] per day).  β was calculated through linear regression analysis of the Log 
data (Figs 4.6 a, b, Table 4.4).  Each point displaying 2* the standard error calculated using 
LINEST function Excel (Microsoft Office Word) (n=6).   
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Figure 4.7 Growth of Map K10/GFP with 3 NPs normalised to the control.  Map K10/GFP 
grown in 200 µL of 7H9 in a microplate format, with Ag, Cu(II)O and ZnO NPs at different 
concentrations (6.25-100 µg/mL) normalised to the slope of the control where β represents the 
change in fluorescence (representing mycobacterial growth) per day, with each point displaying 
2* the standard error, calculated using LINEST function Excel (Microsoft Office Word) (n=min 
of 3 for each NP type).  
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4.3.4 Anti-mycobacterial properties of NPs compared with salt controls  
 
Figure 4.8 depicts the efficacy of the 3 different NPs and their corresponding salt controls 
at inhibiting the growth of Map K10/GFP and it shows that there was a dose dependent 
inhibition of growth, with an obvious difference in efficacy between the different NPs 
and salt controls.  Ag NP and AgNO3 were highly toxic to the mycobacteria and very 
similar to each other in terms of their toxicity, whereas ZnO NP and ZnCl2 both induced 
no significant toxicity over the 7 day period.  Cu(II)O NP were less toxic to the 
mycobacteria than its salt control, as CuSO4 inhibited growth at nearly all concentrations 
tested and was similar in toxicity to Ag NP/AgNO3 by day 7 (Fig 4.9).  
 
 
 
Figure 4.8 NP v Metal Salt Efficacy against Map K10/GFP.  Map K10/GFP grown in 200 µL 
of 7H9 in a microplate format, with salts or NP at different concentrations (6.25-100 µg/mL) 
normalised to the slope of the control where β represents the change in fluorescence (representing 
mycobacterial growth) per day, with each point displaying 2* the standard error, using LINEST 
function Excel (Microsoft Office Word) (n=min of 3 for each substance). 
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Figure 4.9 illustrates the relative growth rate of the mycobacteria (the β data plotted in 
PROAST [38.9]) on treatment with each of the NP (and salt controls) re-plotted in 
PROAST (38.9).  This plot allowed the estimation of the EC50 for each substance and to 
determine whether the NPs and the salt controls differed significantly from each other 
(Fig 4.10, Table 4.6).  Figure 4.10 shows the EC50 values with confidence intervals for 
each NP/salt control, plotted from Table 4.6.  Comparing the confidence intervals for the 
3 NPs it was clear that they did not overlap, therefore we could be reasonably confident 
that there was a significant difference between the 3 NPs and the 3 salt controls tested 
(Fig 4.10, Table 4.6).  There was no significant difference between the Ag/ZnO NPs and 
both their corresponding salts however, which were very similar (Figs 4.9 & 4.10).  The 
EC50 values for Cu(II)O NPs and CuSO4 were significantly different, with the copper salt 
being more toxic (Figs 4.9 & 4.10).  Using this analysis, the toxicity of the different NPs 
was ranked in the following order: Ag>Cu(II)O>ZnO.   
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Figure 4.9 NP v Salt efficacy: comparison between NP and salt controls on the growth of 
Map K10/GFP NP normalised to the control, re-plotted in PROAST 38.9.  Map K10/GFP 
grown in 200 µL of 7H9 in a microplate format, with salts or NP at different concentrations (6.25-
100 µg/mL).  β data obtained as described (Fig 4.7 a,b) and all substances were plotted using 
PROAST 38.9* to allow comparison between NP and salts.   
 
*please note PROAST 38.9 does not allow allocation of figure legend or choice of colours/symbols 
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Table 4.6 EC50 value for each substance with the lower (CEDL) and upper (CEDU) 90% 
confidence intervals to plot Figure 4.11, derived from Figure 4.10.  
Treatment Ag NP Cu(II)O NP ZnO NP AgNO3 CuSO4 ZnCl2 
EC50 5.71 149 399 2.45 28.8 566 
CEDL 3.11 22.5 180.3 0.75 7.2 184.1 
CEDU 5.99 36.9 761 0.95 10.3 333 
 
 
 
 
Figure 4.10 The half maximal effective concentration (EC50) for each compound with the 
upper and lower 90% confidence intervals.  Plot of the mean EC50 values and corresponding 
confidence intervals (on the common logarithmic scale) for each treatment on the rate of 
mycobacterial growth.  
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4.3.5 Colony Counts  
 
Figure 4.11 depicts the growth of Map K10/GFP on solid agar after incubation for 12 
weeks, following 7 day exposure to the NPs/salt controls.  This experiment was conducted 
as a control alongside the fluorescence assay, as it is the conventional approach to 
assessing the impact of substances on mycobacterial growth.  These results were in 
general variable and some were completely disregarded (e.g. due to signs of 
contamination or where counting individual colonies wasn’t possible).  From this data, 
Ag NPs and AgNO3 have exerted the most toxicity against Map K10/GFP.  Cu(II)O NPs 
and CuSO4 were similar in their effects, unlike what was observed in the 7 day 
fluorescence assay.  Interestingly ZnO NPs had an effect on mycobacterial growth after 
12 weeks incubation on agar, whereas ZnCl2 had very little effect on growth.  Compared 
to the control plates, morphological differences were observed in colonies treated with 
NPs/salt controls.  Generally colonies tended to be much smaller and less well defined, 
probably caused by stress, but this phenomenon did increase the variability when cell 
counting, as a ‘pinpoint’ colony was still counted as 1 along with a ‘healthy’ colony.  
Using the conventional method of toxicity testing it was clear that toxicity could be 
ranked in the same order, where: Ag>Cu(II)O>ZnO.   
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Figure 4.11 Colony counts after 12 weeks culture on 7H11 agar.  Using conventional colony 
counts, the toxicity of the different NPs can be ranked in the following order: Ag>Cu(II)O>ZnO.  
Each concentration displaying the SEM (n=min of 3 repeats). 
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4.3.6 Cytotoxicity of NPs to macrophages  
 
Cytotoxicity was tested over a concentration range of 0.14 - 300 µg/mL, by serial 
dilutions (plate set up, with controls, displayed in Fig 4.12) using the alamar blue assay 
(Chapter 2 [section 2.4]).  Results were expressed by determining the mean value of the 
positive controls (0.1% triton) and subtracting this from the mean value of the negative 
controls (medium only [giving an overall mean control, n= min of 3]).  All readings were 
then divided by the overall mean control (negative control minus the positive control) and 
*100, to show toxicity by the % of cells viable at each concentration of NP/salt tested 
after 24 hours incubation.  Figure 4.13 illustrates that cytotoxicity of the three NPs was 
relatively cytotoxic and very similar.  Statistical significance was first determined using 
an analysis of variance (ANOVA) test, which found an overall high level of significance 
(p <0.001), therefore, each NP was considered separately to compare each concentration 
between particle types via a student’s t-test (2 sample t-test) (MINITAB®, version 17).  
Results were considered significant if p <0.05 (significance level was denoted by: 
p<0.001 [***], <0.01 [**] and <0.05 [*]).  
All three NPs were found to be cytotoxic to the macrophages.  Concentrations >37.5 
µg/mL decreased cell viability to below 50% and differed significantly from the control 
(0 µg/mL) for Cu(II)O and ZnO NPs.  There was an obvious colour change (from blue to 
pink) in the highest four concentrations tested (300, 150, 75 and 37.5 µg/mL), then the 
colour change became more subtle as the concentrations decreased (Fig 4.13). 
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Figure 4.12 NP cytotoxicity 96 well plate following 24-hour incubation with ZnO NPs 
(alamar blue assay).  Where the blue colour is visible, cells were no longer viable thus 
representing cell death, detected upon fluorescence readings.  As shown in the negative control 
and lowest NP concentration wells, a strong colour change is evident, from blue to pink.  
 
 
 
 
 
Figure 4.13 NP cytotoxicity to macrophages after 24-hour incubation.  All NPs display a 
similar level of cytotoxicity, decreasing cell viability below 50% from 37.5 µg/mL of each NP 
type.  Significance level is denoted by: p <0.001 (***), <0.01 (**) and <0.05 (*).  Each 
concentration displaying the SEM (n=3). 
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4.3.7 Imaging macrophages following treatment with metal/metal oxide NPs  
 
High-resolution TEM images were obtained of Map K10/GFP infected macrophages, 
treated with NPs.  In each case, cells were infected and treated for 4 hours with NPs at a 
concentration of 12.5 µg/mL.  Figure 4.14 (a) illustrates the control; untreated and non-
infected macrophages by TEM, and (b) highlights a common problem when imaging 
macrophages treated with NPs by TEM, the precipitation of heavy metals in the staining 
process creating dark strains which can be misinterpreted.  Please note the difference in 
scales.  
 
 
            a)                                                        b) 
 
Figure 4.14 Macrophages by TEM (TEM magnification ranging from 30-90K) (note the 
different scale bars).  (a) depicts a macrophage and (b) the staining process for TEM uses heavy 
metals (e.g. lead, uranium) that can precipitate out, which can be wrongly interpreted as NPs as 
indicated by the arrow.  
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Figure 4.15 (a-c) illustrate Map K10/GFP infected macrophages following 4 hour 
treatment with Ag NPs at 12.5 µg/mL.  It appears that the NPs (of different sizes [possibly 
metal ions]) were engulfed by the macrophages, as shown in Figure 4.15 (a-c).  Figure 
4.15 (e) shows the NPs within a cellular organelle, possibly a lysosome.   
Figure 4.15 (d-f) illustrate Map K10/GFP infected macrophages following 4 hour 
treatment with Cu(II)O NPs at 12.5 µg/mL.  The TEM images (d-f) illustrate what looked 
to be engulfed NPs, and their location throughout the cell.  Figure 4.15 (f) shows a 
structure that could be associated with cell damage (possible evidence of cellular contacts 
seeping out).  This was a common pattern observed for macrophages treated with Cu(II)O 
NPs.  
Figure 4.15 (g-i) illustrate Map K10/GFP infected macrophages following 4 hour 
treatment with ZnO NPs at 12.5 µg/mL.  TEM indicates that the ZnO NPs had no toxic 
effect on macrophages.  No pits, or damage to the cytoplasm was observed.  Figure 4.15 
(h-i) illustrate what is possibly a lysosome, with internalised ZnO NPs.  By increasing the 
magnification, a black mass of possible ZnO NPs was observed inside the cellular 
organelle (Fig 4.15 i).  
Unfortunately in all cases, mycobacteria were not detected within NP treated 
macrophages.  It also must be considered that what was assumed to be damage to the 
macrophages could actually be cellular uptake, whereby the membrane is forming around 
NPs to internalise them.  This was deemed unlikely as many cellular fragments were 
imaged thus suggesting cell death, but should be considered.  
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          a)                                                                       b) 
                        
 
                                                c)                                                
 
 
Figure 4.15 (a-c) Macrophages following treatment with Ag NPs (12.5 µg/mL) (TEM 
magnification ranging from 50-90K) (note the different scale bars).  From these images, it 
is assumed that it is Ag NPs which are visible, but as Energy Dispersive X-Ray (EDX) 
Spectroscopy analysis was not carried out, this could not be confirmed.  
 
a) Macrophage with possible intracellular Ag NPs (see arrows), showing the likely 
precipitation of Ag+ from NPs.  
 
b) Macrophage with intracellular Ag NPs (see arrow), NPs appeared to be slightly 
agglomerated, although individual structures can be viewed.  
 
c) Macrophage with intracellular Ag NPs inside a vacuole, possibly a lysosome (see arrow).  
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         d)                                                                    e) 
 
                                              f)                                                
 
Figure 4.15 (f-h) Macrophages following treatment with Cu(II)O NPs (12.5 µg/mL) (TEM 
magnification ranging from 50-90K) (note the different scale bars).  From these images, it 
is assumed that it is Cu(II)O NPs which are visible, but as EDX Spectroscopy analysis was 
not carried out, this could not be confirmed. 
 
d) Macrophage with possible intracellular Cu(II)O NPs (see arrows).  The NPs are much 
smaller than previous TEM images (of NPs in medium), thus suggesting these were 
precipitated Cu2+ rather than NPs.  
 
e) Macrophage with intracellular Cu(II)O NPs (see arrows), where NPs appeared to be 
internalised within a vacuole or were causing structural damage to the cell by creating 
pits/holes.  
  
f) Macrophage with structural damage (to the cellular cytoplasm [see arrow]), likely caused 
by the Cu(II)O NPs.  Conversely, this could be a membrane forming around particles to 
make a phagosome.  Additionally, this could be the formation of an extracellular trap 
by NETosis.   
 
Possible pit 
allowing 
seepage of 
cellular 
contents 
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           g)                                                                   h)                                                 
 
                                      i) 
 
Figure 4.15 (i-k) Macrophages cells following treatment with ZnO NPs (12.5 µg/mL) 
(magnification ranging from 30-90K) (note the different scale bars).  From these images, it 
is assumed that it is ZnO NPs which are visible, but as EDX Spectroscopy analysis was not 
carried out, this could not be confirmed. 
 
g) Macrophage with possible intracellular ZnO NPs (see arrows), again depicting NPs 
within a cellular vacuole.   
 
h) Macrophage with intracellular ZnO NPs.  The nucleus and other cellular organelle are 
visible.  The arrow indicates to a vacuole, which was possibly a lysosome. 
 
i) A magnified view of (j), with the arrow indicating what looks to be internalised, 
agglomerated ZnO NPs within a vacuole, possibly a lysosome.  
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DIC channel images (DAPI stained) taken on a Zeiss Axiovert 200M inverted Epi 
fluorescence microscope (Zeiss, Cambridge, UK) to display information on the 
macrophage surface morphology (see Chapter 5 for further details on this type of 
imaging) are displayed below (Fig 4.16 a-c).  The fluorescent microscope images depict 
uninfected cells treated with NPs.  These NPs were not labelled therefore they were not 
detectable by fluorescent microscopy, and what was observed appears to be damage to 
the macrophage cytoskeleton or ‘shadows’ created by agglomerates.  
   
a)                                                                                          b) 
 
c) 
 
Figure 4.16 NP treated (12.5 µg/mL) macrophage by fluorescence microscopy (63 X 
magnification)  
 
a) Macrophage with arrows indicating possible cytoskeleton damage (pit formation) or 
agglomerated Ag NPs. 
 
b) Macrophage with arrows indicating either possible cytoskeleton damage (pit formation) 
or agglomerated Cu(II)O NPs. 
 
c) Macrophages with no visible signs of cytoskeleton damage following treatment with ZnO 
NPs.  
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Figure 4.17 (a) depicts TEM images of Map K10/GFP.  The mycobacteria were not 
detected intracellularly, but were found adhered to macrophage fragments, possibly 
following macrophage lysis.  Figure 4.17 (a) clearly showed the waxy, rough cell wall 
structure of Map and intracellular vacuoles or inclusions were evident.  Interestingly, one 
of the Mycobacterium cells had small, dark masses, which were comparable to the 
Cu(II)O NPs (below images were obtained from Cu(II)O NP treated macrophage slides).  
These dark spherical structures were easily detected by TEM and were suggestive of 
metal NPs, all being <100 nm in diameter, and very solid entities.  
 
 
a) 
   
b)    c) 
 
Figure 4.17 Map K10/GFP by TEM (magnification ranging from 35-38K) 
(a) A clear picture of Map with internal vacuoles visible.  
(b) Black areas indicated by arrows are possibly intracellular Cu(II)O NPs. 
(c) Magnified view of (b) where possible NPs are indicated by arrows.  
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4.4 Discussion  
 
The anti-microbial properties of NPs, resulting from unique characteristics are well 
documented (Mohanty et al. 2013; Morones-Ramirez et al. 2013; Chatterjee et al. 2014; 
Pandey & Khuller 2006; Park et al. 2009) yet this knowledge base is limited regarding 
the impact of metal/metal oxide NPs on pathogenic mycobacteria (Larimer et al. 2014; 
Islam et al. 2013).  Therefore, it was important to test their effects.  Based on results, the 
NPs tested in this study varied in their toxicity against Map K10/GFP and could be ranked 
in the following order: Ag>Cu(II)O>ZnO.  As expected Ag NPs (and corresponding salt 
control [AgNO3]) were the most toxic to the mycobacteria.  Cu and Zn are essential 
elements for biological systems, playing pivotal roles in cell physiology (Pasquet et al. 
2014), therefore their uptake into cells is relatively well regulated.  At higher 
concentrations they act as toxicants, observed at concentrations 25 μg/mL and above, 
where growth was inhibited.  These 3 NPs all have similarities; reported anti-bacterial 
properties, negative surface charges and solubility in aqueous environments (to some 
extent).  The differences in anti-mycobacterial activities for each particle type were 
interesting and will be discussed relating to the results obtained and the experimental 
conditions of this study.  
The toxicity of NPs is often related to particle size, as uptake and distribution are size 
dependent (as well as surface reactivity) (Ruparelia et al. 2007; Johnston et al. 2012).  The 
TEM images illustrated well-dispersed, spherical Ag NPs in 7H9, measuring <50nm in 
diameter.  Imaging the Ag NPs in distilled water further supported this result which agrees 
with other studies (Johnston et al. 2015).  The images suggest a wide range of Ag NP 
sizes, and perhaps two populations of particles.  The difference in appearance of the 
smallest particles observed in the Ag NPs suspension suggests they may have been 
generated via precipitation of dissolved Ag+ ions as silver salts, as was observed in both 
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7H9 and distilled water.  This would further contribute to the toxicity exhibited by the Ag 
NPs.   
In contrast to the Ag NP, TEM illustrated that both Cu(II)O NP and ZnO NP were 
agglomerated and/or aggregated in 7H9.  This could be an artefact of the drying procedure 
prior to TEM analysis; however, this observation was further supported by the DLS 
measurements of hydrodynamic diameter.  TEM of NPs in 7H9 was originally carried out 
at two concentrations (25 and 100 μg/mL) only in 7H9.  However, as individual particle 
size/shape was not visible for both Cu(II)O and ZnO NPs due to agglomeration, this was 
repeated at 100 µg/mL in DW.  Micrographs of Cu(II)O NPs in DW displayed less 
agglomerated particles, thus suggesting that components of the 7H9 medium caused this 
phenomenon, whereas ZnO NPs were found to be highly agglomerated in both water and 
media.  ZnO NPs are reported to have very fast agglomeration rates in aqueous 
environments (Odzak et al. 2014), as found in this study.  One potential explanation for 
the relatively high toxicity of Ag NPs compared to the Cu(II)O and ZnO NPs, might be 
their better dispersion and hence smaller agglomerate size.  For Cu(II)O and ZnO NPs 
their agglomeration could reduce the interaction with mycobacteria in terms of uptake 
and surface area available to interact with the mycobacteria in the medium, thus being a 
possible contributing factor to the relatively low toxic effects exerted by these NPs 
(particularly ZnO) over the 7 day period.  TEM and DLS data generally complement each 
other, but DLS tends to give a clearer view of what is happening to NPs in any given 
solution.  
Overall, the ICP-OES data yielded results that make it difficult to have confidence in 
them.  The results suggest that there was no Ag in the solutions and there was little ion 
release from all NPs tested in the experimental conditions.  It is possible that the NPs 
were interacting with organic material in 7H9 (e.g. proteins) preventing analysis, as well-
established protocols were employed in this process.  It seems likely that the 7H9 medium 
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interfered with the procedure by either preventing accurate detection of the NPs, or the 
NPs were not fully dissolved in the nitric acid.  These studies could have been repeated 
in DW; however as the NPs were added to the mycobacteria in the 7H9, such results 
would not have given any further insight to ion release/metal content in the assay 
conditions.  Furthermore, it was hard to compare these results to those in the literature as 
most studies prepare NPs in distilled or deionised water and not a complex growth 
medium such as 7H9.  The following text draws some limited suggestions, rather than 
conclusions, from the data obtained here.  
When NP are in an aqueous environment one factor that can influence the rate of ion 
release is the pH of the medium/liquid (Mumper et al. 2013) (other factors [e.g. 
temperature] will also play a role).  As the pH of an aqueous solution becomes more 
acidic, the dissolution rate has been reported to increase (Mumper et al. 2013).  The pH 
of 7H9 is 6.9 ± 0.2, the medium thus being a very weak acidic/neutral solution, and would 
likely not affect ion release from the NPs significantly.  All the NPs types used in this 
study were reported to be soluble (Bondarenko et al. 2013b) but using the protocols 
employed in this study it was not possible to accurately assess Ag NP dissolution in these 
experimental conditions.  The problems in analysis could be accounted for by the fact that 
Ag has a long wash out time, as it tends to be retained in the pump of the ICP-OES 
(personal communication with laboratory technician Dr Lorna Eades, School of 
Chemistry, University of Edinburgh).  Alternatively it is possible that the medium 
interfered with the analysis.  Due to this, it was not feasible to ascertain whether Ag+ ions 
contributed to the toxicity of the Ag NP.  However, the relative toxicity of the Ag NP and 
the AgNO3 were comparable, suggesting that either the NPs completely dissolved during 
the exposure or that neither would dominate the mechanism of Ag NP induced toxicity.  
Previous studies have ascertained that solubility of the NM300 Ag NP to be less than 1% 
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(Kermanizadeh et al. 2012), whereas others reported that bacterial toxicity of Ag NPs is 
related directly to the amount of soluble Ag released from the NPs (Zhao & Wang 2012).    
The ICP-OES data suggested that the Cu(II)O NP were the most soluble NP tested in the 
conditions used for this study.  The CuSO4 was more toxic than the Cu(II)O NP over 7 
days, suggesting that Cu2+ are toxic to Map K10/GFP cultures.  Dissolution has also been 
reported to play an important role in the toxicity of ZnO NPs (Brunner et al. 2006; Pasquet 
et al. 2014) with ZnO usually having a very fast dissolution rate, releasing Zn ions (Zn2+) 
and leaving few to no particles detectable after 2 hours in aqueous medium (Odzak et al. 
2014).  A relatively slow dissolution rate in 7H9 was observed; possibly contributing to 
the low toxicity of the ZnO NP, yet dissolution cannot be attributed to toxicity alone.  
Another report found that the NP was the mediator of toxicity (to THP-1 cells) and 
released metal ions were not solely responsible (Prach et al. 2013).  The ZnO NP and the 
ZnCl2 salt solution were remarkably similar in terms of their toxicity to the Map K10/GFP 
cultures.  Taken together, this data would suggest that the NPs alone or both the NPs and 
the metal ions contribute to the low levels of toxicity exerted by ZnO NP, possibly with 
neither inducing a dominant effect. 
The alamar blue assay demonstrated that all three NPs were cytotoxic to the macrophages 
from concentrations >30 µg/mL.  The overall cytotoxicity, including the nature of the 
dose response curves were very similar in respect to each other.  Results for the Ag NPs 
were akin to another project, where macrophage viability was reduced by 50% at the 
higher concentrations for similar sized particles (from 50 µg/mL) (Arai et al. 2015).  
Gaiser et al., (2013) reported an EC50 of 20 µg/mL for Ag NPs (NM 300) via the alamar 
blue assay, again similar to the results generated in this project.  It was surprising that the 
ZnO NPs were so cytotoxic to these cells after 24 hours treatment if compared to the 
effect they had after 7 days incubation with the mycobacteria and a previously published 
data set (Prach et al. 2013).  These results are important to consider if these NPs were 
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ever to be incorporated into clinical use (primary cell lines should be investigated and in 
vivo testing would be the next steps).   
Following 4 hour treatment with the NPs, TEM was used to determine whether the NPs 
were engulfed by infected macrophages and if so, where the NPs were localised within 
the macrophages and if they co-localised with mycobacteria.  Fluorescent microscopy 
was utilised to determine whether NP agglomerates could be observed intracellularly.  
Both methods were used to gain a better insight into the behaviour of the NPs in an 
intracellular environment and to determine whether any damage to the macrophages was 
visible (to compliment the alamar blue results).   
Unfortunately, the TEM methods employed did not produce visualisation of 
mycobacteria within a macrophage.  This may have been caused by a number of factors.  
Firstly the mycobacteria may have been damaged beyond recognition following close 
contact with the NPs within an intracellular environment or they were already within a 
phagolysosome complex and undetectable.  As control slides (with only macrophage 
infected with Map K10/GFP) also did not offer any results (only macrophages were 
visible), it is likely that the sample fixation and preparation processes rendered the 
mycobacteria impossible to view by this means.  As discussed later in Chapter V, 
macrophage infected with mycobacteria were imaged successfully using fluorescence 
microscopy therefore it suggests that this was caused by the sample processing, and 
mycobacteria were present but unable to be visualised.  Only images of extracellular 
mycobacteria were identified.  As stated in the results, it appears that a Mycobacterium 
may have had internalised Cu(II)O NPs, which would concur with speculation that NPs 
are toxic through their internalisation of bacterial cells.  As only one image of this was 
obtained, it does not hold any statistical significance, but it was exciting to observe and 
may offer more of an insight into how NPs might be toxic to mycobacteria. 
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The fluorescent microscopy yielded interesting images.  It is possible that the dark masses 
observed on and around some of the macrophages were a shadow effect created by NPs 
or NPs were agglomerating enough to be detected, but individual NPs would not be 
visible as the microscope utilised had a plan apochromat 63 X lens with a numerical 
aperture of 1.4, thus preventing resolution for anything below 0.3 µm, or more.  
Apparently something impacting on the macrophage cytoskeleton/membrane was 
detected, such as pits and burrows, caused by the NPs as previously observed (Yuan et 
al. 2012; Feng et al. 2000).  Thus, it was hard to conclude what was observed in these 
images. 
In the case of treatment of NPs on macrophage, images of what seemed to be engulfed 
NPs were obtained, particularly for the Ag and ZnO NPs.  These could have been intact 
NPs or partially dissolved NPs.  In each case, they seem to be internalised within a cellular 
organelle, possibly a lysosome; the organelle where mycobacteria reside, thus being a 
desirable site for the toxic Ag NPs to be trafficked to by macrophage cells.  EDX analysis 
would be useful to confirm this. 
Counting colonies of Map K10/GFP was difficult as clumping occurred readily and 
therefore it was very hard to distinguish between a single colony or a clump of colonies.  
Additionally, colonies from cultures which had been exposed to NPs/salt controls were 
generally very small.  This was probably because the cells were sub-lethally stressed 
and/or damaged and they may have had trouble multiplying, resulting in pinpoint-like 
colonies, but 1 of these colonies counted the same as 1 ‘healthy’ colony from the control 
plates (which was much larger and morphologically different).   This data did agree with 
results from the fluorescence assay however, even with the variation in colony 
size/morphology observed.  
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4.4.1 Ag and AgNO3  
 
Ag NP are reported to have anti-bacterial properties against many bacterial species (Park 
et al. 2009; Ansari et al. 2011; Islam et al. 2013) and as shown, exhibited a very potent 
effect on this Mycobacterium species.  Most Ag NPs studies use AgNO3 as a control when 
testing toxicity against bacterial species, and some found the salt control less toxic to 
bacterial species (Lok et al. 2007; Pal et al. 2007) whereas some found the salt more toxic 
than the NPs (Besinis et al. 2014; Jiang et al. 2012) and/or the difference in toxicity was 
related to exposure length (Völker et al. 2013).  In this study, the Ag NPs and salt were 
not statistically different in terms of their toxicity against Map K10/GFP.  ICP-OES data 
did not offer information on the dissolution of silver, and as there are mixed reports in the 
literature on its solubility, we can only assume that toxicity could include either ion and/or 
particle mediated mechanisms.  It is known that Ag+ (from NP or salt) damage bacterial 
cell walls, and as anti-mycobacterial drugs target the cell wall, it is likely that Ag+ causes 
structural damage to cell wall components (e.g. mycolic acids), either through entering 
the cell or by adhering to the outer structure causing rupturing.  Ag+ may also cause 
protein misfolding and aggregation through interaction with sulphydryl groups, as 
aforementioned, which are present in many proteins and hence disrupt multiple cellular 
processes including disruption of internal iron homeostasis (Morones-Ramirez et al. 
2013).  
As NM 300 Ag NPs were supplied in dispersion before serial dilutions in 7H9 were made, 
it is feasible that the amount of individual Ag NPs in the different concentrations would 
have varied between experiments, thus adding variation to the data sets (e.g. DLS, toxicity 
testing) as observed in some of the raw data.  Furthermore, ion release from these NPs 
could have been hampered due to the Polyoxylaurat Tween 20 cap, as another study found 
that any coatings could directly affect ion release (Zhao & Wang 2012).  Some coatings 
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can prevent aggregation of NPs, therefore increasing the surface area exposure (Sharma 
et al. 2009).  Additionally, these were spherical NPs, but many reports state that variable 
and truncated NPs are more toxic (Pal et al. 2007; Zhao & Wang 2012), therefore it would 
be interesting to test different shaped and uncoated or capped NPs against Map K10/GFP 
to determine whether they are more or less toxic.  
Unlike Cu and Zn, Ag is not an essential element in biological systems and it is not 
required for any cellular processes.  It is known that Ag NPs can be engulfed by 
macrophages and localised in the lysosome, giving an advantage over bulk Ag and Ag 
salt (Fig 4.18).  Therefore these are very interesting NPs to consider for mycobacterial 
infections.  A Nature news publication titled ‘Silver makes antibiotics thousands of times 
more effective’ briefly discusses the benefits of the metal’s use and the advantages it 
offers in combating antibiotic resistance (Owens 2013a).  Ag has the potential to become 
common place in clinical medicine, however, the use of Ag as a treatment against 
infections need to be used with caution as there would be implications for toxicity against 
mammalian cells, genotoxicity and the accumulation of Ag in non-target organs such as 
the liver (Gaiser et al. 2013; Pinto et al. 2013).  
 
 
 
 
 
 
Figure 4.18 DIC light microscopy overlaid with fluorescent image obtained by confocal 
microscopy of J774.1 cells incubated with 10 µg/mL Ag NPs depicting likely co-localisation with 
lysosomes (where the square in image [a] is enlarged to image [b]).  Taken from (Arai et al. 2015). 
 
a) b) 
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4.4.2 Cu(II)O and CuSO4 
 
Literature on the anti-bacterial properties of Cu(II)O NPs was difficult to obtain and it is 
acknowledged that such information is scarce (Bondarenko et al. 2013b).  Over the 7 day 
fluorescence assay, CuSO4 exerted greater inhibitory properties than Cu(II)O NPs against 
Map K10/GFP.  In the salt form, soluble Cu could have been readily released in the 
medium and directly available to the mycobacteria, whereas solubility for the NPs 
appeared relatively low.  Another study found that CuSO4 was more effective at inducing 
DNA damage and ROS than CuO NPs against E.coli over a relatively short period of time 
(Bondarenko et al. 2012), and again this could relate to metal dissolution.  The colony 
count data in this study surprisingly showed the CuO NPs to be relatively more toxic than 
first assumed (from the 7 day fluorescence assay), and toxicity was more comparable to 
the salt control following 12 weeks growth.  Over the 7 day period Map K10/GFP would 
have replicated approximately 7 times (the doubling time for Map is estimated as 22-26 
hours under optimum conditions) and the mycobacteria and the NPs were constantly 
moving (at 250 rpm) to prevent clumping in the 96 well plate format.  However, when 
the mycobacterial solution and NPs were inoculated onto agar for 12 weeks, they may 
have been in direct contact if all the Cu(II)O NPs had not dissolved so allowing the NPs 
to exert increased toxicity by adhering to the mycobacterial cell wall or by entering 
mycobacterial cells as possibly imaged via TEM. 
Overall, Cu(II)O NPs could offer a potential toxicant against mycobacteria at higher 
concentrations.  It is assumed they can be engulfed by macrophages, yet they are cytotoxic 
to macrophages at concentrations >35 µg/mL therefore their use in clinical applications 
should also be with caution as Cu(II)O NPs may exhibit toxicity to mammalian cells 
which is difficult to predict in vitro (Bondarenko et al. 2013b).  Toxicity to epithelial cell 
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lines has been reported (Thit et al. 2013).  What is clear, is that the anti-bacterial properties 
of Cu(II)O NPs are under reported in the literature and should be further investigated. 
 
4.4.3 Zn and ZnCl2 
 
Zn NP and ZnCl2 did not exert significant toxicity to Map K10/GFP over the 7 day 
fluorescence assay, and both were very similar in their effects.  Zn2+ are essential in 
cellular growth, required for many catalytic reactions and structural activities.  The 
concentration of Zn in cells is tightly controlled by many transporters which regulate the 
metals intracellular levels (Pasquet et al. 2014).  It therefore seems at the low 
concentrations of NPs and salt tested in the assay, that Map K10/GFP either utilised the 
ions to aid cellular growth, or was able to metabolise Zn2+, so that no anti-mycobacterial 
effect was observed over the 7 day period.  When concentrations were increased to 50-
100 µg/mL, some toxicity (although minor) was observed.  Generally, Zn2+ are 
considered to be more toxic than Zn NPs or bulk metal against bacteria (Li et al. 2011), 
therefore if ZnO (NM100) NPs had very low solubility it could explain the results 
observed for the NPs.  Importantly, it is reported that the size of ZnO NPs significantly 
affect their anti-bacterial activity (Padmavathy & Vijayaraghavan 2008),  and as only 
agglomerates were detected in 7H9 by TEM it could further add to poor efficacy 
observed.  Another study reported that the anti-bacterial effects of Zn take longer than Cu 
to be observed (Allen et al. 1956), which could account for the difference observed 
between the 7 day fluorescence assay and the 12 week colony count data, especially with 
the slow growth of the mycobacteria.  It may take longer for the NPs to exert toxicity by 
adhering to the cell wall as reported previously (Li et al. 2011), yet a recent report carried 
out toxicity studies on ZnO NPs against M. bovis-BCG and like this work, found it 
ineffective at killing Mycobacterium (Pati et al. 2014);  M. bovis-BCG and ZnO NPs were 
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incubated for 24 hours with little affect on the CFU recorded.  Through scanning electron 
microscopy it was evident that no morphological damage had occurred to M. bovis-BCG 
rods, thus suggesting that the NPs were unable to disrupt the cell wall, likely because of 
the resilient mycolic acids, during this time period.  In this study, no morphological 
changes to the ZnO NP treated macrophages was detected.  
Although Zn did not exhibit remarkable anti-mycobacterial properties, it would be worth 
further investigating the metal based on the colony count data, as their use is vast in 
consumer products and foods.  They do not exhibit high levels of cytotoxicity to cell lines 
and the NPs are known to be up taken by macrophages where mycobacteria reside (Pati 
et al. 2014).  Many ZnO NPs are considered safe by the FDA as vigorous testing on their 
safety has been carried out (Pati et al. 2014).  ZnO NPs could be used as a drug carrier or 
drug excipient for example, however ZnCl2 displayed very poor anti-mycobacterial 
affects shown by both the fluorescence assay and the colony counts, thus ZnCl2 do not 
offer results that warrant further investigation into properties against mycobacterial 
strains.  
The mechanisms underlying NP toxicity to bacterial species has been shown to involve 
disruption of the cell wall through direct NP contact and plasma membrane leakage and 
production of ROS (Pasquet et al. 2014; Kim et al. 2007; Theophel et al. 2014; Ruparelia 
et al. 2007).   The mechanisms of toxicity were not investigated in this study, but it was 
hypothesised they would be similar.   
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4.5 Conclusions 
 
Each of the metal/metal oxide NPs tested here displayed interesting results, particularly 
the very high toxicity of the Ag NPs and the relatively lower toxicity displayed by ZnO 
NPs over the 7 day period.  Ag NPs and the AgNO3 control were the most toxic, thus 
suggesting that for this NP toxicity against Map K10/GFP could be either particle and ion 
mediated.  The ZnO NPs and ZnCl2 control were very similar in their effects whereas 
Cu(II)O NPs were significantly less toxic compared with the CuSO4 control over the 7 
day assay.  These results suggest that dissolution was not the only factor that mediates 
toxicity of metal/metal oxide NPs, and that there are likely to be many factors influencing 
this (e.g. composition, size, agglomeration status in medium).  Further work is clearly 
required to determine the dissolution of Ag in 7H9, and the overall solubility of this NP 
as the literature gives very mixed reports.  The TEM offered a small insight into how 
metal/metal oxide NPs might behave intracellularly for both macrophages and bacteria, 
and had time allowed this work would have been repeated.  Ag showed the most 
promising results in terms of anti-mycobacterial properties and its use in clinical 
applications should be considered, possibly as an antibiotic drug carrier or drug excipient.  
Finally, these results demonstrate that the newly developed florescence assay gives a 
good insight into which NPs show anti-mycobacterial properties.  
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CHAPTER V  
 
SOLID DRUG 
NANOPARTICLES: 
SCREENING THEIR EFFICACY 
AND UPTAKE INTO 
MACROPHAGES  
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5.1 Introduction  
 
Robert Koch (1882) stated “If the importance of a disease for mankind is measured by 
the number of fatalities it causes, then tuberculosis must be considered much more 
important than those most feared infectious diseases…One in seven of all human beings 
dies from tuberculosis…tuberculosis carries away one-third, and often more.” (cited 
from (Jain et al. 2008)).  Remarkably, even with tremendous medical advancements, 
superior knowledge of the causes and screening/development of anti-TB drugs, 134 years 
later TB remains a leading cause of human mortality throughout the world.  Today’s TB 
treatments are constructed to attempt to either: cure patients, to prevent relapse (thus 
minimising death) or to stop disease transmission (Pham et al. 2015).  The primary aims 
of current anti-TB drug development are: to simplify and shorten treatment periods, to 
eliminate problems with drug-drug interactions (particularly for HIV patients), to identify 
novel, safe, anti-mycobacterial substances and to reduce side effects (Ginsberg & 
Spigelman 2007; WHO 2015b; Boogaard et al. 2009).  New treatments are sorely needed 
because of the complexity and toxicity of current drug programmes and emergence of 
MDR/XDR TB.  Drug development is always an immense undertaking, involving highly 
complex, often risky and lengthy pre-clinical and clinical trials at large expense.  Despite 
so many advances in bio-medical science and technology, the aim of bringing out a novel 
treatment for TB has proved elusive.     
 
5.1.1 Current treatments: the costs and complications 
 
The first line TB treatment regimen involves multiple drugs over 6-9 months.  MDR TB 
treatment, relies on the use of second line drugs, is highly complex, taking 18-24 months 
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of multi-drug therapy which is both very expensive (up to 200 times more expensive than 
drug susceptible strains), and very demanding on both the patient and health professionals 
(Ginsberg & Spigelman 2007; WHO 2015b).  Drugs used to treat MDR TB are found to 
be less well tolerated (with more serious side effects) and up to 50% of those diagnosed 
with MDR TB die from the infection (190,000 deaths in 2014) (WHO 2015b).  Current 
literature suggests only 10 new drug candidates are in the pipeline, with only BDQ and 
Delamanid recently being approved by the FDA, the first drugs in over 40 years to be 
introduced (Chapter 1 [section 1.8]) (Goel 2014; WHO 2014b; WHO 2015b).  BDQ is 
only recommended for MDR TB, its safety and efficacy are still under investigation in 
Phase III clinical trials (WHO 2015b).  Delamanid is only recommended for adults with 
MDR TB who are HIV positive, as little is known about its effects on specific populations 
(e.g. infants and the elderly) and it too is being further investigated.  There have been 
recent human trials testing a variety of novel substances (e.g. Pretomanid) or piloting 
different combinations of first line drugs and/or changing drug dosages (Boeree et al. 
2015; Dawson et al. 2015; Hurdle et al. 2008; Grosset & Ammerman 2013).  Pretomanid, 
developed by the Global Alliance for TB drug development, is being investigated for its 
properties against both drug susceptible and MDR TB with results reported as being 
promising (Grosset et al. 2012).   
There is debate about whether clinicians are prescribing patients with the correct dose of 
first line antibiotics, such as RIF (van Ingen et al. 2011).  Currently patients are dosed 
with 10 mg/kg up to a maximum of 600 mg per day of RIF, yet little literature exists on 
how or why this concentration was established.  Boeree et al., explain that from 3000 
published papers, extracting information on this accepted dose was difficult to find and 
that the only explanation discovered was that it loosely related to pharmacokinetics, drug 
toxicity and financial costs (Boeree et al. 2015).  It has been suggested that this dose is 
not optimal, it certainly requires fresh investigation and should possibly be increased (van 
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Ingen et al. 2011; Boeree et al. 2015).  An increase in RIF however, could lead to further 
side effects already reported by patients (e.g. increase the severity already reported or 
lead to new side effects not observed at lower doses).  Along with all the side effects 
listed in Chapter 1, hepatotoxicity is frequently reported following administration of RIF 
(Hest et al. 2004; Shu et al. 2013), which is a matter of great concern and makes the 
proposed increase in RIF concentration perturbing.  Overall it is clear from much of the 
literature, that anti TB drugs and/or the correct concentration of drugs are not getting to 
exactly where they are needed in the patient.  The pharmacokinetic data is poorly 
understood, hence why RIF (and INH) is not being dosed accordingly (Longo et al. 2015).  
Anti-microbial pharmacokinetic/ pharmacodynamic data is highly important for drug 
development, and should be integrated when determining optimal clinical doses (Gumbo, 
Angulo-Barturen, et al. 2015). 
As well as drug dosing being a problem which limits the effectiveness of currently 
available drugs, up to 49% of patients are thought not to complete the recommended 
dosing regimen due to; side effects, costs associated with treatment (e.g. purchasing 
drugs, travelling to clinics, time required off work etc), the stigma linked with TB, and 
the feeling of ‘being better’ following the initial treatment phase (Longo et al. 2015).  The 
practicalities in taking multiple drugs daily is a burden on patients therefore studies have 
investigated how to ‘fix’ dose treatment plans to reduce this (Lienhardt et al. 2011).  By 
reducing table numbers of the first line drugs to 3-4 (from 9-16) per day during the 
intensive phase, the authors found that patient compliance improved, and their results 
supported the WHO recommendations for use of fixed-dose combinations of drugs, 
although an improved efficacy from using these drugs was not demonstrated (Lienhardt 
et al. 2011). 
The financial cost of treating TB is staggering when considering a third of the world’s 
population are thought to be latently infected.  An estimated $100-500 (USD) per patient 
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for drug susceptible TB is required, increasing to $10,000-50,000 per patient for MDR 
that can escalate to $250,000 (WHO 2015b).  As most TB cases are in the developing 
world, it brings with it a huge financial burden to many poor countries that often have 
both a fragile economy and weak infrastructure.  The cost of identifying a new anti-
mycobacterial substance and bringing it into commercial circulation is estimated at $2.5 
billion (Global Business Intelligence, retrieved from http://gbiresearch.com/media-
center/press-releases/pharmaceutical-deals-crucial-to-offsetting-25-billion-cost-of-
developing-a-novel-drug, accessed 04/02/2016), a staggering figure, but as it’s  
associated with a disease that primarily affects developing countries, where there is little 
return to be gained from treatments, the lack of investment is unsurprising. 
If it was possible to find a means to lower the drug dose yet keep drug efficacy the same, 
this would be advantageous, yet if efficacy could be increased with a lower dosage this 
could be an extraordinary achievement in the TB field, hugely beneficial both medically 
and financially when considering the global scale of the problem.   
 
5.1.2 The intracellular pathogen  
 
Macrophages are mononuclear cells of the innate immune system.  Reaching Mtb inside 
infected immune cells (e.g. alveolar macrophages) and killing it is difficult as there are 
great challenges in getting enough drugs to the intracellular mycobacteria.  Once engulfed 
by the immune cells, bacilli cause the activation of multiple microbiocidal mechanisms, 
including the fusion of the phagosome and generation of pro-inflammatory cytokines.  
Macrophages aim to remove Mtb through rapid acidification, by presenting pathogen 
antigens to the adaptive immune system, and fusion with lysosomes, containing 
proteolytic and lipolytic enzymes (Podinovskaia et al. 2013).   Phagocytosis is a process 
by which pathogens are trafficked within a macrophage into fluid-filled, double-
  
166 
 
membrane vesicles to be killed (Manivannan et al. 2012).  Mtb manipulates this process, 
preventing phagosomal maturation.  These infected macrophages, which are unable to 
kill the bacilli, recruit uninfected macrophages to ultimately form a granuloma (Flynn et 
al. 2011).  
Caseous granulomas are well-organised, dynamic structures, and are typical of an Mtb 
infection.  They may be described as the meeting of innate and adaptive immunity and 
are classic to active, latent and reactivated TB (Flynn et al. 2011).  Granulomas are poorly 
vascularised, and the blood supply to the centre where Mtb resides is further reduced, thus 
restricting the delivery of drugs (Grobler et al. 2016).  Therefore, in essence, granulomas 
protect Mtb from drugs, as although Mtb is contained and often unable to replicate, many 
TB treatments are unable to penetrate this immune defence and reach their target in 
macrophage intracellular compartments (Pham et al. 2015; Ehlers & Schaible 2012).  As 
such, the mycobacteria in the centre of granulomas are either, not dosed at all or are under-
dosed, which can lead to resistance.  If these granulomas rupture, latent TB infection 
becomes active TB and the disease then becomes transmittable.  Due to the importance 
of these complexes in an Mtb infection, the use of in silico, in vitro and in vivo models of 
intracellular Mtb have been used to study drug response (Guirado & Schlesinger 2013; 
Grobler et al. 2016; Dube et al. 2013).  By modelling granulomas in silico, investigators 
have been able to compare drug concentration in the blood compared to the macrophages 
and found that generally, drug concentration inside macrophages was low (Grobler et al. 
2016), thus suggesting that uptake of conventional antibiotics into immune cells is 
insufficient.  Griffiths et al., investigated drug concentrations inside macrophages in vitro 
when drugs were delivered via a nano-carrier and reported a greater than 20 fold increase 
of intracellular drug compared to the traditional, aqueous drug (Griffiths et al. 2010).  In 
vivo models of Mtb infection largely use mice and guinea-pigs.  Pandey et al., 
encapsulated RIF, INH and PZA in PLG NPs and administered these orally to mice to 
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measure biodistribution (RIF 12 mg/kg, INH 10 mg/kg and PZA 25 mg/kg) (Pandey et 
al. 2003).  The mice were euthanised at different time points and various tissues were 
examined.  They reported therapeutic concentrations (MIC levels) for up to 11 days in 
the lungs, liver and spleen of the mice following administration from the PLG NP, 
whereas the aqueous drugs were cleared after only 24 hours following oral administration 
(Pandey et al. 2003).  
Nanomedicines may be suitable for treating problematic, intracellular pathogens such as 
Mtb.  Studies demonstrate that macrophage cells engulf NPs and internalise NPs by 
endocytic mechanisms (Clift et al. 2008).  The physical advantages include the reported 
ability to pass through fine capillary vessels, uptake by macrophages, increased 
circulation time in the blood stream and surface modifications allowing specific targeting 
(Onoue et al. 2014; Clift et al. 2008; Navalakhe & Nandedkar 2007).  Furthermore, NPs 
can be targeted to specific sites using surface modifications (Hirota et al. 2010; Byrne et 
al. 2011).  With this knowledge, the adaption of anti-TB drugs into nano-formulations 
will mean better targeting, reduced dosage, and thus possibly decreasing side effects and 
increasing patient compliance.  This could in-turn decrease MDR cases, and has opened 
up many new avenues for TB medical research to follow.  Smith stated “Using current 
anti-TB drugs, nanoparticle-based formulations may shorten drug regimen duration, 
reduce frequency, and deliver medications more efficaciously, ultimately reducing patient 
default and improving completion rates. In turn, this holds significant potential in the 
reduction of DR (drug resistant)-TB cases...” (Smith 2011).  This proposal is now a 
reality, as SDNs are a novel and exciting development in nanotechnology.   
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5.1.3 Solid drug nanoparticles (SDNs) 
 
SDNs are excipient stabilised nanoparticulate versions of FDA approved therapeutics 
(Fig 5.1) (McDonald et al. 2014).  Drugs are rarely administered in an unformulated 
condition, they are composed of two (or more) components, the Active Pharmaceutical 
Ingredient (API, the chemically active substance [e.g. RIF]) which is delivered with 
excipients.  Excipients are inactive substances which act as carriers for the medication, 
allowing for accurate dosage.  They also enhance the release and prevent the degradation 
of some drugs (Pandey & Ahmad 2011).  SDNs were synthesised by the University of 
Liverpool (Professor Andrew Owen, Dr Macro Giardiello [Department of Chemistry]) 
for this PhD project.  The technique involved the preparation of an oil-in-water emulsion 
in which the drug (e.g. RIF) was present in a volatile organic oil phase while the aqueous 
phase contained a mixture of stabilisers (e.g. water-soluble polymers, Hyamine®).  The 
emulsified mixture was then cryogenically frozen and both the drug and water solvent 
were removed via freeze-drying.  Upon addition of water the drug was released, yielding 
nano-suspensions.  The process employed a large number of screening systems in which 
a range of active pharmaceutical ingredients, polymers and surfactants were studied to 
optimise the formulation and NP dispersion production (personal correspondence with 
Dr Marco Giardiello [Department of Chemistry, University of Liverpool]).  This 
technique allowed SDN size, surface charge and drug loading to be controlled and pre-
determined, to enhance SDN stability.  SDNs for the treatment of HIV by the same group 
are currently undergoing clinical trials and preliminary results are very promising (results 
are not yet published [see EudraCT 2013-004913-41 
https://clinicaltrials.gov/ct2/show/NCT02631473]).   
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Figure 5.1 Schematic diagram of an SDN (e.g. RIF) with stabilising excipients. 
 
There are many advantages to developing SDNs. One, for example, is that by using 
existing FDA approved pharmaceutical ingredients it saves time and the inordinate cost 
involved in novel drug development and testing.  As SDN drugs are produced at the nano-
scale they increase drug bioavailability and may offer an opportunity to lower treatment 
dose as well as improve targeting (Mcdonald et al. 2014; Bawa 2008).  These attributes 
are essential when considering novel TB treatments.  If the correct dose of anti-TB drugs 
could reach intracellular Mtb, the problem of latent infections could be decreased, and 
further, as resistance often occurs due to patient noncompliance, if drugs were 
administered over a shorter time period it would likely decrease the levels of MDR/XDR 
TB currently reported.   
 
5.1.4 Aims 
 
The aim of this chapter is to compare the ability of the novel SDNs to kill mycobacteria 
with traditional aqueous antibiotics, using the newly developed screening assay (Chapter 
NP of pure drug 
Stabilisers 
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3).  The ability of SDNs and traditional aqueous antibiotics to kill intracellular 
mycobacteria (within a macrophage) was also compared.  It was hypothesised that a lower 
concentration of SDNs would be required to kill mycobacteria, using the screening assay.  
In addition, it was hypothesised that macrophages would uptake SDNs to enhance killing 
of intracellular Map K10/GFP.  Results from this chapter are currently in preparation for 
a joint publication between the Moredun Research Institute, the University of Liverpool, 
the University of Nottingham, and Heriot Watt University. 
 
5.2 Methods and Materials 
5.2.1 SDN development  
 
SDNs (RIF, INH and PZA) were developed and supplied by project collaborators at the 
Institute of Translational Medicine, Department of Chemistry, University of Liverpool 
(Professor Andrew Owen and Dr Marco Giardiello).  Please see Appendix B for 
information on their manufacture.  
 
5.2.2 SDN Preparation and characterisation 
 
All SDNs were sub sampled under sterile conditions and kept in the dark at ambient 
temperature until use.   A stock concentration of SDNs (1 mg/mL) in sterile 2% (vol/vol) 
FCS (prepared in sterile DW) was prepared and sonicated for 16 minutes at 400 W in a 
bath sonicator from Ultrawave® (Cardiff, UK) and then placed on ice as previously 
outlined in Chapter 4 (section 4.2.1).  NPs were then diluted in 7H9 (see Chapter 2 
[2.6.1]).   
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5.2.3 Aqueous drug preparation 
 
RIF and INH were purchased from Sigma-Aldrich® (UK) and prepared (and stored) 
following product documentation.  Briefly, 150 mg of RIF was solubilised in 6 mL 
methanol yielding a stock solution of 25 mg/mL and vortexed for one minute prior to use.  
INH was solubilised in 2 mL DW yielding a 1 mg/mL solution and vortexed for one 
minute prior to use.  Stock solutions were stored in tin-foil wrapped bottles at 4ºC.  From 
these stock solutions, appropriate serial dilutions were made in 7H9 for the desired 
concentrations.   
 
5.2.4 Dynamic light scattering  
 
Agglomeration status, zeta potential and hydrodynamic sizes were analysed by DLS at a 
concentration of 100 µg/mL (in 7H9 medium) using a Zetasizer Nano-ZS instrument 
(Malvern Instruments Ltd., UK).  SDNs were prepared as outlined above (5.2.2).  
 
5.2.5 SDN 96 well plate setup  
 
The antimicrobial properties of SDNs and aqueous drugs were screened using the 
previously described assay (Chapter 3), with all optimisation parameters and data analysis 
carried out as in Chapter 4.  Briefly, Map K10/GFP was cultured in 7H9K+ until the 
exponential stage of growth, at which point they were seeded (2x106 CFU/100 µL/well) 
into a 96 well, sterile, black plates (Nunc, Themo Fisher) at a turbidity to match McF 
standard 2.  SDN and aqueous drugs in 7H9 were exposed to Map K10/GFP at 
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concentrations ranging from 0.001875 to 4 µg/mL (final volume per well of 200 µL).  
The samples were incubated at 37°C with medium agitation (250 rpm) and kept in the 
dark throughout the experimental procedure.  Medium only (no bacteria, no SDN/drug) 
and SDN/drug and medium (no bacteria) were included to check for SDN/drug 
interference.  Fluorescence was measured using a GloMax® Multi+ plate reader 
(Promega, UK) (ex/em 490/510-570 nm).  Bacterial fluorescence was monitored 
immediately after SDN/drug addition (day 0), then at the same time each day for 7 days.  
All experiments were performed in triplicate, a minimum of three times, under sterile 
conditions.  
 
5.2.6 Colony counts 
 
Following 7 days of Map K10/GFP incubation with SDNs/drugs in 7H9, 100 µL of the 
cultures at each concentration were serial diluted and inoculated onto 7H11 agar in 
bacteriological plates (as outlined in Chapter 2) for 12 weeks, incubated at 37ᵒC allowing 
for conventional colony counts (see Chapter 2.1.5).  
 
5.2.7 Cytotoxicity of substances to macrophages  
 
Macrophages were cultured as described in Chapter 2 (section 2.3). Cytotoxicity to 
macrophages of the SDNs and aqueous drugs was evaluated using the alamar blue assay 
(Chapter 2, section 2.4). 
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5.2.8 Macrophage infections and drug treatments 
5.2.8.1 Infection   
 
 Macrophages were cultured as described in Chapter 2 (section 2.3).  Cells were detached 
from flasks using TrypLETM and centrifuged at 850 g for 2 minutes before resuspension 
into 8 well chambered Permanox® slides at a density of 1x105 cells/well (final volume of 
200 µL) and incubated for 24 hours at 37ºC, 5% CO2.  Supernatant was removed from 
chambers and cells were washed twice with 200 µL PBS.  Map K10/GFP was cultured 
as described in Chapter 2 (section 2.1.1) and 10 mL of bacterial culture (in the exponential 
phase of growth) was centrifuged at 3090 g for 20 minutes and resuspended in 1 mL of 
PBS.  The bacterial cell suspension was then centrifuged for 5 minutes at 670 g to remove 
any residual antibiotic (from the 7H9), and resuspended in 1 mL of PBS and passed 
through a Gilson tip several times to break apart any clumping.  At a 30:1, 10:1 and 5:1 
multiplicity of infection (MOI [bacilli counts see Chapter 2, section 2.5.2]) the 
macrophages were infected with mycobacteria in complete medium (without 
streptomycin or penicillin) at a final volume of 200 µL per chamber (each MOI was done 
in triplicate) and incubated for 4 hours at 37ºC, 5% CO2.  Supernatant was removed and 
each chamber was washed twice with 200 µL of PBS to remove any residual/surface 
bound mycobacteria before fixing using 4% paraformaldehyde (Chapter 2, section 2.7.1).  
Control chambers were subject to the same procedures and contained macrophages and 
medium only.  
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5.2.8.2 Macrophage uptake of SDNs  
 
To investigate uptake of SDNs by infected and uninfected macrophages, a label was 
required to allow visualisation of the SDNs by fluorescent microscopy.  To achieve this 
1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindodicarbocyanine, 4-Chlorobenzenesulfonate 
salt (DiD [ex/em: 596/670 nm]) was incorporated into the DCM phase of SDN production 
(see Appendix B).  
Macrophages were seeded in 8 well chambered Permanox® slides at a density of 1x105 
cells/well and incubated for 24 hours at 37ºC, 5% CO2.  Cells were then infected with 
Map K10/GFP as described in section 5.2.8.1.  SDNs (with DiD) were prepared as 
described previously (section 5.2.2) and diluted in complete medium (without 
streptomycin or penicillin) to concentrations of a concentration range of 10 μg/mL- 20 
μg/mL and added to the chambers (final volume of 200 µL) in triplicate.  Infected 
macrophages were incubated for 4 hours with the SDNs at 37ºC, 5% CO2.  The 
supernatant was removed and each chamber was washed twice with 200 µL of PBS to 
remove any residual/surface bound SDNs and/or mycobacteria before fixing using 4% 
paraformaldehyde (2.7.1).  Control chambers contained macrophages and medium only, 
macrophages with 1 mM 10 mM or 100 mM DiD dye (stocks prepared in DMSO) and 
macrophages and 20 nm fluorescent carboxylated polyester NP beads (NP beads 
[Molecular Probes, USA], ex/em: 580/605 nm).   
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5.2.9 Staining and fixed cell imaging   
 
Following fixation (using 4% paraformaldehyde, Chapter 2 [section 2.7.1]), macrophages 
were stained with 4’,6-diamidino-2-phenylindole dihydrochlodire (DAPI) nuclear stain 
(1:10 dilution in PBS [ex/em: 358⁄461 nm]) and/or Alexa Fluor®568 (phalloidin [Thermo 
Fisher Scientific, UK], ex/em: 578/600 nm) an F-actin stain.  After 15 minutes the slides 
were washed twice with distilled water before being mounted onto slides with Fluoro-Gel 
Mounting Medium with TES Buffer solution (EMS, USA).   
Cellular uptake was imaged using a Zeiss Axiovert 200M inverted Epi fluorescence 
microscope with an Axiocam MR3 camera using objective magnifications of X10, X40, 
X63 and X100.  Cy3, Cy5, DAPI, GFP and DIC (differential interference contrast) or 
phase contrast channels (depending on objective) were used.  Images were processed 
using Image-J (Fiji) software (Schindelin et al. 2012) and Zeiss Axio vision Rel 4.8 
software (Z-stacks) thus showing the DIC (grey), DiD control dye (yellow) and DiD 
incorporated SDNs (red [RIF] and yellow [TRIPLE]),  polyester beads (pink), Map 
K10/GFP (green), macrophage nucleus (blue) and actin (cyan).  
 
5.2.10 Phage amplification assay to quantify viable mycobacteria following drug 
contact 
 
A phage-PCR amplification assay was utilised to compare the killing of RIF SDN to that 
of aqueous RIF intracellularly (within a macrophage).  The FASTPlaqueTBTM assay is a 
rapid test which uses bacteriophage amplification technology to detect viable 
mycobacteria.  Originally developed for detecting Mtb, it has also been successfully used 
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to detect viable Map (Botsaris et al. 2010; Altic et al. 2007).   Bacteriophages are viruses 
that infect and kill bacterial cells.  When added to a sample containing live and dead 
bacteria, the bacteriophages will infect only viable cells where they attach to cell surface 
receptors (a process termed adsorption) and inject their genetic material into the cell to 
be replicated (a process termed penetration).  Replication occurs and phage are released 
following lysis of the bacterial cells.  In the phage amplification assay, the sample-
containing Map is mixed with the phage and incubated to permit adsorption and 
penetration.  Before lysis of the infected Map cells, a virucide is added to kill any 
extracellular phage and the sample then mixed with fast growing M smegmatis mc2155 
and plated out in agar.  Products of phage amplification can then be viewed as lysed areas 
(plaques) on a lawn of M smegmatis.  Each plaque formed represents one Map cell from 
the original sample.  The assay was performed using a modification of the method 
described by Swift et al., 2013.   
Macrophages (seeded into the wells of flat-bottomed, cell culture 96 well plates at a 
density of 5 x105/mL) were infected with Map K10/GFP (at an MOI 1, 10 and 30) and 
incubated for 30 minutes at 37ºC, 5% CO2 as previously described (section 5.2.8).  
Aqueous and SDN RIF were added at a concentration of 4 µg/mL.  Control wells were 
included that contained infected macrophages only and no SDN or drug.  The infected 
cells were incubated for a further 24 hours at 37ºC, 5% CO2.  Following 24 hours 
incubation, the supernatant was removed and cells were washed twice with 200 µL of 
PBS to remove any residual/surface bound drug/SDN and/or mycobacteria.  Macrophages 
were lysed by adding 400 µL of 7H9 (for 10 minutes) to the wells thus releasing 
intracellular Map K10/GFP.  The 400 µL of 7H9 (with lysed macrophages and Map 
K10/GFP) was then added to 600 µL of 7H9, which was mixed with 1 x 108 
mycobacteriophage D29 (100 µL) and incubated for 1 hour.  After this time, remaining 
extracellular phage were inactivated using 100 µL of 10 mM ferrous ammonium sulphate 
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[virucide] for 5 minutes.  The virucide was then neutralised by dilution in 7H9 and the 
phage-infected cells were mixed with growing M smegmatis (1 mL, 107 CFU/mL) using 
soft agar (FASTPlaqueTBTM agar [BIOTEC Laboratories Ltd, UK]) (0.8% w/v) and 
incubated at 37ºC for 24 hours.    Positive (M. smegmatis) and negative (no mycobacteria) 
controls were included (standard FASTPlaqueTBTM assay controls).  This assay was 
carried out only once (due to project time restraints).  M smegmatis, soft agar, virucide 
and mycobacteriophage D29 were provided by Dr Benjamin Swift (Faculty of Medicine 
& Health Sciences, The University of Nottingham), who also provided training for this 
assay.  
 
5.2.11 Data analysis  
 
For the fluorescence assay, results expressed in AFU against time were transformed and 
normalised to obtain the usual dose response relationship, to compare the effects of the 
SDNs and aqueous drugs on the growth of the mycobacteria as outlined in Chapter 3 
(novel method of data analysis).  Some results were also plotted using the common Log 
scale to allow easier visualisation of data close points and other results  were plotted using 
the dose response modelling software PROAST (version 38.9) in the R software (version 
3.1.0).  By setting the critical CES to 50% it was possible to obtain the EC50 and 90% 
CEDL/CEDU to allow for statistical comparisons, as carried out in Chapter 4.  Statistical 
testing varied between different experiments depending on the data type.  See results 
section for further details.  Results were considered significant if p<0.05.   
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5.3 Results 
5.3.1 SDN characterisation  
5.3.1.1 Particle drug loading  
 
The aqueous drug and SDN drug loading information and concentration is presented in 
Table 5.1.  The difference loading of each drug is an important factor to consider when 
interpreting the results.  Each SDN had a different drug loading, RIF had 30% drug, 
TRIPLE had 53.3% drug and DUAL had 30% drug (Table 5.1).  
 
5.3.1.2 DLS 
 
Characterisation of the SDNs was carried out in 7H9 growth medium by DLS.  The 
average hydrodynamic diameter for RIF SDNs was found to be <50 nm (Table 5.2), thus 
being the smallest of all the SDNs analysed.  DUAL SDNs on average were found to be 
93.78 nm (Table 5.2).  The TRIPLE SDNs were either larger NPs or were agglomerating 
in the medium as the primary particle size was 161.78 nm (Table 5.2) thus being 
considerably larger than the RIF SDNs.  SDNs with the incorporation of the DiD 
increased in size, RIF SDN increased in size to 70 nm and TRIPLE SDNs increased in 
size to 253.53 nm (Table 5.2).   
The size distribution graphs (Appendix B) display a spread in the sizes detected by DLS.  
As shown in all figures, there was quite a spread in primary particle size, suggesting that 
agglomerates were being detected in some cases, rather than individual particles.   Like 
the metal/metal oxide NPs the zeta potentials were all low, negative values, thus 
suggesting that they were unstable in 7H9 (Table 5.1).  
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Table 5.1 Drug types and drug loading (%) 
(partly supplied by the University of Liverpool) 
 
*Sigma-Aldrich® Product number R8883 
** Sigma-Aldrich® Product number I3377 
 
 
 
Table 5.2 DLS Results. Hydrodynamic diameter (Z-average), zeta potential and polydispersity 
index (PdI) of SDN panel was assessed using DLS.  Data expressed as mean ± SEM (n=4). 
With or without 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindodicarbocyanine, 4-
Chlorobenzenesulfonate Salt (DiD).  Temp: 25°C, dispersant: Middlebrooks 7H9 (100 µg/mL), 
pH 6.9, equilibrium time: 30 secs. 
 
SDN Z-Average (d.nm) Zeta Potential (mV) PdI 
RIF SDN 36.75 ±6.34 -9.71 ±0.38 0.77 ±0.07 
DUAL SDN  93.78 ±17.92 -7.49 ±0.49 0.37±0.01 
TRIPLE SDN  161.78 ±8.56 -6.31 ±0.86 0.31±0.07 
RIF  SDN (+ DiD) 107.27±32.93 -10.46±0.47 0.56±0.09 
TRIPLE SDN (+ DiD) 415.3 ±64.81 -10.43±0.81 0.42±0.03 
 
 
 
 
 
SDN/DRUG TOTAL DRUG 
LOADING 
FORMULATION 
RIF aqueous 
(Rifampicin aqueous drug) 
 
≥97% Powder* 
(Stock solution prepared with methanol to 
25 mg/mL) 
 
INH  aqueous 
(Isoniazid aqueous drug) 
 
≥99% Powder** 
(Stock solution prepared with distilled water 
to 1 mg/mL) 
 
RIF SDN 
(Rifampicin solid drug 
nanoparticle) 
30% 30% RIF/55% F68® Protect/ 
15% Hyamine® 
 
 
TRIPLE SDN 
(Rifampin, isoniazid, and 
pyrazinamide solid drug 
nanoparticle ) 
 
53.3% 34% PZA/ 13% RIF/6% INZ/ 
40% Kollicoat® Protect/  7% 
Hyamine® 
 
DUAL SDN 
(Rifampin, isoniazid solid drug 
nanoparticle) 
30% 20% RIF/ 10% INZ/ 60% 
Kollicoat® Protect/ 10% 
Hyamine® 
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5.3.2 Screening the anti-mycobacterial properties of SDNs and aqueous drugs against 
Map K10/GFP 
 
The anti-mycobacterial properties of aqueous drugs and SDNs were screened against Map 
K10/GFP using the fluorescence assay developed and described in Chapter 3.  The results 
are first displayed similarly to the results in Chapter 4, where the raw data was 
transformed using the novel data analysis protocol (Chapter 3, section 3.3.4) depicting 
fluorescence (β) against concentration for each substance.  The results were then analysed 
for statistical significance.  Significance level was denoted by:  p <0.001 (***), <0.01 
(**) and <0.05 (*) (MINITAB®, version 17).  Figure 5.2 (a) depicts the effect of each 
substance on the growth of Map K10/GFP (the different analysis steps can be found in 
Appendix B).  There was a dose dependent inhibition of Map K10/GFP when treated with 
RIF SDN, RIF aqueous, TRIPLE and DUAL SDNs.  However, INH aqueous did not have 
a great effect at inhibiting the growth of Map K10/GFP over the 7 day fluorescence assay 
(Fig 5.2 a).  Interestingly, RIF aqueous appeared to be more toxic to the mycobacteria at 
lower concentrations (e.g. 0.015 µg/mL) than at some of the higher concentrations 
screened (e.g. 0.5 µg/mL) (Fig 5.2 a-b).  Figure 5.2 (a) was re-plotted (Figure 5.2 b) using 
the common Logarithmic scale to better display the spread in the data points at the lower 
concentrations and then again in PROAST (version 38.9) (Figure 5.3) (which included 
only the higher concentrations [0.125 - 4 μg/mL]) to allow statistical analysis (to 
determine the EC50 values). 
Four main questions were asked when analysing this data for statistical significance: 1) 
did the substances tested differ significantly from each other? 2) did the toxicity of the 
treatments differ to the controls (no treatment [0 µg/mL])? 3) was there a significant 
difference between the two RIF treatment types (SDN and aqueous) and 4) was there a 
difference in mycobacterial growth between days with the different treatment types? 
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a) 
 
b) 
Figure 5.2 (a) Growth of Map K10/GFP with different substances normalised to the control.  
Normalised, transformed data showing the growth of Map K10/GFP grown in 200 µL of 7H9, in 
a microplate format, with SDNs and aqueous antibiotics at different concentrations (0.001875 - 4 
µg/mL), normalised to the slope of the control (0 µg/mL) (where β represents the change in 
fluorescence [representing mycobacterial growth] per day).  β was calculated through linear 
regression analysis of the Log data.  Each point displaying 2* the standard error calculated using 
LINEST function Excel (Microsoft Office Word) (n= min of 3).  Figure 5.2 (b) As above 
(concentration plotted on the log scale to display the data at the lower concentrations and with 
data lines to better show the data pattern). 
0
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5.3.2.1 Statistical Analysis 1 
Did the efficacy of all the substances differ significantly from each other?  
 
Each substance was compared to determine whether they had a significantly different 
effect on the growth of Map K10/GFP.  This was achieved by estimating the EC50 
(calculated using PROAST [version 38.9]) when plotting the fluorescence data 
(indicative of bacterial growth) from the concentration range 0.125 – 4 µg/mL.  Figure 
5.3 presents the dose response curves for all substances screened (yielding the EC50 values 
and 95% confidence intervals for all the substances [obtained from the software package 
PROAST [version 38.9] [outlined in Chapter 4, section 4.3.4]).  The EC50 values 
generated from this analysis were 2.98 μg/mL (RIF aqueous), 1380 μg/mL (INH 
aqueous), 40.2 μg/mL (RIF SDN), 17.3 μg/mL (DUAL SDN) and 7.17 μg/mL (TRIPLE 
SDN) (Table 5.3) therefore the substances toxicity could be ranked RIF aqueous> 
TRIPLE SDN> RIF SDN> DUAL SDN> INH aqueous.  This same method of analysis 
was utilised for the metal NPs (Chapter 4, section 4.3.4) and the method was more suitable 
for that data set (where mycobacterial growth was greatly inhibited).  In this case, the 
EC50 values were estimated by the software via extrapolation.  As shown in Figure 5.3, 
the only EC50 obtained directly from the plot was for RIF aqueous, and the others were 
made via an estimation of when the 50% mark would be reached.  A reason for this was 
possibly the significant difference of INH to all the other substances, which may have 
skewed the data.   
 
Table 5.3 displays the confidence interval values, which were plotted in Figure 5.4 to 
allow a visual comparison between the 95% confidence intervals.  RIF in the SDN and 
aqueous form differed significantly from each other in terms of toxicity to the 
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mycobacterium with the aqueous being more toxic (Fig 5.4, Table 5.3).  However, the 
confidence intervals for RIF aqueous overlapped TRIPLE and DUAL SDNs suggesting 
no significant difference, (Fig 5.4, Table 5.3).  The confidence intervals for INH aqueous 
did not overlap with any other substance, suggesting that INH aqueous was statistically 
less toxic, compared to the other treatments. In contrast, the confidence intervals for RIF 
SDN, DUAL SDN and TRIPLE SDN overlapped with each other (Fig 5.4, Table 5.3) 
suggesting no significant difference in the relative toxicity of each of the SDN on an total 
mass dose basis.  
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Figure 5.3 Comparison between the substances on the growth of Map K10/GFP normalised 
to the control and re-plotted in PROAST 38.9.  Map K10/GFP grown in 200 µL of 7H9 in a 
microplate format, with substances at different concentrations (0.125 - 4 µg/mL).   
*please note PROAST 38.9 does not allow allocation of figure legend or choice of colours/symbols 
 
 
 
 
 
 
 
Concentration (μg/mL) 
β
 
RIF AQUEOUS 
INH AQUEOUS 
RIF SDN 
DUAL SDN  
TRIPLE SDN  
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Table 5.3 EC50 value for each substance with the lower (CEDL) and upper (CEDU) 95% 
confidence intervals to plot Figure 5.4 (derived from Figure 5.3).  
 
Treatment RIF 
AQUEOUS 
INH 
AQUEOUS 
RIF 
SDN 
DUAL 
SDN 
TRIPLE 
SDN 
EC50 2.98 1370 40.2 17.3 7.17 
CEDL 1.193 1110.9 17.99 7.393 4.259 
CEDU 3.016 110.9 70.19 35.817 20.341 
 
 
 
 
 
 
 
 
Figure 5.4 The half maximal effective concentration (EC50) for each treatment with the 
upper and lower 95% confidence intervals.  Plot of the mean EC50 values and corresponding 
confidence intervals (on the common logarithmic scale) for each treatment on the rate of 
mycobacterial growth.  INH was the only substance significantly different from all the others on 
its effect on the growth of Map K10/GFP.  It was the least effective substance screened.  
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The graphs above (Fig 5.2(a-b), 5.3) display the data for the ‘mass’ concentration of 
SDNs and aqueous drugs in each case.  For example, RIF SDN contained only 30% 
rifampicin whereas RIF aqueous contained >97% rifampicin at each concentration tested.  
By comparing the mass concentrations, the EC50 value for RIF SDN was calculated as 
40.2 μg/mL via extrapolation by the PROAST (39.8) software (Table 5.3).  In an attempt 
to account for this difference in concentration and obtain a more accurate RIF SDN EC50 
to allow a direct comparison between the two forms of the antibiotic, the data modelling 
software GraphPad Prism (version 5, GraphPad software, Inc, USA) was utilised.  By 
plotting the whole β data range (0.001875 – 4 μg/mL) using a 3 parameter Emax model, 
but considering the API content for RIF SDN, it was possible to obtain a more effective 
EC50 for the RIF API.  Figures 5.5 (a-b) display the two data sets obtained.  The RIF SDN 
displayed a ‘typical’ dose response curve, as RIF concentration increased, the 
fluorescence of Map K10/GFP (β) decreased (Fig 5.5 a,b).  When analysing the mass 
concentration of the SDN, the EC50 for RIF SDN on the growth of Map K10/GFP was 
calculated as 0.075 μg/mL.  This data was then re-plotted, but the concentrations were 
divided by three to represent that the had particle only 1/3 drug (e.g. 4 μg/mL became 
1.33 μg/mL) and by doing so, the EC50 for RIF SDN on the growth of Map K10/GFP was 
calculated as 0.025 μg/mL (Fig 5.5b) 
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RIF SDN

-3 -2 -1 0 1
1.0
1.5
Log10(Mass Concentration)/g/mL
 
 
Figure 5.5 (a) Calculating the EC50.  Efficacy of RIF SDN on the growth of Map K10/GFP, 
considering ‘mass’ concentration of the SDN (excipient and SDN) (where β represents the change 
in fluorescence [representing mycobacterial growth] per day) and EC50 = 0.075 μg/mL (n=9).  
Concentration plotted on the log scale. 
 
RIF SDN
Log10(Concentration)/g/mL

-4 -3 -2 -1 0 1
1.0
1.5
 
Figure 5.5 (b) Calculating the EC50.  Efficacy of RIF SDN on the growth of Map K10/GFP, 
considering effective concentration of the SDN (RIF loading only) (where β represents the change 
in fluorescence [representing mycobacterial growth] per day) and EC50 = 0.025 μg/mL (n=9).  
Concentration plotted on the log scale. 
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5.3.2.2 Statistical Analysis 2 
Did the different concentrations screened differ significantly from the control (0 
µg/mL) for both RIF treatment types (RIF SDN and RIF aqueous)? 
 
It was important to determine whether the different concentrations of RIF in each form 
(SDN and aqueous) differed significantly from the control (0 µg/mL).  The raw data, 
fluorescence (AFU) against time (days), was checked for a normal distribution by plotting 
a histogram (MINITAB®, version 17).  As the data was not normally distributed (see 
Appendix C), the Log data was utilised to run an ANOVA test (using a general linear 
model with Tukey post-test [allowing pairwise comparisons, comparing all mean 
values]).   
In both cases (RIF SDN and RIF aqueous), there was an overall difference (p<0.001) 
between the different concentrations and the control (0 µg/mL) indicating significant 
toxicity for both treatments (Figs 5.6 and 5.7).  For RIF SDN, concentrations 0.125, 0.25, 
0.5, 1, 2 and 4 µg/mL significantly reduced the growth of Map K10/GFP compared with 
the control (p<0.001) (Fig 5.6), whereas concentrations 0.00375, 0.0075, 0.015, 0.03, 
0.0625, 1, 2 and 4 µg/mL for RIF aqueous all significantly reduced the growth of Map 
K10/GFP compared with the control (p<0.001) (Fig 5.7).  As shown in Figure 5.6, four 
(in the low range) of the twelve concentrations tested did not differ significantly from the 
control for RIF SDNs, whereas only one (0.001875 µg/mL) concentration did not differ 
significantly from the control for RIF aqueous (Fig 5.7).  
From these results, it seems that the aqueous form of RIF had greater anti-mycobacterial 
than RIF SDN did, as it was able to significantly inhibit mycobacterial growth at lower 
concentrations.  It must be noted however, that at each concentration for both treatment 
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types, only 30% of this concentration was drug for RIF SDN, unlike RIF aqueous which 
was >97% drug, thus making direct comparisons problematic.  
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Figure 5.6 Impact of RIF SDN on mycobacterial growth.  Comparing the control (0 µg/mL) 
to each concentration of RIF SDN using an ANOVA test (using general linear model with Tukey 
post test).  Bar chart plot of fluorescence data (β), showing where there is a significant difference 
between each RIF SDN concentration on the growth of Map K10/GFP and the control (0 µg/mL). 
(Significance level is denoted by: <0.001 (***), <0.01 (**) and <0.05% (*)).  Each bar showing 
2* the SEM.  Concentration plotted on the log scale.  
 
 
Figure 5.7 Impact of RIF aqueous on mycobacterial growth.  Comparing the control (0 
µg/mL) to each concentration of RIF aqueous using an ANOVA test (using general linear model 
with Tukey post test).  Bar chart plot of fluorescence data (β), showing where there is a significant 
difference between each RIF aqueous concentration on the growth of Map K10/GFP and the 
control (0 µg/mL).  (Significance level is denoted by: <0.001 (***), <0.01 (**) and <0.05% (*)).  
Each bar showing 2* the SEM.  Concentration plotted on the log scale. 
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5.3.2.3 Statistical Analysis 3 
Did the two forms of RIF (SDN and aqueous) differ significantly from each other 
on their overall (at all concentrations/times) inhibition of the growth of Map 
K10/GFP? 
 
To determine whether there was an overall significant difference between the growth 
inhibition of Map K10/GFP over the 7 day fluorescence assay when treated with RIF 
SDN or RIF aqueous, an ANOVA (using a general linear model with Tukey post-test) 
was employed.  The log data (of the fluorescence readings) was utilised in the analysis 
and compared for the 2 forms of RIF (SDN and aqueous) and all the different 
concentrations and time points (i.e. the two mass data sets were compared).  Overall, the 
treatments were found to be highly significantly different (p<0.001).  Although the two 
forms of the drug differed significantly from each other in their effect on Map K10/GFP, 
at the higher concentrations the two treatment types had very similar effects on the 
mycobacterial growth (Fig 5.2 [a-b]) and as RIF SDN has excipients and stabilisers, they 
could have be enhancing or inhibiting the SDNs action on Map K10/GFP therefore a 
direct comparison is not possible by this means.  Overall, a significant difference would 
be expected when one treatment type had 30% drug whereas the other had >97% drug. 
 
These results were plotted in a boxplot (Fig 5.8) to allow a visualisation between the 
treatment types, with the interquartile range box displaying 50% of the data, the extending 
lines (whiskers) representing the upper and lower distribution in the data points and where 
* represented data outliers. 
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Figure 5.8 Treatment data summary.  Boxplot displaying the data spread between RIF in an 
aqueous form and an SDN form, where the log has been calculated from the raw data of 
mycobacterial growth over 7 days. (* denotes outliers in the data sets).  These two data sets were 
highly significantly different from each other (p<0.001).  The RIF SDN data from each 
concentration appears to be more spread than when in the aqueous form with longer whiskers and 
further placed outliers.   
 
Please note the concentration is a mass concentration, where aqueous Rif = >97% drug and SDN = 30% drug.  
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5.3.2.4 Statistical Analysis 4 
Was there a significant difference on the growth of Map K10/GFP between days 
when treated with the different forms of RIF? 
 
The substances were screened over 7 days, therefore it was important to see the affects of 
each substance between days, and how they compared between treatment types.  To 
compare between different days for the different treatments, an ANOVA (using a general 
linear model with Tukey post-test) and 95% confidence interval for each treatment type 
(RIF SDN/aqueous) was utilised.  There was an overall highly significant difference in 
mycobacterial growth between days for both treatment types (RIF SDN and RIF aqueous) 
(p<0.001) (where N= sample size and grouping represented statistical difference via a 
letter overlap).  As shown in Figure 5.9 and 5.10, means that did not share a letter (or 
colour) were significantly different from each other, thus showing which days differed 
significantly.   
For both treatments, via a measure of confidence intervals, day 0 did not overlap with any 
other day, suggesting that for all days tested, significant toxicity was observed (Tables 
5.4 and 5.5).  There was a significant difference for all days for RIF SDN with two 
exceptions (days 6 & 7 overlapped and 3 & 4 overlapped) whereas for RIF aqueous all 
days overlapped (groups of days that overlapped included 5, 7 & 4, 6 & 5, 7, 4 & 3, and 
1 & 2) for RIF aqueous, except day 0 (Tables 5.4 and 5.5).  From these results, it seems 
that there was less of an overlap (and therefore greater difference) between days when 
RIF was in the SDN form than when in the aqueous form, thus suggesting that RIF 
aqueous has a slower kill rate compared to RIF SDN.  Additionally, the difference in R-
Squared predicated (R-Sq pred) values further support this data.  R-Sq pred indicates how 
well a model fits any given data set, the higher the value (0-100), the higher the accuracy 
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of the predictions made.  For RIF SDN R-Sq pred was 80.24%, while for aqueous it was 
51.01%, suggesting that there was greater significance between days when mycobacteria 
was treated with RIF as an SDN than in the aqueous form (Tables 5.4 and 5.5). 
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Table 5.4 Difference in bacteria growth between days when treated with RIF SDN.  
Overall the significant difference of bacterial growth between days (ANOVA, Tukeys test) was 
highly significant (p<0.001) when treated with RIF SDN.  Means that did not share a letter (or 
colour) were significantly different from each other.  As shown, days 3 & 4 and days 6 & 7 
were not significantly different from each other.  Day 0 was significantly different from all 
other days.  
 
Treatment Day N Mean Grouping  
RIF SDN 7 63 6.53 A 
RIF SDN 6 63 6.36 A 
RIF SDN 5 54 6.04      B 
RIF SDN 4 62 5.57          C 
RIF SDN 3 58 5.39          C 
RIF SDN 2 58 4.41              D 
RIF SDN 1 59 4.11                  E 
RIF SDN 0 62 3.18                    F 
 
 
 
 
Table 5.5 Difference in bacteria growth between days when treated with RIF aqueous.  
Overall the significant difference of bacterial growth between days (ANOVA, Tukeys test) was 
highly significant (p<0.001) when treated with RIF Aqueous.  Means that did not share a letter 
(or colour) were significantly different from each other.  As shown, there was some overlap 
between days (e.g. 4, 5 and 7).  Day 0 was significantly different from all other days. 
 
Treatment Day N Mean Grouping  
RIF Aqueous 6 57 5.84 A 
RIF Aqueous 5 57 5.54 A  B 
RIF Aqueous 7 62 5.38      B    C 
RIF Aqueous 4 60 5.37      B    C 
RIF Aqueous 3 62 5.12             C 
RIF Aqueous 2 62 4.54                 D 
RIF Aqueous 1 59 4.19                 D   
RIF Aqueous 0 62 3.56                    E     
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5.3.3 Colony Counts  
 
Colony counts were measured following the growth of Map K10/GFP on solid agar after 
incubation for 12 weeks (from plating out at the end of the fluorescence assay following 
7 the day exposure to the SDNs and aqueous drugs [control = 0 µg/mL]) as described in 
Chapter 2 (section 2.1.5).  This experiment was conducted as a control alongside the 
fluorescence assay, as it is the conventional approach to assessing the impact of 
substances on mycobacterial growth.   
Similarly to the metal/metal oxide NPs (Chapter 4), there was considerable variability in 
the data.  Obtained data allow the toxicity of the test substances to be ranked RIF 
aqueous> RIF SDN> TRIPLE> DUAL SDN> INH aqueous (Fig. 5.9).  Results for RIF 
in both forms, were quite comparable, akin to what was observed in the fluorescence 
assay results.  However, the colony count data for TRIPLE SDN was unusual, particularly 
for concentrations 0.25 and 0.5 µg/mL where a very limited level of inhibition was 
observed (Fig 5.9).  The results for INH were also comparable to the fluorescence assay 
results, where very little anti-mycobacterial properties were observed, however only 2 
repeats were included for INH aqueous.   
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Figure 5.9 Colony counts after 12 weeks culture on 7H11 agar.  Using conventional colony 
counts, the toxicity of the different treatments can be ranked in the following order: RIF aqueous> 
RIF SDN> TRIPLE> DUAL SDN> INH aqueous (although there is some ambiguity with the two 
of the TRIPLE SDN concentrations).  Drug loading for each treatment differs (see Table 5.1).  
Each concentration displaying the SEM (n=min of 3 repeats, except INH where n=2).  
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5.3.4 Cytotoxicity of substances to macrophages 
 
 
Cytotoxicity was tested over a concentration range of 0.0039 - 8 µg/mL, by serial 
dilutions, using the alamar blue assay (Chapter 2, section 2.4).  Results are expressed as 
in Chapter 4 (section 4.3.6) (Fig 5.10).  Statistical significance to the control (no treatment 
[0 µg/mL]) was determined via an ANOVA (using a general linear model with Tukey 
post-test) (MINITAB®, version 17).  Results were considered significant if p <0.05 
(significance level was denoted by:  p <0.001 [***], <0.01 [**] and <0.05 [*]).  No 
significant changes were observed in the cell viability for each substance at all 
concentrations tested, p>0.05 (Fig 5.10).  At the lower concentrations, INH reduced cell 
viability more than the other substances, yet this was not significant from the control (Fig 
5.10).   
 
 
 
Figure 5.10 SDN/drug cytotoxicity to macrophages after 24-hour incubation.  As shown, 
very little cytotoxicity was observed from the different substances, the cytotoxicity exerted was 
not found to be statistically significant (p>0.05) Each concentration displaying the SEM (n=3). 
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5.3.5 Map K10/GFP macrophage infection  
 
Using macrophage cells an infection model was designed to image the infection of 
macrophages by Map K10/GFP.  All imaging was achieved using a Zeiss Axiovert 200M 
inverted Epi fluorescence microscope with an Axiocam MR3 camera.    Optimisation of 
the protocol for the development of an in vitro macrophage infection model was required.  
It was important to firstly determine the optimal number of macrophages per chamber, 
the length of incubation period the macrophage cells required to successfully engulf 
foreign bodies under these experimental conditions, what MOI of mycobacteria 
(mycobacteria per macrophage) was suitable for imaging but minimised clumping, and 
finally the optimal lens resolution for these experiments.  The overall aim was to image 
the uptake of SDNs into Map K10/GFP infected macrophages.  
In each experiment undertaken, macrophage cells were grown in complete medium 
[without streptomycin or penicillin]) for 24 hours prior to any infections/treatments at 
37ºC, 5% CO2. Infection/treatment were for 3 - 24 hour incubation periods (during 
optimisation experiments) at 37ºC, 5% CO2.  In all experiments, macrophages were 
seeded at a density of 5 x105/mL in chambered slides at a final volume of 200 µL per 
chamber, the DIC was grey, DiD labelled SDNs (RIF [red] and TRIPLE [yellow]), NP 
beads (pink), Map K10/GFP (green), macrophage nucleus ([DAPI] blue) and F-actin 
([phalloidin] cyan).  Appropriate controls were included in each experiment (e.g. 
macrophage cells only [no infection or treatment]).  
Figure 5.11 (a-d) illustrates control macrophages, showing healthy cells grown in 
complete medium, stained with DAPI.  The four images (a-d) demonstrate the difference 
between the magnifications employed ([a] 10X, [b] 40X, [c] 63X, [d] 100X), with the 
DAPI and DIC channels in use to show the cell nuclei and the cell edges with some 
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structural detail.  Magnification 63X (Fig 5.11 c) was found to give optimal information; 
displaying enough cells to give a general representation of any infection/treatment.   
Figure 5.12 (a-b) illustrates control macrophages, showing healthy cells grown in 
complete medium, stained with DAPI and phalloidin.  As displayed, the F-actin was 
stained to give information on the cytoskeleton.  Although it gave a clearer portrayal of 
the control cells, it was not used in experimental conditions due to a crossover between 
its wavelength and the far-red wavelength of the DiD SDNs (CY5 channel).  As shown 
in Figure 5.12 (b) in some instances, the DIC channel was removed to display only the 
stained cellular components of interest.  This made interpretation of some images easier 
and allowed a clearer visualisation.  
Figure 5.13 (a-c) illustrates macrophages with different MOIs of Map K10/GFP (5, 10 
and 30).  Mycobacteria were internalised by the macrophage cells and there was little/no 
residual GFP detected out with the cell cytoskeleton.  Figure 5.13 (c[ii]) has had the DIC 
removed to allow a clearer visualisation of Map K10/GFP engulfed by the cells, although 
not all macrophages had mycobacteria. The rod-like structures could be visualised, and 
at an MOI of 30 mycobacterial clumping had occurred (Fig 5.14).  Although engulfed by 
the macrophages, the mycobacteria were still readily detectable at all magnifications 
tested. 
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a)                                                                        b) 
 
c)                                                                              d) 
Figure 5.11 (a-d) Controls for optimisation: macrophages with nuclei stain.  Macrophages, 
after 24 hours incubation, at magnifications 10X (a), 40X (b), 63X (c) and 100X (d).  The intense 
DAPI nuclei stain (blue) was utilised as a marker for focusing in all images (scale bars all 10 
µM).  From these images, the 63X magnification was found to be most informative. DIC: grey, 
DAPI: blue.  
 
      a                                                                       b 
Figure 5.12 (a-b) Controls for optimisation: macrophages with nuclei and F-actin stain. 
Macrophages after 24 hour incubation at 63X, stained with DAPI (blue) and F-actin stain 
phalloidin (cyan) (DIC, DAPI & CY5 channels). Image (b) has had the DIC channel removed to 
show the cellular cytoskeleton.  Some elongated, stretching cells were observed.  DIC: grey, DAPI 
(nuclei): blue, phalloidin (F-actin): cyan (scale bars all 10 µM). 
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a) b) 
 
c) (i)                                                                   (ii) 
 
Figure 5.13 Infected macrophages.  Macrophages infected with Map K10/GFP at a MOI 5 (a), 
MOI 10 (b) and MOI 30 (c[i]) (4 hour infection) at 63X (DIC, DAPI & GFP) where (c[ii]) has 
had the DIC channel deleted).  DIC: grey, DAPI (nuclei): blue, GFP (Map): green (scale bars all 
10 µM). 
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Figure 5.14 Map K10/GFP infected macrophage.  Two macrophages engulfing a clump of 
Map (MOI 30) with DIC removed 100X.  Individual bacilli are visible. DAPI (nuclei): blue, 
GFP (Map): green (scale bar 10 µM). 
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5.3.6 Uptake of SDNs by macrophages   
5.3.6.1 Macrophages and 20 nm carboxylated polyester NP beads 
 
Using J774A.1 (macrophage-like) cells an infection model was designed to image the 
uptake of NPs by macrophages.  As a control, non-toxic, fluorescent 20 nm NP beads (NP 
beads) (section 5.2.8) were initially used to ensure the macrophages would engulf NPs in 
these conditions, and to identify an appropriate incubation period which allow NP uptake 
to be visualised in studies with SDNs and thirdly to determine a suitable concentration of 
SDNs to treat the macrophages with for imaging purposes.   
  
Figure 5.15 (a,b) illustrates macrophages engulfed NP beads 3 and 24 hours post 
exposure.  From these initial experiments, it was determined 3 hours (possibly less) would 
be a suitable incubation period to allow uptake of NP by these macrophage cells to be 
investigated.  Figure 5.15 (c) is a replication of Figure 5.15 (b) but has had the DAPI 
channel removed from the image to show the sub-cellular location of the NPs.  As shown, 
the NPs, which had high intensity fluorescence, look to have been readily engulfed by the 
macrophages at a concentration of 20 µg/mL, and are localised around the cell nuclei 
(blue) and are located throughout the cytoplasm.  Based on these findings it was decided 
that a lower concentration of NPs (10 µg/mL) would be tested in future experiments.  
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a)                                                            b) 
 
 
                                             (c) 
Figure 5.15 (a-c) Control for optimisation: macrophages exposed to NP beads. Macrophages 
following 3 hour (a), 24 hour (b) incubation with 20 µg/mL NP beads 63X (DIC, DAPI & CY3) 
where (c) has had the DAPI filter removed from (b) to allow a clearer representation of the NP 
beads around the nuclei.  DAPI (nuclei): blue, NP beads: pink (scale bars all 10 µM). 
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Figure 5.16 illustrates macrophages which were infected with Map K10/GFP (MOI 5) 
and then exposed to NP beads at a concentration of 10 µg/mL.  Mycobacteria and NP 
were internalised by the macrophages.  It was difficult to determine whether co-
localisation was occurring or whether the NP beads were associated with the 
mycobacteria or not, as the GFP and CY3 signals were found throughout the field of view, 
suggesting good dispersion of NPs and mycobacteria.  
 
 
Figure 5.16 Control for optimisation: infected macrophages exposed to NP beads.  Map 
K10/GFP (MOI 5) infected macrophages following 4 hour incubation with 10 µg/ml NP beads 
63X.  DAPI (nuclei): blue, GFP (Map): green, NP beads: pink (scale bars all 10 µM). 
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5.3.6.2 Macrophages and uptake of SDNs 
 
Following the successful imaging of internalised NP polystyrene beads, macrophages 
were then treated with the DID labelled SDNs and incubated for 4 hours.  Figure 5.17 (a-
c) and 5.18 (a-c) illustrates macrophages and DiD labelled RIF and TRIPLE SDNs at a 
concentration of 10 µg/mL.  The RIF SDNs (Fig 5.17 a-c) were not agglomerated 
throughout the field of view, when imaged at 63 X.  In Figure 5.17 (c) the DIC channel 
has been removed (from b) to try and better display the sub-cellular location of SDNs.  
Overall, RIF SDNs were relatively well dispersed, where approximately 50% of 
macrophages had internalised (or surface bound) RIF SDNs.  Figure 5.17 (a) suggests 
that SDNs were engulfed as small agglomerates by the macrophages.  TRIPLE SDNs 
look to be quite agglomerated in (or on) the macrophages (Fig 5.18) thus concurring with 
DLS results for these SDNs (where average particle size was > 415.3 nm).  Figure 5.18 
(a) has only a weak CY5 signal emitting from the macrophage cells, and the concentration 
of SDN looked to be low.  Figure 5.18 (b) depicts 2 large agglomerates, within (or surface 
bound) a macrophage cell.  The SDNs may have been engulfed as an agglomerate or they 
may have compartmentalised intracellularly.  Figure 5.18 (c) has had the DIC channel has 
been removed to try and better display the SDN agglomerates.  
 
The RIF SDNs were the smaller of the two SDNs with DiD incorporated into their 
manufacture, therefore it seems that they dispersed evenly in the medium thus affecting 
their (possible) uptake by macrophages.  It is possible that the macrophages did not engulf 
the TRIPLE SDNs as readily.  As weaker CY5 signal was emitted for the TRIPLE SDN 
experimental chambers, during the cell wash prior to staining extracellular SDN may have 
been removed hence was less was visible.  Overall, there appeared to be no residual 
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antibiotic, and it appeared that the SDNs were engulfed by the macrophages and not 
attaching to the cell surfaces, although this needed to be confirmed.  
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a)                                                            b) 
 
                                       (c) 
 
 
Figure 5.17 (a-b) RIF SDN treatment to macrophages.  Macrophages following 4 hour 
incubation with 10 µg/mL RIF SDN 63X where (c) has had the DAPI filter removed from (b) to 
allow a clearer representation of the SDNs orientation around the cell nuclei.  RIF SDNs have 
either formed small agglomerates or cellular uptake and trafficking caused this mass formation in 
certain areas.  DIC: grey, DAPI (nuclei): blue, CY5 (RIF SDN): red (scale bars all 10 µM). 
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a)                                                            b) 
 
                                       (c) 
 
 
Figure 5.18 (a-c) TRIPLE SDN treatment to macrophages.  Macrophages following 4 hour 
incubation with 10 µg/mL TRIPLE SDN 63X where (c) has had the DIC filter removed to allow 
a clearer representation of the SDNs orientation around the cell nuclei.  TRIPLE SDN look to 
have formed small agglomerates, and were not dispersed as well as RIF SDNs.  At 10 µg/mL 
TRIPLE SDNs are not as well distributed as the NP beads or the RIF SDNs.  DIC: grey, DAPI 
(nuclei): blue, CY5 (TRIPLE SDN): yellow (scale bars all 10 µM).  
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5.3.6.3 Macrophages and SDNs: 3D images  
 
Following the successful imaging of DiD incorporated SDNs with macrophages, it was 
important to determine whether the SDNs were internalised by the macrophages, or if 
they were surface bound (e.g. if they weren’t removed following cell washing) and to 
visualise the drugs location throughout the macrophage.  This was achieved by using Z-
stacks to examine individual layers of the macrophage cells.  Optimisation for Z-stacks 
was achieved using the microscopes internalised software, with stack depth 
approximately 0.25-0.5 µM in each case.   
 
RIF SDN at 10 µg/mL (4 hours incubation) treated macrophages were imaged using Z-
stacks.  Figure 5.19 (a-f) illustrates a 20 image Z-stack of SDN treated macrophages and 
Figure 5.20 (a-b) illustrates the condensed image of all the stacks.  Figure 5.19 (a-f) and 
Figure 5.20 (a-b) were strongly suggestive that RIF SDNs were internalised by the 
macrophages, and were not surface bound.  Figure 5.19 (a-f) displays RIF SDNs 
throughout the layers, orientated around the cell nuclei as with the NP beads previously.  
Small agglomerates were visible of the SDNs throughout the cells.  Figure 5.20 (a) 
displays the condensed stack, in a 2D image, whereas 5.20 (b) displays the 3D image to 
show the spread and depth of the RIF SDNs compared to the cell nuclei.   
 
 
 
 
 
 
  
212 
 
 
(a) Stack 1                                                     (b) Stack 5 
 
(c) Stack 8                                                          (d) Stack 12 
 
 
(e) Stack 17                                                         (f) Stack 20 
Figure 5.19 Separated Z-stacks of macrophages following 4 hour incubation with 10 
µg/mL RIF SND.  The Z-stacks illustrate the internalisation of RIF SDN throughout the 
macrophage and that the antibiotic was not only surface bound (all scale bars 10 µM).  DAPI 
(nuclei): blue, CY5 (RIF SDN): red (scale bars all 10 µM). 
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a) 
 
 
 
            b) 
Figure 5.20 (a-b) 3D images.  Z-stacks (from Fig 5.19) resorted using Zeiss Axio vision Rel 4.8 
of macrophages following 4 hour incubation with 10 µg/mL RIF SND where (b) displays a 
different orientation of the Z-stack (created using Zeiss Axio vision Rel 4.8).  DIC: grey, DAPI 
(nuclei): blue, CY5 (RIF SDN): red.   
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5.3.7 Map K10/GFP infected macrophages and SDNs 
5.3.7.1 RIF SDNs and infected macrophages  
 
Next, the ability of Map K10/GFP infected macrophages to internalise SDNs (as with the 
NP beads) was investigated.  To do so, macrophages were infected with Map K10/GFP 
(MOI 10) and then incubated with RIF SDNs (20 µg/mL) for 4 hours.  Figure 5.21 depicts 
the detection of mycobacteria and RIF SDN in the cell cytoplasms.  Although both 
mycobacteria and SDNs were detected from initial imaging, it was unclear whether they 
were both internalised by the macrophages and whether they were co-localising or not.  
Therefore Z-stacks were utilised again.  Figure 5.22 illustrates a resorted Z-stack 
following RIF SDN (10 µg/mL) treatment to a Map K10/GFP (MOI 10) infected 
macrophage.  This suggests possible co-localisation within the macrophage, as both the 
CY5 and GFP signals were emitting from a close (or same) cellular region.  Figure 5.23 
(a) illustrates Map K10/GFP (MOI 10) infected macrophage with RIF SDNs at a 
concentration of 10 µg/mL.  As shown, mycobacteria and SDNs appeared to be enclosed 
within a cellular vacuole (possibly a lysosome).  When the images from each channel 
were opened individually (Fig 5.23 c-d), it was clear that the structure the mycobacteria 
were held within was a very contained compartments, such as a vacuole.  The same image 
was also imaged as a Z-stack.  As illustrated in Figure 5.24 (a) from the Z-stack it was 
evident that both GFP and CY5 were detected throughout the cell. Using the Zeiss Axio 
vision Rel 4.8 software, the 3-D image was manipulated to an angle where the orientation 
within the cell was visible (Fig 5.24 b).   
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Figure 5.21 Infected macrophages treated with RIF SDNs.  Map K10 GFP (MOI 10) infected 
macrophages following 4 hour incubation with 20 µg/mL RIF SDN and 63X.  DIC: grey, DAPI 
(nuclei): blue, GFP (Map): green, CY5 (RIF SDN): red (scale bars all 10 µM). 
 
Figure 5.22 3D image of infected macrophages.  Map K10 GFP (MOI 10) infected macrophages 
following 4 hour incubation with 10 µg/mL RIF SND 63X.  Z-stacks resorted using Zeiss Axio 
vision Rel 4.8.  DIC: grey, DAPI (nuclei): blue, GFP (Map): green, CY5 (RIF SDN): red.  
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                             a) 
 
 
       b)                                                              c) 
Figure 5.23 (a-c) Infected macrophages with RIF SDN.  Map K10 GFP (MOI 10) infected 
macrophages following 4 hour incubation with 10 µg/ml RIF SND 63X.  The yellow signal is 
indicative of two overlapping fluoresce signals thus being indicative of co-localisation of 
mycobacteria and SNDs. (b) depicts the GFP (Map K10/GFP) signal only (c) depicts the CY5 
(SDN) signal only, with DAPI and DIC removed.  DIC: grey, DAPI (nuclei): blue, GFP (Map): 
green, CY5 (RIF SDN): red (scale bars all 10 µM). 
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a) 
 
b) 
Figure 5.24 (a-b) Infected macrophages with RIF SDN.  Z-stack resorted of Figure 5.23 using 
Zeiss Axio vision Rel 4.8.  The different angles of the Z-stacks display the orientation of Map 
K10/GFP and depicts SDN throughout the macrophage.  An overlap in the two signals was 
indicative of co-localisation.  DIC: grey, DAPI (nuclei): blue, GFP (Map): green, CY5 (RIF 
SDN): red. 
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5.3.7.2 TRIPLE SDNs and infected macrophages  
 
Although the TRIPLE SDNs did not appear to be so readily engulfed by the macrophages 
compared to the RIF SDNs, a similar intracellular phenomenon was detected for the 
TRIPLE SDNs and Map K10/GFP.  As shown in Figure 5.25 the mycobacteria and 
TRIPLE SDN were possibly co-localising within the same macrophage organelle.  The 
green GFP (Map K10/GFP) and the yellow CY5 (SDN) signals were very intense from 
the same cellular area, and another signal was not detected elsewhere within the field of 
vision.  This overlap in signals was indicative of co-localisation. 
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a) 
 
 
b)                                                                                  c) 
Figure 5.25 (a-c) Infected macrophages with TRIPLE SDN.  Map K10 GFP (MOI 10) infected 
macrophages following 4 hour incubation with 10 µg/mL TRIPLE SDN 63X.  The intense yellow 
signal (a) was indicative of two overlapping fluoresce signals thus suggesting co-localisation of 
mycobacteria and SNDs.  (b) depicts the GFP (Map K10 GFP) signal only (c) depicts the CY5 
(SDN) signal only with DAPI removed.  Although and MOI of 10 was infected, a low proportion 
of macrophages have engulfed mycobacteria.  DIC: grey, DAPI (nuclei): blue, GFP (Map): green, 
CY5 (TRIPLE SDN): yellow (scale bars all 10 µM). 
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5.3.8 Excitation/emission crosstalk  
 
It was important to determine whether there was any level of crosstalk between the 
excitation and emission wavelengths of the mycobacteria and SDNs.  Figure 5.26 (a) 
illustrates macrophages treated with SDNs at a concentration of 10 µg/mL.  Using this 
same field of view, the GFP filter was turned ‘on’ to see if GFP was detected.  As shown 
in Figure 5.26 (b) the GFP was overexposed and gives the entire image a green covering, 
but it does not focus on the areas where the SDNs were in the macrophages.  This control 
measure supported the hypothesis that when two signals (e.g. GFP and CY5) were 
emitting from the same cellular area, the likely co-localisation of mycobacteria and SDN 
within an organelle, such as a lysosome was occurring and it was not an artefact of ex/em 
crosstalk.  This is further explained in the discussion.  
 
 
a)                                                                                b) 
Figure 5.26 (a-b) Crosstalk test: Macrophages following 4 hour incubation with 10 µg/mL RIF 
SDN 63 X (a) DAPI, DIC and CY5 filters and (b) DAPPI, DIC, CY5 and GFP filters to determine 
whether there was any crosstalk between the two channels.  As observed, GFP did not fluoresce 
where the SDNs were present within the cell, suggesting crosstalk was not occurring for the two 
wavelengths (all scale bars 10 µM).  DIC: grey, DAPI (nuclei): blue, GFP (Map): green, CY5 
(RIF SDN): red (scale bars all 10 µM).  
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5.3.9 Intracellular fluorescence intensity  
 
One of the main observations from the fluorescence microscopy was the difference in the 
intensity of the GFP signal from macrophages with and without the SDNs.  Although this 
was not quantified in this project, it was notable.  At an MOI 10, in the cells without 
SDNs the green fluorescence from the Map K10/GFP was very intense, unlike when 
engulfed by cells and localised with SDNs. An example is given in Figure 5.27.  It was 
likely that the mycobacteria were sub-lethally stressed due to the presence of the high 
concentration of antibiotic (this was a reproducible result) and therefore unable to emit 
fluorescence as intensely when macrophages were not treated with SDNs.  Although this 
would need to be further tested.  
 
 
Figure 5.27 (a-b) Control test: GFP intensity. (a) Map K10 GFP (MOI 10) infected 
macrophages and (b) Map K10/GFP (MOI 10) infected macrophages treated with 10 µg/mL 
RIF SDN to compare fluorescence intensity.  DAPI (nuclei): blue, GFP (Map): green, CY5 (RIF 
SDN): red (scale bars all 10 µM). 
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5.3.10 Phage amplification assay to quantify viable mycobacteria following drug 
contact 
 
A preliminary study using the phage-PCR amplification assay was carried out to compare 
the killing of Map K10/GFP by RIF SDN to aqueous RIF, within a macrophage, after a 4 
hour incubation.  The assay was carried out at three MOIs (1,10 and 30) of Map K10/GFP 
(per macrophage).  Control plates were macrophages infected with Map K10/GFP and 
not treated with any drug.  Following 24 hour incubation with treatment then lysing of 
the macrophages to carry out the phage-PCR assay, confluent plaques formed on the soft 
agar and each plaque represented one Map K10/GFP cell.  ‘Neat’ positive control plates 
(no treatment) had plaques which were too numerous to count (TNTC [often due to the 
merging of plaques]) and data was obtained from the serial dilutions of the same sample.  
Negative control plates (no mycobacteria) had no plaques.  An example of a positive 
control plate is given in Figure 5.28, displaying TNTC plaques. 
 
Figure 5.28 Positive control (Map K10/GFP with no treatment following lysing of 
macrophage cells).  As shown, the confluent plaques (where one plaque represents one Map cell 
from the original sample) were TNTC and the merging of plaques was occurring.  
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The FASTPlaqueTBTM assay was only performed once; therefore no statistical analysis 
was possible on the data obtained.  However, preliminary results were obtainable from 
the assay, which are displayed in the following figures.  Results were calculated by 
counting the number of plaques visible on the agar, multiplying this by the dilution factor 
(e.g. 1 or 10  [depending on the serial dilution]) then dividing this by the volume of Map 
K10/GFP added to the phage assay (100 µL) (i.e. number of plaques* dilution 
factor/volume of culture plates).   
Figure 5.29 (a-c) displays the results for both treatment types (RIF SDN and RIF aqueous) 
at the three different MOIs of mycobacteria.  Figure 5.29 (b-c) suggests that RIF SDN 
was more toxic to Map K10/GFP following contact within an intracellular environment.  
The data from this pilot study suggests that an MOI of 1 (1 mycobacteria per macrophage) 
was too low a number, as no counts were found in either of the experimental plates (Fig 
5.29a).  Figure 5.29 (b) shows that at an MOI 10, plaques for both treatment types were 
visible (although less plaques were visible following RIF SDN treatment), whereas at an 
MOI 30 in Figure 5.29 (c) compared to the control (no treatment), there was an 
approximate 2 log reduction in killing when RIF was in the aqueous form, whereas there 
was a complete 4 log reduction in killing in the SDN form.  Although this assay was only 
carried out once, at three different MOIs (1, 10 and 30) and with three different serial 
dilutions for each MOI, it does suggest that RIF as a SDN was more toxic (at only 30% 
drug) compared to RIF in the aqueous form (at >97% drug). 
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Figure 5.29 Plaque forming units (pfu/mL) counted for each treatment (RIF SDN or RIF 
aqueous).  Different MOIs of Map K10/GFP (a) MOI 1, (b) MOI 10 (c) MOI 30 per 5 x105/mL 
macrophages (control = 0 µg/mL [no treatment]).  
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5.4 Discussion 
 
The main aims of novel drug discovery for TB are to lower effective drug dose and 
shorten the treatment period, which will consequently decrease costs and likelihood of 
resistance.  This work aimed to address these factors.  By working with FDA approved 
drugs (RIF, INZ and PZA), excipients from the Inactive Ingredients Database (Kollicoat® 
protect, Hyamine®, F68® Protect) and synthesising formulations of these drugs at the 
nano-scale, this approach may avoid the vast costs and timescales normally associated 
with novel drug development.  Yet these SDNs essentially were novel drugs.  Although 
the SDNs would have had the same target and would kill the mycobacteria by the same 
means, the nano-form offers many advantages, primarily the potential to enable targeted 
treatment (highlighted in Chapter I [section 1.10.1]).  
By comparing the efficacy of the SDNs and the aqueous drugs on the growth of Map 
K10/GFP via the fluorescence assay it was clear to see all substances, except INH, 
inhibited mycobacterial growth over the 7 day period.  As displayed in the screening assay 
results, there was much data generated from this analysis and there were many ways to 
interpret it.  Using statistical means, the data was analysed to try to determine where the 
substances differed from each other (and to see whether it was time and/or concentration 
dependent).  An important factor was the difference between the concentrations in the 
two forms of RIF.  The API for each substance needed to be considered, to allow a direct 
comparison between the two data sets.  Through expressing the concentration of the API 
(and not the mass of the treatment), comparing the difference in mycobacterial growth 
over days and the EC50 values, RIF in the SDN form was the most anti-mycobacterial 
substance tested.  The fluorescence assay results also correlated with the colony count 
and the phage assay results, thus strongly advocating the highly toxic properties to 
mycobacteria of RIF as an SDN.  There were high levels of variation in the colony count 
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data, but again a distinct pattern was observed for nearly all substances and 
concentrations.  More specifically, as with the metal/metal oxide NPs, the colony counts 
related to the fluorescence assay results on the toxicity of the substances.  The phage 
assay (which was unfortunately only performed once) demonstrated the potential potency 
of nano-RIF at killing intracellular pathogens and when presented with the microscopy 
images demonstrating co-localisation, presents strong evidence for the highly potent 
nature of the SDNs.  
 
5.4.1 SDNs: an overall summary  
 
Overall, results from the screening assay suggest that all substances, except for INH, 
significantly inhibited the growth of Map K10/GFP over the 7-day fluorescence assay.  
By comparing the results from RIF SDN and RIF aqueous, initial conclusions are 
suggestive that both substances significantly inhibited Map K10/GFP growth at the time 
points and concentrations screened, but their overall effects were relatively similar.  The 
EC50 value calculated for the SDN was 0.075 µg/mL whereas aqueous was 2.98 µg/mL 
against Map K10/GFP.  However, the API of each substance differed greatly, as RIF SDN 
was only 30% drug, whereas RIF aqueous was >97% drug, and when this was considered, 
the EC50 for RIF SDN was calculated at 0.025 µg/mL (this being almost a 100-fold 
difference to RIF aqueous) and results were therefore more indicative that RIF SDN had 
greater anti-mycobacterial properties.  
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 5.4.1.1 DLS 
 
DLS revealed a mix of SDN sizes in 7H9 medium.  RIF SDN and TRIPLE SDN were 
significantly larger when they had DiD added (DiD was incorporated for imaging 
purposes).  With the addition of a further substance on to the SDNs, this increase in size 
was expected, but additionally, agglomeration could have increased giving a larger 
hydrodynamic diameter measured by DLS.  As it was not possible to carry out TEM on 
these organic samples, DLS was the only available means to determine particulate size.  
Overall, DLS results suggest that RIF SDN were very small and well dispersed NPs, the 
DUAL SDNs were <100 nm on average, whereas the TRIPLE SDNs were >100 nm.  
Both particle types with DiD incorporated were >100 nm.  The zeta potentials for all 
SDNs had low, negative values.  The greater the charge (negative or positive) the more 
stable a suspension is assumed to be, the lower the values, the higher the chance of 
agglomeration, where +/- 30 mV is usually considered sufficient charge to allow 
repulsion between NP to prevent agglomeration (Kalbassi et al. 2013).  However, in 
regards to the RIF SDNs, agglomeration did not seem to be occurring when measured by 
DLS and imaged using microscopy.   
 
5.4.1.2 TRIPLE SDNs 
 
The efficacy of the TRIPLE SDN was not as potent as anticipated, where an EC50 of 7.17 
µg/mL was calculated, but this was considering the total mass concentration of the NP.  
TRIPLE SDNs were composed of three first line antibiotics, RIF, INH and PZA.  The 
loading of each drug differed from each other, (13% RIF, 6% INH and 34% PZA).  
Interestingly INH (aqueous) was found to have little/no effect against a Map K10/GFP 
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strain.  INH is a bactericidal prodrug requiring activation from a catalase-peroxidise 
KatG, encoded by the katG gene in Mtb (Zhang & Yew 2009).  Although Mtb and M. 
bovis are known to be very sensitive to INH, Map is known to have much greater levels 
of resistance to this antibiotic (Williams et al. 1999) therefore these results were not 
unexpected.  As such, toxicity exerted would need to have been derived from either PZA 
and/or RIF.  PZA kills non-replicating bacilli which is the opposite of many antibiotics 
and it disrupts the membrane potential of Mtb.  PZA works in an unusual manner against 
Mtb and its mechanism is not well elucidated.  The drug needs to be converted into 
pyrazinoic acid by pyrazinamidase to confer anti-TB properties, it is only effective in 
acidic pHs in anaerobic conditions during active inflammation and is not active against 
Mtb in ‘normal’ culture conditions at neutral pH levels (Zhang & Yew 2009; Zhang et al. 
2003; Lanoix et al. 2015) which would have been the conditions of these experiments.  
Due to a mutation in the pncA gene (which codes for pyrazinoic acid), M. bovis is resistant 
to PZA (Zhang & Yew 2009) and M. avium is known to be non-susceptible due to a 
problem with pyrazinoic acid transport (Sun et al. 1997).  Therefore, it is reasonable to 
conclude that RIF was the predominantly active API in this triple-drug NP.  Even at a 
loading of only 13%, RIF still exerted considerable anti-mycobacterial properties against 
Map K10/GFP. 
 
5.4.1.3 DUAL SDN 
 
The DUAL SDN displayed the weakest anti-mycobacterial effect to Map K10/GFP 
compared to the other SDNs, screened under these experimental conditions with an EC50 
of 17.3 µg/mL.  These SDNs were composed of two first line antibiotics, (20% RIF and 
10% INH), and as aforementioned, INH did not display potent anti-mycobacterial affects 
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against this strain of mycobacteria, therefore RIF was likely the predominantly active API 
in this dual-drug NP.  However, it was surprising that the DUAL SDN with 20% RIF 
were less potent than the TRIPLE SDN with only 13% RIF.  DUAL SDNs were smaller 
particles and the colony count data suggests they were considerably toxic when compared 
to the control (no treatment).   Overall, this was a difficult result to comment on, and 
another factor may have influenced the fluorescence assay results (e.g. their stability in 
medium).  
 
5.4.1.4 RIF SDNs and aqueous drug 
 
RIF is a bactericidal antibiotic that works by inhibiting the RNA synthesis of Mtb by 
binding the β subunit of the RNA polymerase thus preventing elongation of the RNA 
chain and it is active against bacilli in both growth and stationary log phases (Zhang & 
Yew 2009).  There is scarce published literature on the efficacy of RIF against Map 
strains.  One report suggests an MIC of 0.5-4 µg/mL and Rifabutin (a structural analogue 
of RIF) was found to be highly toxic against a Map K10 strain (MIC 0.03-0.5 µg/mL) 
(Zanetti et al. 2006).  Results obtained from this study concur with others, that Map is a 
highly sensitive Mycobacterium to RIF, where an EC50 of 2.98 μg/mL was calculated 
from the screening assay.  Its mode of action against Map is likely to be very similar to 
its action against Mtb, although this was not verified.  The aqueous form of RIF was 
screened to allow comparisons between the SDN and the conventional form of the 
antibiotic, but due to the differences in the API it made data analysis more challenging.  
To allow a direct like-for-like comparison, three fold RIF SDN would need to have been 
diluted in 2% FCS, but this would have increased agglomeration of the NPs and created 
a very viscous solution, which was not ideal for the 96 well plate screening assay, 
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therefore mass concentration was utilised.  Furthermore, mass concentration was more 
reflective in clinical terms, as SDNs require excipients.   
 
5.4.1.5 SDN drug loading  
 
The drug/drug ratio of the loading was chosen to try and reflect what is used clinically 
(TRIPLE SDN) but with respect to maximising excipients wherever possible.  Excipients 
are required to stabilise the pre-spray of freeze-drying, generally more excipient resulted 
in smaller particles (which was confirmed by DLS) by preventing particle growth and 
agglomeration.  A series of drug ratios were initially produced and in essence, through 
trial and error, the drug combination that was the most reproducible was selected and 
supplied for this study.  Specific excipients were chosen by the project collaborators based 
on their stability, and following feedback on initial SDN screening.  
 
5.4.2 Cytotoxicity to macrophages  
 
There was very little toxicity observed at the concentrations the macrophages were 
exposed to for both SDNs and aqueous drugs, determined using the alamar blue assay.  
No treatments were significantly different from the control (no treatment).  Although 
cytotoxicity from all the substances tested was very low, it was surprising that RIF SDN 
was more cytotoxic to the cells than the other SDNs, particularly the TRIPLE (which had 
a 53.3% total drug loading).  In the SDN form, the NPs may possibly cause toxicity by 
mechanisms associated with other NPs.  Such mechanism might include ROS/oxidative 
stress (Oberdörster et al. 2007) and pro-inflammatory responses (Gaiser et al. 2013) due 
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to physicochemical characteristics associated with the nano-size range of the particles 
(e.g. the large surface area) phagocytosed by the cells (Kermanizadeh et al. 2014).  
 
5.4.3 Macrophage infection models 
 
Fluorescently labelled NPs have provided the information on how macrophages/cells take 
up and process NMs (Weissleder et al. 2014).  In this study, the localisation of SDNs in 
relation to cellular structures and mycobacteria was investigated, allowing an 
understanding into the effectiveness of targeting.  Macrophages are reported to engulf 
smaller particles more readily than larger (Clift et al. 2008).  The RIF SDNs appeared to 
have been internalised by a higher proportion of macrophage cells compared to the 
TRIPLE SDNs, which were found in agglomerated masses, often in only 1 or 2 cells in a 
X63 field of view, although this was not quantified.  This was probably due to the 
hydrodynamic diameter difference between the particle types, where the smaller RIF 
SDNs were more readily engulfed over the 4 hour incubation period.  It is important to 
note such a difference, as this would be important if SDNs were to be manufactured for 
clinical treatment.  Whether these drugs stay as intact SDNs following addition to the 
Map K10/GFP infected cells or whether they readily dissolve is hard to assert, although 
the microscope images suggest full or partial SDN uptake by the macrophages after 4 
hours of treatment before fixing.    
Z-stacks were utilised to determine whether SDNs and mycobacteria were associated with 
the cell surface or internalised into the cell interior and also to get an insight into whether 
co-localisation (of drug and mycobacteria) occurred following macrophage uptake.  The 
minimum number of stacks taken was 15, and a maximum of 30 (although this would 
take approximately 1 hour to image one field of view), therefore this was a highly time 
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consuming process.  Z-stacks indicated that internalisation of drugs (RIF and TRIPLE) 
was occurring as in nearly all the 3D images obtained, mycobacteria and SDNs were 
found throughout the cell, with fluorescent signals being detected in all layers imaged.  In 
many instances, both signals were emitted from the same position within the cell.  In 
many cells imaged, there was a strong (yellow) fluorescence signal emitted and the GFP 
(green) and CY5 (red) signal was emitting from the same position, therefore, it was 
important to determine whether this was just crosstalk between signals occurring.  Wild 
type GFP has two excitation peaks, generally for viewing GFP, excitation is set at 490±40 
nm and emission of 510-570 nm.  Far red (the CY5 channel for SDNs) excitation is 
640±30 nm and an emission of 690 nm therefore the excitation of GFP does not overlap 
with the emission of the CY5, thus indicating that crosstalk was not the phenomenon 
observed.  Additionally, the Zeiss fluorescence microscope had a bandpath interference 
filter, which rejects frequencies outside the set range.  A previous study reported that a 
mix of colours was indicative of co-localisation of two labelled entities (Panyam et al. 
2002) therefore this intense yellow colour was likely produced by partial or full co-
localisation of Map and SDNs (the green Map and red SDNs).  Unfortunately it was not 
possible to determine whether co-localisation was occurring within a lysosome as 
LysoTracker Red (a fluorescent stain commonly used to visualise lysosomes in cells) 
requires live, viable macrophages and not fixed cells, therefore it was not possible in the 
microscopy facilities available to carry out such a test (they were not containment level 
2).  
The results generated may corroborate some of the results displayed in Chapter 4, where 
NPs look to have been engulfed by macrophages and trafficked to specific vacuoles (e.g. 
lysosomes).  Macrophages are known to readily engulf Mtb but as outlined in Chapter 1, 
Mtb is able to arrest the normal phagosome maturation where bacteria are usually 
destroyed, thus allowing them to lay dormant or reproduce following disruption to the 
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phagosome environment (Podinovskaia et al. 2013).  Further analysis would be required 
to confirm these results, and as stated in a previous study, the intracellular localisation of 
NPs should be reported with caution and backed-up wherever possible (Brandenberger et 
al. 2010).  Yet this PhD project supports the concept that SDNs are engulfed by infected 
macrophage cells, and then trafficked by the immune cells.  As the SDNs and Map looked 
to have been co-localising, this may suggest a specific form of trafficking.  
 
5.4.4 Intracellular killing of Map K10/GFP 
 
The phage assay displayed the potent effects of RIF SDN after 24 hours incubation with 
Map K10/GFP within a macrophage.  In the nano form, RIF may have been in direct 
contact with the bacilli (within a phagolysosome) thus offering a direct, and targeted 
killing.  Following infection of Mtb in an in vivo mouse study, after four weeks, up to 
95% of bacilli were found to be intracellular (predominantly in alveolar macrophages) 
(Hoff et al. 2011).  After ten weeks, the bacilli were eventually described to be largely 
‘extracellular’, enclosed within the necrotic zone of a granuloma, where latent 
mycobacteria reside (Hoff et al. 2011).  Until an acquired immune response occurs, and 
granuloma development occurs to contain the bacilli, it may be easier to ‘catch’ Mtb at 
the early stages of macrophage infection.  There are four potential consequences 
following uptake of Mtb, it can be eliminated immediately, becomes indefinitely dormant 
within the host cell, causes active disease or causes disease many years later due to 
reactivation (Giacomini et al. 2001).  Upon initial internalisation within a macrophage 
and following alteration of the behaviour of the phagosome formation, it allows a period 
of cell division and exponential growth for the bacilli (Russell et al. 2010).  During this 
time before adaptive immunity begins granuloma construction, the bacilli are held within 
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an ‘ineffective’ phagolysosome and this could be a suitable target for anti-TB SDNs.  
Further to this, granulomas are highly complex and would require in-depth investigation 
to determine entry methods for SDNs, achieved possibly through surface modifications 
to allow entrance into this composite.  Granuloma formation is driven by the onset of an 
acquired immune response following Mtb uptake by macrophages and the production of 
cytokines (e.g. TFN-α), but this formation can also lead to tissue damage.  Aggressive 
granuloma response can lead to acute disease, destroying tissues (Russell et al. 2010), 
thus asserting that early treatment to reach bacilli before they are trafficked into 
granulomas may be more beneficial. 
 
5.4.5 Other studies  
 
Most studies investigating nanotechnology for TB treatment, are preclinical studies using 
PLGA polymer therapeutics (Hirota et al. 2010; Onoshita et al. 2010; Gelperina et al. 
2005) as highlighted in Chapter 1 (section 1.12).  There are other avenues to explore 
however.  Liposome based delivery systems have many advantages associated with their 
use (e.g. protection of drug, controlled release).  Liposomes have a phospholipid bilayer, 
surrounding a core encapsulating either hydrophobic or hydrophilic drugs (Cukierman & 
Khan 2011).  Gaspar et al., manufactured Rifabutin encapsulated liposomes (500 nm) and 
compared their potency at killing Mtb (H37Rv) in vivo to free RIF drug (dose 20mg/kg) 
(Gaspar et al. 2008).  They reported no statistical difference between the treatment types 
on bacilli found in the lungs however they report a statistical difference on bacilli in other 
sites (spleen and liver) where liposome encapsulated RIF was more effective (Gaspar et 
al. 2008).  Additionally, they reported a lesser inflammatory response in the lungs of 
liposome treated mice, and the liposomes delivered a higher concentration of drug to 
target sites (Gaspar et al. 2008).  Due to being vulnerable to intestinal degradation, 
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liposomes tend to require delivery via the intravenous route (Pandey & Khuller 2006), 
increasing the labour required in their use as a potential TB treatment. Yet further 
investigation into their administration via inhalation is being investigated (Pandey & 
Khuller 2006).   
The manufactures of the SDNs for this project have designed similar SDNs for HIV 
treatment that are currently undergoing clinical trials (see EudraCT 2013-004913-41 
https://clinicaltrials.gov/ct2/show/NCT02631473).  This is the first ever human clinical 
trial using oral delivery of a nano-medicine against an infectious disease (personal 
correspondence with Dr Marco Giardiello [Department of Chemistry, University of 
Liverpool]).  Titled ‘Pharmacokinetics of efavirenz and lopinavir nano-formulations in 
HIV negative healthy volunteers: an adaptive design study’ the trial recruited healthy 
volunteers to partake, and preliminary results from this trial correlate with the results 
generated in this PhD project, that a particle loaded with less than 50% drug, resulted in 
a 50% reduction in the EC50 compared with the traditional drug which was approximately 
100% drug (personal correspondence with Dr Marco Giardiello [Department of 
Chemistry, University of Liverpool]).  The success of these studies in the HIV field, offer 
verification for the ability for this technology to be adapted to many more types of drugs, 
such as anti-TB drugs.  
The screening of anti-TB SDNs has offered an insight into their anti-mycobacterial 
properties, and microscopy studies have revealed their likely co-localisation with 
mycobacteria within a macrophage, therefore, an interesting consideration would be their 
potential delivery system if these drugs were to make clinical trials, as with the HIV 
drugs.  As pulmonary TB is the most common form of the disease, a respiratory method 
of drug delivery would be a very attractive means.  NPs have improved adherence to the 
mucosal tissues of the lungs over conventional drugs (Pandey & Khuller 2006) therefore 
nebulisation would be an ideal way to administer antibiotic SDNs in the form of mist 
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aerosols via the pulmonary route (Dolovich & Dhand 2011).   Atomizers, a common type 
of nebuliser, use compressed gas to generate high velocity drug aerosols, sprayed through 
a tight opening (Kleinstreuer et al. 2014).  Inhalation of drugs could deliver a significant 
amount of drug throughout the lungs, akin to the common entry of Mtb.  Suarez et al., 
manufactured 1-5 μM RIF-PLGA microspheres (particles with diameters in the 
micrometer range) and delivered them via the respiratory route to guinea-pigs by 
nebulisation.  Guinea-pigs were then infected with Mtb (H37Rv), and authors reported 
that a significant (10 fold) reduction in bacilli was recovered compared with the control 
(animals treated with conventional RIF treatment, also delivered via nebulisation) 5 
weeks post infection (Suarez et al. 2001).  Additionally, animals treated with RIF-PLGA 
had reduced inflammatory response/tissues damage when compared to control animals 
upon analysis of the lung tissue (Suarez et al. 2001).  It is unclear however, whether the 
authors propose this as prevention rather than a cure, as animals were treated prior to 
being infected with Mtb.  
The use of biodegradable polymers (e.g. PLGA) and/or chitosan shells (Dube et al. 2013; 
Semete et al. 2010; Patel et al. 2013) as anti-TB drugs have some drawbacks.  They have 
high costs associated with their production, therefore whether they are suitable for mass 
production is not yet established.  Also, there are still some safety concerns in therapeutic 
applications, as further in vivo studies are required to demonstrate their safety and efficacy 
as drug carries.   
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5.4.6 Future work with SDNs 
 
The SDNs displayed encouraging results against a pathogenic strain of mycobacteria and 
there are many avenues to be explored.  The initial next step would be to screen these 
substances against a human strain of mycobacteria.  Both INH and PZA displayed weak 
anti-mycobacterial properties, but this would likely differ against many Mtb strains, 
which are known to be more sensitive to these antibiotics.  It would be interesting to 
screen these drugs against Mtb, using the screening assay with a GFP-modified strain and 
then intracellularly, preferably using primary macrophages.  The data generated from this 
project could also be utilised to plan a comprehensive in vivo study, to compare bacilli 
loading within alveolar macrophages following infection (with Mtb or Map) between 
treatment groups of RIF aqueous and RIF SDN treated mice.  Additionally, a direct 
comparison between the stability of the two drug types would be interesting, evaluating 
their stability under transportation and storage (long term), and their sensitivity to heat 
and light.  I would hypothesis the SDN form of RIF to be significantly more stable.   
As smaller particles tend to induce cytotoxicity as more molecules/atoms are exposed due 
to the large surface area presented to cells/molecules/bacteria (Semete et al. 2010) further 
analysis into the potentially adverse effects of these SDNs would be required.  NPs 
behave differently (and are often more toxic) when compared to their bulk forms, 
similarly to metal NPs (Rai et al. 2015).  Therefore, changing a material to fall within the 
nano-scale could create adverse effects to biological systems as well as the desirable 
effects already discussed.  As the first line TB drugs have many side effects associated 
with their use normally, it must be considered whether in the nano-form if these drugs 
pose a potential hazard to patients.  Results obtained here do not indicate this 
(macrophage cytotoxicity tests) but it should be considered.  Further investigations could 
include the use of different assays, such as the water-soluble tetrazolium (WST) 1 assay 
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(a colorimetric non-radioactive assay for quantification of cell proliferation, cell viability 
and cytotoxicity using a microplate format) or studies to monitor cytokine production.   
Another important point to consider is the stability of the SDNs compared to 
conventional, aqueous antibiotics.  Although not formally tested in this project, the 
stability of the SDNs was observed.  RIF solution has a shelf life of approximately 2-3 
months (Sigma 1997), whereas RIF SDNs stability was monitored  and they were stable 
for up to 6 months.  DLS data suggested particle stability and through monitoring the 
potency of the SDNs for up to six months in the screening assay, it did not exhibit any 
notable differences.  This may suggest that the SDNs offer greater stability and shelf life.  
However, the stability of these NPs is an important part of the development by Liverpool 
University in order to ascertain their suitability for clinical trials and large-scale 
manufacture, therefore data on these aspects is soon expected.  SDNs do not require 
storage at 4ºC, therefore again making them advantageous to the traditional form, as 
appropriate storage facilities can be problematic in some high burden TB countries.   
 
5.4.7 Conclusions 
 
To conclude, the screening of these SDNs has offered an insight into their anti-
mycobacterial properties within an in vitro cell culture setting and an in vitro intracellular 
setting.  The most exciting results generated are the efficacy results of the RIF SDN 
compared to the aqueous drug plus the likelihood of the co-localisation and the toxicity 
exerted to the mycobacteria by the SDN within a macrophage vacuole.  Further work is 
clearly required to try to determine how these SDNs behave in a cell culture over time 
(i.e. do they dissolve or as stay intact NPs?), what roles the excipients play and whether 
the SDNs pose less (or more) adverse side effects.  Overall, it was not known how stable 
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or efficacious these SDNs would be, and what concentration ranges would be suitable to 
show a decrease in bacterial growth, therefore these results offer a good foundation for a 
continued study with these particles.   
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CHAPTER VI 
 
GENERAL DISCUSSION  
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6.1 Final Discussion 
 
Killing approximately 1 person every twenty seconds, nearly 5000 per day, and up to 2 
million per year, TB remains one of the world’s greatest health threats.  The WHO has 
called for an urgent surge in drug development and the NHS has invested significantly in 
the irradiation of TB in the UK, where incidents are the highest in Western Europe and 
five times higher than in the US (NHS 2015; WHO 2015b).  TB is predominantly found 
in developing counties (WHO 2015b; WHO 2014b; WHO 2013).  The United Nations 
has predicted that the world’s population will reach in excess of 9.7 billion by 2050 and 
11.2 billion by 2100 with the increase principally in the developing world (The UN, 2015 
https://www.un.org/development/desa/en/news/population/2015-report.html accessed 
20/02/16).  This highlights the need for rapid disease control, before MDR/XDR TB 
escalates further.  Through evasion of the host’s immune surveillance, the inherently 
robust Mtb is a well-adapted pathogen.  By preventing organism degradation through 
phagocytosis evasion and transition into a dormancy state, Mtb is rendered resilient to 
both host defence mechanisms and drug actions.  Latency is characterised by the slowing 
down of the pathogens metabolic machinery, allowing the organism to sit dormant in a 
secure environment.  Mtb has a heterogeneous, dynamic nature, and the yin-yang model 
(Chapter I [section 1.9.2]) demonstrates this well, highlighting the difficulties in 
producing suitable treatment programmes.  The intensive first phase of treatment 
followed by the continuation phase still has problems with disease relapse, and 
development of MDR/XDR TB (WHO 2015b).  Nanomedicine offers huge potential in 
the fight against bacterial infections and this avenue of research may produce a suitable 
therapy to combat drug resistance strains of TB and curtail the problems with current 
treatments (e.g. side effects through lower doses).   
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Here, a review of this project is given, conclusions are drawn and gaps in the work are 
highlighted so that they may be addressed in future work.  It is hoped this project will 
lead to more screening and testing of SDNs/NPs/drugs and eventually lead to clinical 
trials of these novel compounds.   
A key objective of this thesis was the development of a rapid drug screening assay 
(Chapter III).  The assay should ideally be HTS amenable, have relatively low costs 
associated, be simple and reproducible, and provide the ability to screen a variety of 
compounds, including nanomedicines.  The assay allowed the efficacy of NPs/drugs 
against a pathogenic Mycobacterium to be screened over a period of 7 days, yielding data 
in replicate sets with suitable controls.  The assay’s success resulted in a peer-reviewed 
publication.  However, due to the inability to commercialise this assay in its exact form 
for profitable gain (because of constraints by the provider of the Map K10/GFP reporter 
strain), a GFP reporter of Mtb would be required to bring this assay forward.  
There were challenges involved in its optimisation including, cell number, cell growth 
stage, plate type, well dehydration and which controls were the most suitable.  These 
optimisation steps have now been resolved by systematic repeats, monitoring and 
observations generating a published protocol that it can be employed by others working 
in the field.  The assay offers a means to screen substances at the early stages of drug 
development, giving rapid information on whether such substances warrant further 
investigation or not.  Being in a 96 well plate format, multiple repeats can be included 
and different substances can be screened in unison.  Improvements for the assay have 
been highlighted in Chapter III, but a major drawback is the inability to calculate 
MIC/MBCs directly from the fluorescence readouts.  Although GFP is stable, and 
fluorescence is independent of cofactors or substrates, a disadvantage is following cell 
death GFP is still detectable (as found with the highest concentrations of Ag NPs 
screened).  It is known that the signal is significantly reduced (likely due to the redox 
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changes during the apoptotic process) (Steff et al. 2001).  However, it would be difficult 
to standardise, as if a threshold of GFP signal was determined (i.e. indicating cell death), 
it would be hard to conclude whether this was a form of auto-fluorescence from dead 
cells, or a smaller population of resistant, viable cells.  This requires further consideration.  
The results on the metal/metal oxide NPs gave a good insight into the efficacy of the NPs 
and effective concentrations required to inhibit this pathogenic mycobacterial strain.  
Although there are many studies on the effects metal/metal oxide NPs have on E.coli and 
other bacterial strains, there is little literature on the efficacy of these NP types against 
mycobacteria (Larimer et al. 2014; Islam et al. 2013).  It was interesting to observe the 
poor anti-mycobacterial effects of the ZnO NPs, as generally they are reported to be 
highly anti-bacterial (Azam, Ahmed, Mohammad Oves, et al. 2012; Li et al. 2011; 
Padmavathy & Vijayaraghavan 2008; Jiang et al. 2009).  The highly potent effects from 
Ag NPs were expected, as silver is widely regarded as toxic, anti-bacterial agent (Zhao & 
Wang 2012; Kim et al. 2007; Besinis et al. 2014; Choi et al. 2008), whereas the literature 
on Cu(II)O NPs is limited, therefore it is hoped this study helped towards bridging this 
gap.  Interestingly, Kim et al., investigated the ability of the immune system to clear a 
bacterial infection when treated with Cu NPs (Kim et al. 2011).  They reported that 
Klebsiella pneumoniae infected mice exposed to Cu NPs (32 µg/mouse) had impaired 
pulmonary bacterial clearance and more viable bacteria in their lungs compared to non-
Cu NP exposed mice.  The authors suggest that Cu NP exposure may in-fact increase the 
risk of a pulmonary infection through impairment of the host defence.  This therefore 
warrants serious consideration if such NPs were to be considered as part of a treatment, 
and again highlights the potentially adverse effects of materials in the nano-scale.   
Whether metals can be integrated into modern medicine or not is debatable but metals 
have been used in medical applications since ancient times.  Hippocrates described the 
use of silver to treat wounds and ulcers and the ancient Egyptians sterilised water using 
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copper (Rai et al. 2015; Medici et al. 2015).  It is therefore reasonable to contemplate the 
use of metals/metal oxides NP as antibiotic carriers, or as drug excipients (at suitable 
concentrations), to allow an enhanced anti-microbial affect (Owens 2013b; Rai et al. 
2009; Morones-Ramirez et al. 2013). 
By investigating the efficacy of metal/metal oxide NPs it was established that the 
screening assay could not accommodate NPs with inherent reflective properties, such as 
TiO2 NPs.  TiO2 NPs were going to be included in the NP selection to be investigated in 
this study, but had to be removed following initial experiments whereby the readouts were 
3-fold greater than the control well readings (Map K10/GFP only) demonstrating the 
importance of checking for interference in such light-based assays.   
An integral part of this work was to use the fluorescence assay to screen the newly 
developed SDNs.  The SDNs were manufactured for this PhD project and are an exciting 
development.  Although comparing the efficacies of these particles to aqueous antibiotic 
was challenging due to the differences in drug loading, it was possible to calculate an 
EC50 to compare RIF SDN to RIF aqueous.  The results demonstrated almost a 100-fold 
difference between the two forms of the drug, with the SDN being more potent, thus being 
a very exciting result.  Other studies have shown RIF in the nano-scale be more effective 
than ‘free’ RIF, therefore this work correlates with other studies (Suarez et al. 2001; 
Hirota et al. 2010; McCarron et al. 2008; Onoshita et al. 2010; Chuan et al. 2013).  
However, these studies have not used SDNs, which I hypothesis to offer an even greater 
anti-mycobacterial effect, as effective targeting is possible and drug loading is adjustable.  
The microscopy aspects took some optimising, but once a protocol was established, 
images depicting the uptake of SDNs by infected macrophages and the possible co-
localisation of SDN and mycobacteria were obtained.  Other studies have shown NP 
uptake into macrophages (Clift et al. 2008) and lysosomes (Arai et al. 2015), by Mtb 
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infected macrophages (Chuan et al. 2013) and by M. bovis BCG infected macrophages 
(Kalluru et al. 2013), thus again correlating with the results obtained here.  Through the 
use of Z-stacks and 3D imaging software, it was clear the SDNs were internalised by 
macrophages and not surface bound.  If time had prevailed, it would have been interesting 
to have quantified the GFP signal in SDN treated macrophages, to compare to the GFP 
signal in untreated macrophages.  This would be possible using the Zeiss Axio vision Rel 
4.8 software, which measures the level of GFP per pixel in any given image and is 
therefore able to deduce where the signal fluctuates and thus compute a numerical 
difference between two images.  However, this process required in-depth optimisation of 
standards to allow a consistent system to permit comparison between images.  Another 
option would be flow cytometry.  Additionally, an investigation to compare the uptake of 
RIF SDNs to TRIPLE SDNs by macrophages would have been interesting.  For example, 
it is known macrophages (J774A.1 cells) more readily uptake smaller NPs to larger NPs 
(Clift et al. 2008) but other factors may have influenced the macrophages preference to 
RIF SDNs (e.g. the excipient used in manufacture or SDN stability), and it may have been 
the drug loading difference between the SDN types rather than SDN size. 
Although the purpose of this project was to develop and optimise the screening assay for 
NPs, a limitation of this work was that an Mtb strain was not utilised in the screening of 
SDNs.  This assay was developed for TB drug screening, and a surrogate organism was 
suitable for this purpose.  Though interesting results were generated, it only offered an 
indication of the susceptibility for Mtb, rather than an absolute assessment, and there 
would likely be differences in susceptibility and mechanism of toxicity due to strain 
differences.  If all the SDNs were screened against Mtb, the results generated would have 
a greater impact and more clinical relevance.  Although genetically and physically 
similar, Map and Mtb are different species that cause different diseased states in different 
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mammals (although a link between Map infection and Crohn's disease in humans exists).  
Thus leading to the future work envisioned for this project.  
 
6.2 Future work 
 
As highlighted in each of the chapters, there are many aspects which could be further 
investigated.  As both Ag and Cu(II)O NPs offered efficacious properties that kill Map 
K10/GFP at the higher concentrations, it would be interesting to determine the 
mechanism of action and how they compare to each other.  Two of the main targets in 
Mtb treatment is the β subunit of the RNA polymerase and the mycolic acids of the 
cellular wall (Zhang & Yew 2009).  From the results generated and the imaging carried 
out in Chapter IV, I would hypothesis that structural damage is exerted by the NPs to the 
bacilli.  Whether the NPs are able to enter the bacilli or not is still ambiguous but 
intriguing results were obtained, showing dark NP-like entities within the pathogen.    
The next major step would be to screen the SDNs against a drug susceptible strain of GFP 
modified Mtb and compare this to an aqueous form of the same drug to allow a like-for-
like comparison.  The results generated from such a test would have great clinical 
significance.  Further, screening the same substances against an MDR TB strain would 
be very interesting.  Using the DiD incorporated SDNs, it would be advantageous to 
repeat these experiments in live macrophages, using LysoTracker Red to be able to 
confirm whether the SDNs and mycobacteria were trafficked to the lysosome.  This would 
require a high containment imaging facility, yet it could offer vital information on how 
the infected macrophages process the engulfed SDNs.  
The SDNs manufactured for this project could be created for other TB drugs (e.g. EBM) 
and screening of these would be required.  Further, the manufacture of PZA and INH 
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SDNs for the screening of these individually, could offer a further insight into the toxicity 
exerted by these individual drugs.  It would be interesting to determine whether a 
quadruple SDN could be manufactured, including EMB for a 4-drug combination.  
Overall, it would be advantageous to have all first-line TB antibiotics produced as SDNs.  
An important consideration is whether saving the host cell (e.g. macrophage) is important 
during an infection.  As found with the highly anti-mycobacterial Ag NPs, they were also 
very toxic to macrophage cells.  If cell death occurs by apoptosis, there would be no 
adverse effect on the surrounding tissue (except for re-exposure to Ag NPs), but if death 
occurs by necrosis this could cause tissue damage through an inflammatory response.  
Although macrophages offer host protection, in essence they also offer a form of 
protection to Mtb, and therefore if the pathogen could be killed whilst sacrificing the host, 
this could be significantly unfavourable in a clinical setting.  Macrophages are known to 
have an intracellular threshold load.  It is reported they can engulf ∼25- 40 bacilli before 
‘bursting’ occurs (Repasy et al. 2013; Wong & Jacobs 2016).  An infected macrophage 
with an MOI of 40:1 would be an ideal target for SDNs, delivering maximal drug to 
maximal pathogen.  Whether deliberately killing the infected host cell would be 
favourable or not is an interesting concept.  This would likely have a big impact on overall 
infection control.  
 
6.3 Concluding remarks  
 
There is much to be investigated and learned from nanomedicine and TB.  This thesis 
tried to combine the relevant literature from the two fields to give an overview of the 
ongoing progress and limitations.  Combining expertise from a range of disciplines is 
required to allow an amalgamated, coherent and thorough evaluation where the next steps 
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of research should be taken.  A further understanding of how drugs are penetrating the 
lung cavities is required which may allow a more tailored nano-based regime to be 
designed, to exploit the unique properties NPs offer.  Faster disease diagnosis and 
initiation into treatment programmes is paramount if TB is ever to be controlled.  A 
cohesive effort between governments, funding bodies, scientists, clinicians and patients 
akin is essential to combat this disease.   
In conclusion, more screening of substances is required to identify anti-mycobacterial 
compounds as MDR/XDR TB levels escalate.  Metal/metal oxide NPs have the potential 
to be integrated into clinical medicine, their inherent anti-bacterial properties should be 
exploited.  SDNs display interesting results that warrant further investigation.  This PhD 
project has developed a novel drug screening assay to study the anti-mycobacterial 
properties of NPs/drugs, and further, has identified the potential of newly developed 
SDNs.  These, delivered as nanomedicine, may offer hope for the eventual eradication of 
this global pathogen. 
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APPENDICES 
Appendix A 
 
Additional metal/metal oxide NP data  
Table A.1 β Values calculated from the linear regression of the Log data (growth of Map 
K10/GFP with Cu(II)O NP).  These values were normalised to the slope of the control (0 
µg/mL) to plot Fig A.1 
 
Concentration (µg/mL) Slope of the line (β) β (Normalised) 
0 0.2254 1 
6.25 0.2311 1.025288 
12.5 0.2239 0.993345 
25 0.1951 0.865572 
50 0.1635 0.725377 
100 0.1323 0.586957 
 
 
Figure A.1 Growth of Map K10/GFP with Cu(II)O NP normalised to the control (where β 
represents the change in fluorescence [representing mycobacterial growth] per day).  Map 
K10/GFP grown in 200 µL of 7H9, in a microplate format, with Cu(II)O NP at different 
concentrations (6.25-100 µg/mL), normalised to the slope of the control.  β calculated through 
linear regression analysis of the Log data (Table A.1).  Each point displaying 2* the standard error 
calculated using LINEST function Excel (Microsoft Office Word) to cover the variation of the 
mean (n=4).   
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Table A.2 β Values calculated from the linear regression of the Log data (growth of Map 
K10/GFP with ZnO NP).  These values were normalised to the slope of the control (0 µg/mL) to 
plot Fig.A.2 
 
Concentration (µg/mL) Slope of the line (β) β (Normalised) 
0 0.1944 1 
6.25 0.1761 0.905864 
12.5 0.154 0.792181 
25 0.1854 0.953704 
50 0.177 0.910494 
100 0.1579 0.812243 
 
 
Figure A.2 Growth of Map K10/GFP with ZnO NP normalised to the control (where β 
represents the change in fluorescence [representing mycobacterial growth] per day).  Map 
K10/GFP grown in 200µl of 7H9, in a microplate format, with ZnO NP at different concentrations 
(6.25-100 µg/mL), normalized to the slope of the control.  β calculated through linear regression 
analysis of the Log data (Table A.2).  Each point displaying 2* the standard error calculated using 
LINEST function Excel (Microsoft Office Word) to cover the variation of the mean (n=4).  
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a) 
 
b) 
 
c) 
Figure A.3 Zeta potential distribution graphs (DLS) (n=6) 
 
(a) Ag NPs in 7H9  
(b) Cu(II)O NPs in 7H9  
(e) ZnP NPs in 7H9  
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Appendix B 
 
SDN manufacture (Professor Andrew Owen and Dr Macro Giardiello, University 
of Liverpool) 
 
SDNs of first line TB drugs were prepared as outlined below.  The incorporation of a 
fluorescent dye (1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindodicarbocyanine, 4-
Chlorobenzenesulfonate Salt [DiD]) to confer a fluorescent signal to each particle was 
included in some incidences for imaging purposes.  Both freeze and spray drying methods 
were utilised, essentially producing the same product, while spray drying only was used 
to scale up the samples as freeze drying could only produce relatively small quantities 
(up to 10 mg).   
 
Preparation of Emulsion-Templated Freeze-Dried Monoliths Containing 30% RIF 
Nanoparticles (RIF SDN). 
Stock solutions of RIF (30 mg/mL in Dichloromethane [DCM]), Pluronic F68® (22.5 
mg/mL in water), and Hyamine® (22.5 mg/mL in water) were dissolved.  The three stock 
solutions were combined in the ratio 100:245:67 (μL) (RIF : Pluronic F68®: Hyamine®) 
plus 88 μL water.  The final solid mass ratio was therefore 30% RIF: 55% Pluronic F68®: 
15% Hyamine® in a 1:4 DCM to water mixture (total volume 0.5 mL).  The sample was 
emulsified using a Covaris S2x acoustic homogenization system for 30s with a duty cycle 
of 20, an intensity of 10 and 500 cycles/burst in frequency sweeping mode.  Immediately 
after emulsification, the sample was cryogenically frozen and lyophilized using a Virtis 
benchtop K freeze-drier for 48 hours.  The orange dry porous product was stored in the 
dark at room temperature. 
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Preparation of Emulsion-Templated Freeze-Dried Monoliths Containing 29% RIF 
Nanoparticles labelled with 1% of the dye DiD (RIF SDN + DiD). 
Preparation followed the same procedure as described above, however a stock solution 
of 30 mg/mL DiD was prepared.  The four stock solutions were added to a sample tube 
in the ratio 97:3: 267:133 (μl) (RIF: DiD: Pluronic F68®: Hyamine®) plus 88μl water.  
The final solid mass ratio was therefore 29% RIF: 1% DID: 55% Pluronic F68®: 15% 
Hyamine® in a 1:4 DCM to water mixture, with a total volume of 0.5 mL. 
 
Preparation of Emulsion-Spray-Dried 53% TRIPLE Drug Powders Containing RIF, 
INH, PZA (TRIPLE SDN). 
A mass of 51.2 mg PZA, 20 mg RIF and 8.8 mg INH were weighed directly into a sample 
vial.  A volume of 1 mL DCM was then added and the powders mixed (inverted and 
vortexed) [note: they did not fully dissolve]).  Stock solutions of Kollicoat Protect® (22.5 
mg/mL in water), and Hyamine® (22.5 mg/mL in water) were dissolved.  The aqueous 
stock solutions were added to the 1 mL API mix in DCM in the ratio 267:0.44 (mL) plus 
0.89 mL water.  The final solid mass ratio was therefore 34% PZA, 13% RIF: 6% IZH: 
40% Kollicoat® Protect: 7% Hyamine® in a 1:4 dichloromethane to water mixture (total 
volume 5 mL, 53% combined API).  The sample was emulsified using a Hielscher 
UP400S ultrasonic processor equipped with H14 Probe at 100% output (140 W) for 
300secs.  Immediately after emulsification, the sample was spray dried on a benchtop 
spray dryer (BUCHI Mini-290) using an air-atomizing nozzle and compressed air as the 
drying gas.  Spray drying process conditions were 5 mL/min solution flow rate and 65oC 
outlet temperature (120oC inlet temperature).  The orange powder was collected and 
stored in the dark at room temperature. 
  
254 
 
Preparation of Emulsion-Spray-Dried 52 % TRIPLE Drug Powders Containing RIF, 
INH, PZA labelled with 1% of the dye DiD (TRIPLE SDN + DiD)  
Preparation followed the same procedure as described above, however a sock solution of 
53 mg/mL DiD was prepared. A mass of 50.7mg PZA, 19.8mg RIF and 8.7mg INH were 
weighed directly into a sample vial.  A volume of 97ml DCM was then added and the 
powders mixed (note, they did not fully dissolve).  To this, 0.03 mL of DiD stock was 
added.  The aqueous stock solutions were added to the 1 mL API mix in DCM in the ratio 
267:0.44 (mL) plus 0.89 mL water.  The final solid mass ratio was therefore 33.7% PZA, 
13% RIF: 6% IZH: 1% DiD: 40% Kollicoat® Protect: 7% Hyamine® in a 1:4 
dichloromethane to water mixture (total volume 5 mL, 52% combined API, 1% DiD). 
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Additional SDN data  
Figure B.1 β Values calculated from the linear regression of the Log data (growth of Map 
K10/GFP with RIF aqueous).  These values were normalised to the slope of the control (0 
µg/mL) to plot Figure AB.1 
Concentration 
(µg/mL) 
Compound Slope of the line 
(β) 
β (Normalised) 
0 RIF Aqueous 0.2151 1 
0.001875µg/ml RIF Aqueous 0.236 1.097164 
0.00375µg/ml RIF Aqueous 0.1608 0.747559 
0.0075µg/ml RIF Aqueous 0.1558 0.724314 
0.015µg/ml RIF Aqueous 0.1383 0.642957 
0.03µg/ml RIF Aqueous 0.1251 0.58159 
0.0625µg/ml RIF Aqueous 0.1195 0.555556 
0.125µg/ml RIF Aqueous 0.1738 0.807996 
0.25µg/ml RIF Aqueous 0.1737 0.807531 
0.5µg/ml RIF Aqueous 0.1692 0.786611 
1µg/ml RIF Aqueous 0.1497 0.695955 
2µg/ml RIF Aqueous 0.1155 0.53696 
4µg/ml RIF Aqueous 0.0976 0.453742 
 
 
Figure B.1 Growth of Map K10/GFP with RIF aqueous normalised to the control (where β 
represents the change in fluorescence [representing mycobacterial growth] per day).  Map 
K10/GFP grown in 200 µL of 7H9, in a microplate format, RIF aqueous at different 
concentrations (0.001875 – 4 µg/mL), normalised to the slope of the control.  β calculated through 
linear regression analysis of the Log data (Table B.1).  Each point displaying 2* the standard error 
calculated using LINEST function Excel (Microsoft Office Word) to cover the variation of the 
mean (n=9).   
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Table B.2 β Values calculated from the linear regression of the Log data (growth of Map 
K10/GFP with INH aqueous).  These values were normalised to the slope of the control (0 
µg/mL) to plot Figure B.2 
Concentration 
(µg/mL) 
Compound Slope of the line (β) β (Normalised) 
0 RIF SDN 
0.277 1 
0.001875µg/ml RIF SDN 0.266 0.960289 
0.00375µg/ml RIF SDN 0.259 0.935018 
0.0075µg/ml RIF SDN 0.239 0.862816 
0.015µg/ml RIF SDN 0.246 0.888087 
0.03µg/ml RIF SDN 0.256 0.924188 
0.0625µg/ml RIF SDN 0.275 0.99278 
0.125µg/ml RIF SDN 0.262 0.945848 
0.25µg/ml RIF SDN 0.2579 0.931047 
0.5µg/ml RIF SDN 0.267 0.963899 
1µg/ml RIF SDN 0.265 0.956679 
2µg/ml RIF SDN 0.262 0.945848 
4µg/ml RIF SDN 0.259 0.935018 
 
 
Figure B.2 Growth of Map K10/GFP with INH aqueous normalised to the control (where β 
represents the change in fluorescence [representing mycobacterial growth] per day).  Map 
K10/GFP grown in 200 µL of 7H9, in a microplate format, INH aqueous at different 
concentrations (0.001875 – 4 µg/mL), normalised to the slope of the control.  β calculated through 
linear regression analysis of the Log data (Table B.2).  Each point displaying 2* the standard error 
calculated using LINEST function Excel (Microsoft Office Word) to cover the variation of the 
mean (n=2).   
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Table B.3 β Values calculated from the linear regression of the Log data (growth of Map 
K10/GFP with RIF SDN).  These values were normalised to the slope of the control (0 µg/mL) 
to plot Figures B.3.  
Concentration 
(µg/mL) 
Compound Slope of the line (β) β (Normalised) 
0 RIF SDN 0.2344 1 
0.001875µg/ml RIF SDN 0.236 1.006826 
0.00375µg/ml RIF SDN 0.2431 1.037116 
0.0075µg/ml RIF SDN 0.2357 1.005546 
0.015µg/ml RIF SDN 0.2377 1.014078 
0.03µg/ml RIF SDN 0.2233 0.952645 
0.0625µg/ml RIF SDN 0.1921 0.819539 
0.125µg/ml RIF SDN 0.1822 0.777304 
0.25µg/ml RIF SDN 0.1734 0.739761 
0.5µg/ml RIF SDN 0.1691 0.721416 
1µg/ml RIF SDN 0.1549 0.660836 
2µg/ml RIF SDN 0.1532 0.653584 
4µg/ml RIF SDN 0.1477 0.630119 
 
 
Figure B.3 Growth of Map K10/GFP with RIF SDN normalised to the control (where β 
represents the change in fluorescence [representing mycobacterial growth] per day).  Map 
K10/GFP grown in 200 µL of 7H9, in a microplate format, RIF SDN at different concentrations 
(0.001875 – 4 µg/mL), normalised to the slope of the control.  β calculated through linear 
regression analysis of the Log data (Table B.3).  Each point displaying 2* the standard error 
calculated using LINEST function Excel (Microsoft Office Word) to cover the variation of the 
mean (n=9).   
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Table B.4 β Values calculated from the linear regression of the Log data (growth of Map 
K10/GFP with DUAL SDN).  These values were normalised to the slope of the control (0 
µg/mL) to plot Figures….  
Concentration 
(µg/mL) 
Compound Slope of the line (β) β (Normalised) 
0 RIF SDN 0.25 1 
0.001875µg/ml RIF SDN 0.2488 0.9952 
0.00375µg/ml RIF SDN 0.2587 1.0348 
0.0075µg/ml RIF SDN 0.2678 1.0712 
0.015µg/ml RIF SDN 0.2591 1.0364 
0.03µg/ml RIF SDN 0.2433 0.9732 
0.0625µg/ml RIF SDN 0.274 1.096 
0.125µg/ml RIF SDN 0.2202 0.8808 
0.25µg/ml RIF SDN 0.213 0.852 
0.5µg/ml RIF SDN 0.2038 0.8152 
1µg/ml RIF SDN 0.1912 0.7648 
2µg/ml RIF SDN 0.1491 0.5964 
4µg/ml RIF SDN 0.149 0.596 
 
 
Figure B.4 Growth of Map K10/GFP with DUAL SDN normalised to the control (where β 
represents the change in fluorescence [representing mycobacterial growth] per day).  Map 
K10/GFP grown in 200 µL of 7H9, in a microplate format, DUAL SDN at different 
concentrations (0.001875 – 4 µg/mL), normalised to the slope of the control.  β calculated through 
linear regression analysis of the Log data (Table B.4).  Each point displaying 2* the standard error 
calculated using LINEST function Excel (Microsoft Office Word) to cover the variation of the 
mean (n=6).   
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Table B.5 β Values calculated from the linear regression of the Log data (growth of Map 
K10/GFP with TRIPLE SDN).  These values were normalised to the slope of the control (0 
µg/mL) to plot Figure B.5. 
Concentration 
(µg/mL) 
Compound Slope of the line (β) β (Normalised) 
0 RIF SDN 0.2305 1 
0.001875µg/ml RIF SDN 0.2546 1.104555 
0.00375µg/ml RIF SDN 0.2573 1.116269 
0.0075µg/ml RIF SDN 0.2558 1.109761 
0.015µg/ml RIF SDN 0.2527 1.096312 
0.03µg/ml RIF SDN 0.2336 1.013449 
0.0625µg/ml RIF SDN 0.1745 0.75705 
0.125µg/ml RIF SDN 0.1685 0.73102 
0.25µg/ml RIF SDN 0.1754 0.760954 
0.5µg/ml RIF SDN 0.1984 0.860738 
1µg/ml RIF SDN 0.1602 0.695011 
2µg/ml RIF SDN 0.1576 0.683731 
4µg/ml RIF SDN 0.156 0.67679 
 
 
Figure B.5 Growth of Map K10/GFP with TRIPLE SDN normalised to the control (where β 
represents the change in fluorescence [representing mycobacterial growth] per day).  Map 
K10/GFP grown in 200 µL of 7H9, in a microplate format, TRIPLE SDN at different 
concentrations (0.001875 – 4 µg/mL), normalised to the slope of the control.  β calculated through 
linear regression analysis of the Log data (Table B.5).  Each point displaying 2* the standard error 
calculated using LINEST function Excel (Microsoft Office Word) to cover the variation of the 
mean (n=9).   
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Figure B.6 (a-e) Size intensity graphs (DLS) (n=4) 
(a) RIF SDN 7H9 
(b) TRIPLE SDN 7H9 
(c) DUAL SDN in 7H9 
(d) RIF SDN (with DiD) 7H9  
(e) TRIPLE SDN 7H9 (with DiD) 7H9  
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Appendix C 
Statistical analysis  
 
Figure C.1 Histogram of RIF SDN data (the data was skewed therefore it was 
normalised prior to analysis).  
 
 
Figure C.2 Histogram of RIF aqueous data (the data was very skewed therefore it was 
normalised prior to analysis). 
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